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ABSTRACT
MICRONUTRIENTS, INFLAMMATION AND DEPRESSION AMONG WOMEN OF
REPRODUCTIVE AGE FROM THE NATIONAL HEALTH AND NUTRITION
EXAMINATION SURVEY 2005-2008

MAY 2017
JOYCELYN M. FARAJ, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Associate Professor Alayne Ronnenberg
Depression is the leading cause of disease burden among women of childbearing
age, rendering female mental health a major public health problem in the U.S.
Recent evidence indicates that inflammation is associated with depression, and
many of the factors that contribute to inflammation can be addressed through
nutritional and lifestyle interventions. There are two micronutrients that have been
linked previously with depression and have established roles in inflammation:
vitamins B6 and D. There is scarce research on the potential association between
these micronutrients, inflammation, and depression. The purpose of this research
was to investigate how high sensitivity C-reactive protein (hs-CRP), a biomarker of
inflammation, may be contributing to different dimensions of depression and to
determine to what degree inflammation or lifestyle factors may be affecting the
association between vitamins B6 and D and depression symptoms among women of
reproductive age. We carried out a secondary data analysis of non-pregnant women
vi

ages 18-44 from the National Health and Nutrition Examination Survey (NHANES)
2005-2008. All analyses were weighted using NHANES sample weights to account
for the complex survey design, survey non-response, and post-stratification.
Depression scores were calculated based on the Patient Health Questionnaire-9
(PHQ-9) and categorized into total depression, somatic depression and non-somatic
depression. High depression score (PHQ-9≥10) use was also used as an outcome, as
well as individual symptoms of depression. Overall, 7.5% of our population
experienced high depression symptoms.
In the first study, hs-CRP was positively associated with sum depression scores after
adjustments for demographics and behavioral characteristics, but prior to
adjustment by body mass index (BMI), which significantly attenuated this
association. In stratified analysis, hs-CRP was associated with higher depression
scores after adjustments among underweight women (p<0.05). With regards to
individual depression symptoms, hs-CRP was associated with sleep disturbance
(OR: 1.31, 95% CI 1.01-1.71) and changes in appetite.
In the second study, vitamin B6, as serum pyridoxal-5'phosphate (PLP), was
categorized as deficient (<20 nmol/L), insufficient (20-29.9 nmol/L) or normal (≥30
nmol/L). We found the prevalence of depression to vary by CRP level and by vitamin
B6 concentration. Among those with moderate inflammation, the prevalence of
depression was highest among women with vitamin B6 deficiency (20%), followed
by those with vitamin B6 insufficiency (10%), and those with normal vitamin
B6 status (5%) (p= 0.02). In multivariable models including individual depression
symptoms, vitamin B6 levels below 30 nmol/L were associated with higher odds of
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experiencing suicidal ideation (OR: 7.33, p=0.01 and OR: 3.5, p=0.06 for B6
deficiency and insufficiency, respectively) and depressed mood (OR: 3.12, p=0.004
for B6 insufficiency). Among those with moderate CRP levels, vitamin B6 deficiency
was associated with a higher score for psychomotor abnormalities (β: 0.14, p=0.02).
In our third study, suboptimal vitamin D levels were significantly associated with
higher odds for depression among women who had elevated CRP (OR: 6.55, p=0.02
and OR: 9.54, p=0.001 for 25-OHD<75nmol/L and 25-OHD<50nmol/L, respectively).
Among women who reported sleeping 7 or more hours per night, vitamin D was
inversely associated with depression, whereas the opposite was true among women
who slept less than 7 hours per night (p-interaction: 0.01). Together, the results of
these studies suggest that inflammation may be interacting with BMI, sleep, or
micronutrient deficiencies, and altogether contributing to different symptoms or
severities of depression. Lifestyle factors, such as BMI or sleep could be used
together with nutritional interventions, to aid in efforts to prevent or help treat
depression among women of reproductive age.
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CHAPTER 1
INTRODUCTION
Depression is the leading cause of disability world-wide, affecting 350 million
individuals. 1 Within developed countries, major depression is second only to heart disease
as the leading source of disease burden, and for women, it is already the primary cause of
disease burden. 1 Women in their childbearing years make up the largest group of
Americans with depression and women are 2 to 3 times more likely than men to
experience depression. 2,3 This high prevalence of depression among women renders
female mental health a major public health problem in the U.S., especially since not all
depressed individuals respond to drug treatment and additional therapies are urgently
needed. 4
The complexity of depression is unmistakable, yet a key to its prevention and
treatment may be a factor so fundamental that it has been broadly overlooked: overall
nutritional status. 5 Recent evidence indicates that inflammation is associated with
depression 6 and many of the factors that contribute to inflammation can be addressed
through nutritional interventions. 7 Two micronutrients – Vitamins D and B6 – have
potential roles in both inflammation 8,9 and depression, 10,11 but to date, no studies have
examined the potential association between these nutrients, inflammation, and depression,
which is the main objective of my dissertation.
Depression is a multifaceted construct with a large range of symptoms. Research
into the etiology of depression needs to account for the heterogenous nature of the
condition and requires developing methods to characterize and objectively assess the
1

severity of depression and to classify depression into its different subtypes. 12 In order to
address the issue of symptom diversity, subtypes of depressive symptoms have been
proposed based on specific combinations of symptoms. 13 Somatic depression,
characterized by sleep disturbance, fatigue, or changes in appetite, has been found to be
more prevalent in females compared to males. 14 Evidence suggests that gender differences
may account for heterogeneity in depression symptoms and the involvement of
inflammation in the etiology of depression may be affected by lifestyle factors. 15 To the
best of our knowledge, prior literature has not assessed how inflammation or nutritional
deficiencies may be contributing to different sub-types of depression or individual
depression symptoms among women of childbearing age. This lack of knowledge is
problematic because an understanding of the modifiable nutritional and lifestyle factors
that may be contributing to depressive symptoms, especially in the context of
inflammation, is important for the prevention and early treatment of depression. This
dissertation examined cross-sectional data from 1,489 non-pregnant women ages 18-44
years from the National Health and Nutrition Examination Survey (NHANES) to evaluate
the extent to which inflammation, suboptimal vitamin B6 and D concentrations, and
lifestyle factors are associated with different dimensions of depression in women
representative of the U.S. population.

2

CHAPTER 2
DEPRESSION

2.1 Epidemiology of Depression
Depression is a commonly occurring, seriously impairing, and often recurring
psychiatric disorder.4,5 The World Health Organization identified depression as the leading
cause of disability world-wide, affecting 350 million individuals.1 In the US, recent samples
estimate a lifetime depression prevalence of 16.2% (approximately 33 million adults) and a
12-month prevalence of 6.6% or 13.5 million adults.6 It is also the leading cause of
disability for people ages 15-44 years old, resulting in almost 400 million disability days
per year. 19 With a quarter of women all ages reporting depression symptoms according to
recent national estimates,7 they are 2 to 3 times more likely than men to experience
depression.2,3 Not only is depression the most common mental illness experienced by
women, but rates of depression are on the rise.8 The chance of suffering from depression is
ten times greater for women today than it was for their grandmothers.9

2.2 Definition of Depression
Major depressive disorder goes beyond the normal bounds of sadness and is marked by
hopelessness, loss of mood reactivity, inability to experience pleasure, suicidal thoughts,
and psychotic symptoms such as delusions or hallucinations.10 The actual diagnosis of
major depressive disorder is based on criteria established in the Diagnostic and Statistical
Manual of Mental Disorders, fifth edition (DSM-V) by the American Psychiatric Association
(APA).11 Major depressive disorder is characterized by discrete episodes of at least 2 week
3

duration involving clear-cut changes in affect, cognition, and neuro-vegetative functions
and inter-episode remissions.11 Common symptoms of major depressive disorder or
unipolar depression include a persistent sad mood, loss of interest or pleasure in activities
that were once enjoyed, changes in appetite or weight, difficulty sleeping or oversleeping,
physical slowing or agitation, energy loss, feeling worthlessness or inappropriate guilt,
difficulty thinking or concentrating, and recurrent thoughts of death or suicide.11 A
diagnosis of major depressive disorder is made if a person has five or more of these
symptoms and experiences impairment in usual functioning nearly every day during the
same 2-week period and at least one of the symptoms must be either depressed mood or
anhedonia (loss of interest of pleasure).11
Other manifestations of depressive disorders include: dysthymic disorder (or
dysthymia), which is characterized by long-term (2 years or longer) symptoms that may
not be severe enough to disable a person but can prevent normal functioning or feeling
well; and minor depression, which is characterized by having symptoms for 2 weeks or
longer that do not meet full criteria for major depression.12 Those with minor depression
are at increased risk for developing major depressive disorder.12 Other forms of
depression vary slightly or may develop under different circumstances, such as postpartum
depression or seasonal affective disorder.12

4

2.2.1 Subtypes of Depression
Major depressive disorder patients vary considerably in clinical presentation, cause,
treatment response, genetics, and neurobiology.13,14 One explanation for this diversity is
the polyethic definition of major depressive disorder, meaning that a patient needs to only
satisfy some but not all symptoms to be classified as depressed.14 This approach suggests
there are 227 possible combinations of symptoms leading to a diagnosis of depression.14
In order to tackle the issue of symptom diversity, subtypes of depressive disorders have
been proposed based on specific combination of symptoms (i.e. melancholic depression,
psychotic depression), onset (seasonal affective disorder postpartum, early versus late in
life), course (single, recurrent, chronic), or severity.15 Several subtypes of depression such
as atypical, psychotic, cognitive, somatic and melancholic depression have been found in
theoretical frameworks.14 Of these, somatic symptomology has been found to be more
prevalent in females compared to males.16 Research into the etiology of depression needs
to account for the heterogenous nature of the condition and requires developing methods
to characterize and objectively assess the severity of depression and to classify depression
into its different subtypes.5 Investigating risk factors for specific symptoms offers
opportunities to discover potential biological factors that may be related to specific
syndromes but may be masked by aggregate scoring; individuals with similar total
depression scores often have drastically different clinical conditions.16 In conclusion,
depression is a heterogeneous disorder with a highly variable course, 30 an inconsistent
response to treatment, 4 and no established mechanism.13 Therefore, further attempts to
characterize depression and find new potential treatments are warranted.

5

2.3 Public Health Challenge
Currently, depression is one of the three leading causes of global disease burden, but it
is predicted to become the leading cause by 2030.17 This poses an important public health
challenge because depression is often undiagnosed and untreated by physicians in primary
care settings.18 Despite heightened awareness and treatment of depression in primary
care settings, the prevalence of depressive symptoms remains high, treatment levels
remain low, and control of depressive symptoms are suboptima.7 A recent study of a
nationally representative sample of adults from NHANES found that even among
individuals with severe depressive symptoms, a large proportion (36.9%) did not receive
treatment for depression.7 Furthermore, not all depressed individuals respond to drug
treatment and additional therapies are urgently needed.4 Among U.S. adults taking
antidepressants, 26% reported feeling mild depressive symptoms and 19% reported
feeling moderate, moderately severe, or severe depressive symptoms.7 This suggests that
antidepressants alone may not be the optimal treatment for depression, and further
avenues, such as nutritional therapy, could be beneficial in treating depression.
Among women, maternal depression is a major public health problem in the United
States20 encompassing a range of emotional and physical changes that mothers can
experience especially during pregnancy (prenatal) or in the year after giving birth
(postnatal).21 Ante-, peri- and postpartum depression occur in 10-20% of women, with
rates of depression increasing in the last 2 trimesters of pregnancy up to 51% in the
general population of pregnant women.21 These estimates are likely conservative due to
under-reporting and under-diagnosing maternal depression. Indeed, as many as half of all
cases of perinatal depression go undetected, in part because many of the symptoms can be
6

wrongly attributed to the hormonal and physiological changes characteristic of
pregnancy.22 Furthermore, studies have shown that depression in the postpartum period
can last for months or even years after giving birth.23,24

2.4 Public Health Impact of Depression
Depression has a major impact on functioning and quality of life, on public health and
on the economy. In 2000, the estimated costs of depression totaled $83.1 billion, including
$26.1 billion for direct medical costs, $5.4 billion for suicide-related mortality costs, and
$51.5 billion for workplace costs, including absenteeism and disability.25 Based on a
nationally representative sample of U.S. workers, Kessler and colleagues (2006) estimated
that major depression resulted in 27.2 lost workdays per ill worker each year.26
Additionally, they found that the major workplace impact of depression is more likely to be
due to presenteeism (being physically present at work, but unable to function) than
absenteeism, which can be several times the cost of work loss time alone.26
From an interpersonal and domestic perspective, depression can have devastating
effects on a child’s development and family health. Parents represent the earliest, most
constant, and most proximal influence on child development. Their psychological health, in
addition to parenting behavior, serves as an important environmental risk or protective
factor in the developmental outcomes for children, especially with regard to emergence
and course of behavior problems.27 Depression among mothers is increasingly recognized
as a common and devastating public health problem affecting not only women but also the
children in their care. Maternal depression can have devastating effects on a child’s health,
starting in pregnancy. Depressed mothers are more likely to have poor nutrition and to
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smoke, drink, and/or use illicit drugs compared to non-depressed women; they are also
more likely to engage in risky behavior, including suicidal thoughts, as well as
underutilization of prenatal care services.28 Maternal depression is one of the most
common complications during pregnancy and it can lead to increased obstetrical
complications, such as pre-eclampsia, excessive bleeding, placental rupture, and preterm
birth and low birth weight babies.29 The effects of maternal postpartum depression on
infants can be long-lasting, affecting a child’s development and well-being. Infancy is a vital
developmental period, covering the time-frame when children develop social interaction
skills, experience parental attachment and bonding, and learn how to communicate. If a
mother’s ability to interact with her child is impaired due to her own depression, her infant
may fail to develop these important skills. Infants of depressed mothers often suffer from
developmental delays in their emotional, social, cognitive, and linguistic abilities.30,31
Furthermore, even mild or unrecognized maternal depressive symptoms in the first 4
months postpartum may have a significant impact on bonding with the infant.32 In addition
to emotional and development issues, maternal depression during the first years
postpartum is a also a strong predictor of child overweight and obesity.39 Long-term effects
of maternal depression include increased risk of depression and anxiety in childhood and
adolescence.40 This is especially important because the earlier onset of depression in life is
associated with greater severity of illness and higher risk of suicide than later onset
depression.40

8

2.5 Risk factors for Depression in Women
Depression is a multifactorial condition involving genetic and environmental risk
factors.41 Even though depression may have a large genetics component including
polymorphisms of the serotonin transporter promoter gene (5-HTTLPT),213 studies on
mood disorders have not provided consistent evidence regarding the roles of specific
susceptibility genes or their pattern of inheritance. 50,51 A genetic predisposition, in
combination with several potential environmental influences, is likely involved in the
development of depression.22 54,55 Environmental factors associated with depression in
women include stress (e.g. physical, mental, and emotional trauma); viral infections;
hormonal disorders; chronic diseases; and some medications (e.g. sedatives). 22,42
However, environmental factors do not appear to act alone, but can increase the risk for
depression in those with a genetic susceptibility for the condition.22
In addition to genetic predisposition and environmental risk factors, several social and
biological factors are associated with an increased risk for developing depression for
women. Social risk factors include a history of depression/anxiety, lack of marital partner
or marital difficulties,44 low socioeconomic status,45 lack of social support or social
isolation,46 major life events as well as family violence,47 increased life stress, and
substance abuse.21 Psychological factors include history of depression 48 and history of
psychiatric illness, such as premenstrual dysphoric disorder,46 and depressive symptoms
during pregnancy.49
Biological risk factors associated with depression in women are more challenging to
determine. Some biological factors that may contribute to the pathophysiology of
depression include hormonal fluctuations,50 neurotransmitter function, 62–64 metabolic
9

syndrome,54 increased inflammation,55 and nutrient deficiencies from malnutrition or poor
diet quality.56
In summary, depression is a multifaceted construct whose etiology remains a
mystery, and this may partly be due to the many potential risk factors that may be playing a
role in its development and severity.
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CHAPTER 3
INFLAMMATION

3.1 What is the Immune System and How Does it Function?
The immune system includes two major components: specialized cells that carry out
the wide array of immune processes, and the chemical messengers that enable
communication among immune cells, and between immune cells and other cells and tissues
within the body.57 The specialized cells and the messengers are coordinated to carry out
two forms of protection, innate and acquired immunity, which also work together in a very
complex manner to protect the body from foreign pathogens. Innate immunity is a general,
non-specific first line of defense comprised of anatomic, physiologic, endocytic and
phagocytic, and inflammatory barriers.58 Innate immunity is moderated and enhanced by
the acquired immune system, a specific form of defense that targets and labels pathogens
for elimination.59 Innate and acquired immunity operate in cooperative and
interdependent ways. The activation of innate immune responses produces signals that
stimulate and direct subsequent acquired immune responses, which involves cell-mediated
responses.58 The innate immune system continuously surveys the body for presence of
invaders, and when activated, it sets in motion a localized inflammatory response to fight
most pathogenic threats.60
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3.2 What is Inflammation?
Inflammation is an essential immune response that enables survival during
infection or injury and maintains tissue homeostasis under a variety of conditions.61 The
inflammatory response was first characterized in the 1st century AD by Cornelius Celsus,
who coined the four cardinal symptoms of inflammation: rubor et tumor cum calore et
dolore (redness and swelling with heat and pain).62 The physiology behind these
symptoms was discovered in the 1800s, when Augustus Waller (1846) and Julius
Cohnheim (1867) discovered leukocyte emigration from blood vessels and other vascular
changes characteristic of an acute inflammatory response. Upon microscopic observation
of living tissue, Cohnheim noticed vasodilation, leakage of plasma, and migration of
leukocytes out of blood vessels and into the surrounding tissue.62 The 5th cardinal symptom
of inflammation, function laesa (disturbance of function), was added in 1858 by Rudolph
Virchow in this book Cellularpathologie.62
Currently, it is known that inflammation may be of different forms and modalities,
which are directed by different mechanisms of induction, regulation, and resolution.61 In
the past few decades, the spectrum of inflammatory conditions has shifted from acute
inflammatory reactions in response to wounds and infections to chronic inflammatory
states that accompany chronic diseases such as type 2 diabetes, atherosclerosis, asthma,
cancer, and neurodegenerative diseases.61

12

3.2.1 Acute Inflammatory Response
A typical acute inflammatory response consists of four components: inflammatory
inducers, the sensors that detect them, the inflammatory mediators induced by the sensors,
and the target tissues that are affected by the inflammatory mediators.61
Each component comes in various forms, and their combinations function in distinct
inflammatory pathways. The type of pathway induced under given circumstances depends
on the source of the inflammatory stimulus. Thus, bacterial pathogens are detected by
receptors of the innate immune system expressed on tissue-resident macrophages and
induce the production of inflammatory cytokines and chemokines, as well as
prostaglandins.61 These inflammatory mediators then act on target tissues, including local
blood vessels, to induce vasodilation, extravasation of neutrophils, and leakage of plasma
into the infected tissue. Depending on the type of infection (bacterial, viral, or parasitic),
the sensors, mediators, and target tissues vary such that the most adequate type of
inflammatory response is induced.61 The acute inflammatory response is normally
terminated once the trigger insult is eliminated, the infection is cleared, and damaged
tissue is repaired. This is known as the resolution of inflammation.

3.2.2 Chronic Inflammation
Many chronic inflammatory conditions have been described where the initiating
trigger is not well defined but does not seem to involve infection or tissue damage. These
inflammatory conditions accompany many chronic diseases, including obesity and type 2
diabetes, atherosclerosis, neurodegenerative diseases, and cancer.61 Several inflammatory
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mediators, such as acute-phase proteins, cytokines or chemokines, can be used to assess
inflammation.

3.2.3 Inflammatory Mediators: Cytokines and Acute-Phase Reactants
As part of the inflammatory response, damaged or infected cells secrete chemical
messengers or mediators called cytokines, which act as chemoattractants. The term
“cytokines” encompasses a large family of proteins, including interleukins (IL), interferons
(IFN) and colony-stimulating factors, as well as various growth factors and eicosanoids,
including prostaglandins.63 To differentiate among cytokines’ biological activity, they are
often described as either pro-inflammatory or anti-inflammatory. Following damage to or
infection of cells and tissues, pro-inflammatory cytokines are produced and secreted to
stimulate the activation of the immune system.64 Anti-inflammatory cytokines, such as IL10, are also secreted during inflammation in order to terminate pro-inflammatory cytokine
activity.63
Cytokine expression normally occurs in a step-wise manner, with the expression of
certain cytokines dependent upon the prior expression of others; for example, IL-1 is
necessary to induce production of IL-2, IL-6 and tumor necrosis factor (TNF).63 Cytokines
are mainly produced by immune cells, but are also produced by a variety of other cell types,
such as brain cells and adipose cells.63 Peripheral cytokine production depends to a great
degree on the state of immune activation. In pathological conditions of acute or chronic
inflammation and tissue damage, the immune system is activated and macrophage activity
increases, accounting for increased production of cytokines, such as IL-1, IL-6, and TNF-α.
In the case of a viral infection, IFNs, released by activated T-cells, play a major role.59 These
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mediators, when secreted in sufficient amounts, can have systemic effects and can induce
liver cells to produce acute phase proteins such as C-reactive protein (CRP) and
coagulation factors, including pro-inflammatory prostaglandins.61

3.3 C-Reactive Protein: The Main Acute-Phase Reactant
C-reactive protein (CRP) is the prototypical acute phase protein in humans.65 CRP is a
serum protein that is massively induced as part of the innate immune response to infection
and tissue injury.66 CRP is composed of five 23-kDa subunits, and was named for its
capacity to precipitate the somatic C-polysaccharide of Streptococcus penumoniae.65 Even
though it was the first acute-phase protein to be described and traditionally was viewed
only as an acute phase reactant, CRP is currently considered the “best” systemic marker of
non-specific inflammation and tissue damage.67

3.3.1 Biosynthesis of CRP
CRP was traditionally thought to be produced only by hepatocytes, but recent
studies showed that CRP can be produced by non-hepatic tissues such as the renal
epithelium and respiratory tract.68,69 CRP synthesis is stimulated by inflammatory
cytokines, such as IL-6 70 and this synthesis is enhanced synergistically by IL-1β.71 De novo
hepatic synthesis initiates rapidly after a single stimulus, leading to serum concentrations
above 5mg/L for approximately 6 hours and peaking at 48 hours.72 The plasma half-life of
CRP is roughly 19 hours and is constant under all conditions of health and disease, so that
the sole determinant of circulating CPR levels is the synthesis rate, which is a direct
reflection of the intensity of the pathological process stimulating CRP production.67 When
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the stimulus for increased production ceases, the circulating CRP level falls rapidly, at
almost the rate of plasma CRP clearance.67

3.3.2 Circulating CRP Concentration
Healthy individuals in the general population tends to have stable CRP
concentration, apart from occasional spikes thought to be related to minor or subclinical
infections, inflammation, or trauma. There is no significant seasonal variation in baseline
CRP concentration, and, remarkably, the self-correlation coefficient of measurements
repeated years apart is approximately 0.5, which is comparable to that of cholesterol.67
Acute-phase CRP values also show no diurnal variation and are unaffected by the fed state.
Liver failure impairs CRP production, but no other pathologies and very few drugs reduce
CRP values unless they also affect the underlying pathology providing the acute-phase
stimulus.67 The CRP concentration is a useful nonspecific biochemical marker of
inflammation, measurement of which contributes importantly to screening for organic
disease, monitoring of the response to treatment of inflammation and infection, and
detection of intercurrent infection in immunocompromised individuals.67
In healthy young adults, the median concentration of CRP is 0.8 mg/L, the 90th
percentile is 3.0 mg/L and the 99th percentile is 10 mg/L.73 However, CRP is part of the
acute phase response, and following injury, CRP levels increase dramatically, up to 10,000fold from less than 50 ug/L to more than 500 mg/L.67 This increase is rapid, but not
immediate: circulating concentrations reach 5 mg/L by approximately 6 hours and peak at
48 hours.72 CRP is clearance occurs at a constant rate, rendering CRP levels a reliable
index of ongoing inflammation.72 Dramatic elevations in CRP levels indicate ongoing
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infection, and in the absence of infection, CRP reflects the degree of background
inflammation characteristic of an individual.67

3.3.3 Role of CRP in the Inflammation Process
There are several mechanisms through which CRP enhances inflammation and
activates the immune response. Human CRP binds with high affinity to phosphocholine
residues, but it also binds to a variety of other autologous and extrinsic ligands, and it
aggregates or precipitates the cellular, particular, or molecular structures bearing these
ligands.67 Autologous ligands include native and modified plasma proteins,74 damaged cell
membranes,75 several different phospholipids and related compounds as well as small
nuclear ribonucleoprotein particles,76 and apoptotic cells.77 Extrinsic ligands include many
glycan, phospholipid, and other constituents of microorganisms, such as components of
bacteria, fungi and parasites, as well as plant products. When aggregated or bound to
macromolecular ligands, human CRP is resembles some of the key properties of antibodies,
suggesting that under various circumstances CRP may contribute to host defense against
infection, function as a pro-inflammatory mediator, and participate in physiological and
pathophysiological handling of autologous constituents.65

3.4 Lifestyle Factors that can Impact Inflammation
3.4.1 Obesity and Inflammation
Increasing evidence indicates that obesity causes chronic low-grade inflammation,
which contributes to the development of obesity-associated disorders, mainly
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characterized by metabolic dysfunction.78,79 Excess adipose mass is associated with
increased levels of the pro-inflammatory marker CRP in the blood in children and adults.80
Furthermore, weight loss interventions in those who were previously obese lead to
reductions in the levels of pro-inflammatory proteins, including CRP.81–83
Adipose tissue is traditionally considered a long-term energy storage organ, but it
also functions as a key endocrine organ by releasing multiple bioactive substances, known
as adipose-derived secreted factors or adipokines, that have pro-inflammatory or antiinflammatory activities.78,84 The expression of adipokines varies depending on whether the
fat is stored in visceral or subcutaneous adipose tissues, as each of these sites produces a
unique profile of adipokines 85. The production of most adipokines is upregulated in the
obese state, and these pro-inflammatory proteins include: leptin, TNF, IL-6, resistin,
retinol-binding protein 4, lipocalin 2, IL-18, angiopoietin-like protein 2, CC-chemokine
ligand 2, CXC-chemokine ligand 5, and nicotinamide phosphor-ribosyltransferase.78 Among
these, leptin upregulates production of TNF and IL-6 by monocytes and increases the
production of the TH1-type cytokines IL-2 and IFN-, therefore acting as a proinflammatory adipokine.86 Tumor-necrosis factor is another pro-inflammatory cytokine,
mainly produced by monocytes and macrophages in visceral depots whose levels are
increased in adipose tissue and plasma of obese individuals, and reduced following weight
loss.87,88 Interleukin-6 increases transcription of CRP, and is positively associated with
adiposity in human populations.89 Similarly to CRP and TNF, increased levels of IL-6 are
seen in obese subjects, with weight loss leading to reduced IL-6 levels.83 Furthermore,
approximately one third of total circulating IL-6 is produced by adipose tissue.89
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Interleukin-18 is another pro-inflammatory adipokine produced by adipose tissue, whose
levels fall after obese subjects undergo weight loss.90

3.4.2 Estrogens and Inflammation
Studies conducted among users of exogenous hormones suggest that oral
contraceptive (OC) use 91,92 and orally administered hormone replacement therapy (HRT)
consistently elevate CRP, whether the preparation includes progesterone and estrogen or
estrogen alone.91,93 A study by Dreon (2003) comparing CRP levels in 18 OC users vs 12
non-OC users found that plasma CRP levels were twice as high among OC users compared
to non-OC users (2±0.2 vs 0.9 ±0.3 mg/L; p<0.001) independent of phase of menstrual
cycle. Furthermore, they found that in this group, OC use predicted 32% of the variance in
CRP levels (p<0.001).92 Even though exogenous estrogen has been demonstrated to
increase CRP, dose and delivery method appear to mediate this increase. Prestwood et al
(2004) found significantly higher CRP among women taking a higher estrogen HRT
preparation and significantly lower levels among women taking a lower estrogen
preparation; transdermally administered HRT has no observable effect on CRP.94,95
Studies examining the effects of endogenous hormones on CRP are inconsistent with
the trends shown for exogenous hormones. Jilma et al (1997) examined CRP changes in 18
women during the follicular phase, at mid-cycle, and in the luteal phase of one menstrual
cycle, and found that median CRP levels increased by 44% (p<0001) at mid-cycle and by
31% (p=0.002) in the luteal phase compared to the follicular phase.96 Additionally, they
found a significant association between an individual’s relative increase in CRP and
progesterone concentration from the follicular phase to mid-cycle (r=0.60, p=0.01) and
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from the follicular phase to the luteal phase (r=0.71, p=0.001).96 In a second study of
endogenous hormones, Blum et al (2005) examined 15 measures from 15 women across
one menstrual cycle, and found an inverse association between estrogen and CRP (β=-0.23,
p<0.001) such that a 10-fold increase in estrogen was associated with a 41% decrease in
CRP.97 A third study of the effects of endogenous hormones on CPR found a 10-fold
increase in progesterone to be associated with a 23% increase in CRP (p=0.01), a ten-fold
increase in estrogen was associated with a 29% decrease in CRP (p=0.05).98
Thus the effects of exogenous and endogenous hormones on CRP appear to differ:
exogenous estrogen at most doses is associated with elevations in CRP,91–93 whereas
endogenous estrogen seems to be correlated with lower CRP,97,98 conversely, exogenous
progesterone may be associated with decreases in CRP,99–101 whereas endogenous
progesterone seems to be associated with increases in CRP.96,98

3.4.3 Smoking and Inflammation
Environmental factors, such as smoking, have been reported to modify
inflammation progression, severity and outcome.102 Chronic inhalation of cigarette smoke
alters a wide range of immunological functions, including innate and adaptive immune
responses.103 Inflammatory mediators have been detected at higher levels in smokers in
several studies.104,105 A large scale analysis with 2,920 healthy men ages 60-79 found that
current cigarette smokers showed significantly higher levels of CRP (2.53 vs 1.35 mg/L)
compared with never-smokers.104 In women, Bermudez et al (2002) found higher levels of
plasma CRP in smokers enrolled in the Women’s Health Study compared to never smokers
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(3.80 vs 3.0 mg/L, p=0.032). 105 Therefore, the systemic inflammatory process appears
heightened in those who smoke compared to nonsmoking subjects.

3.4.4 Physical Activity and Inflammation
Cross-sectional studies show an inverse association between regular physical
activity and the serum concentration of inflammatory markers, suggesting that physical
activity may have anti-inflammatory properties. Pitsavos et al found that CRP levels
decreased with increasing physical activity in the ATTICA study, as sedentary subjects had
the highest CRP concentration (1.47±1.4 mg/dL), followed by those who reported lightmoderate physical activity (1.01±1.5 mg/dL); finally those with highest level of physical
activity had the lowest serum CRP (0.91±1.3 mg/dL; p=0.020).106 A study in older adults
measuring weekly caloric expenditure and inflammation found a dose-response
relationship between physical activity and CRP in the Cardiovascular Health Study.107 The
results from several cross-sectional studies suggest that physical activity and fitness are
associated with lower CRP levels.108 Furthermore, recent longitudinal studies suggest that
physical activity reduces CRP levels. A 2-year dietary and lifestyle intervention study in
postmenopausal women showed that serum CRP was reduced by 34% in obese
postmenopausal women; however, it is unclear as to whether the reduction in CRP was due
to weight loss, the physical activity or a combination of both.83 In a second longitudinal
study, Obisesan et al found a 15% reduction in CRP following a six-month exercise and diet
intervention, which did not result in weight loss.109
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3.4.4.1 Effect of type, duration, and intensity of physical activity on CRP levels
Despite limited evidence on the relationship between physical activity and CRP,
several studies have tried to ascertain the effect of type, duration, and intensity of physical
activity on inflammatory markers in healthy adults. For the mode of physical activity that
may most impact CRP, King et al (2003) found that activities such as jogging, swimming,
cycling, aerobic dance and weight lifting performed over 12 times per month were
associated with a lower likelihood of elevated CRP in adults ages 17-65 years old when
compared to non-exercisers using data from NHANES III.110 In particular, frequent jogging
and aerobic dance were associated with the lowest proportion of exercising individuals
with high CRP.110 This analysis was limited, however, by the inability to assess differences
in duration or intensity of each activity. Albert and colleagues assessed the baseline
frequency of physical activity in adults participating in the Pravastatin Inflammation/CRP
Evaluation (PRINCE) study, a multicenter community-based study.111 They created 4
groups of physical activity based solely on frequency: less than once per week, once per
week, 2-3 times per week, and 4 or more times per week; they found that CRP levels
decreased progressively with increasing levels of physical activity frequency (p-trend
<0.001). 111 In order to assess the relationship between intensity of physical activity and
CRP levels, Pitsavos et al (2003) studied leisure-time activities such as walking, cycling,
running, swimming, etc, in healthy adults ages 18 and older from the ATTICA study.106 They
found that among individuals who claimed to exercise at least once a week, a high exercise
intensity (7 kcal/minute or more) was associated with a 38% decrease in CRP levels
compared with light exercise intensity (<4 kcal/min. 106 With regards to overall duration of
physical activity, the minimum length of time observed associated with lower CRP levels in
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longitudinal studies has been 2 months.108,112 Geffken et al (2001) observed that 3-4 days
of physical activity per week, for 40-80 minutes per day at an intensity of 70-80% of
V02max can lower CRP levels in as little as 2 months in a healthy elderly population.107
Despite all the limitations encountered, there is sufficient evidence to suggest that physical
activity lowers inflammatory biomarkers such as CRP in a variety of settings and
populations.

3.4.5 Sleep and Inflammation
Inadequate sleep and sleep deprivation cause several neurobehavioral and
physiological changes, including increases in a range of inflammatory markers. 216 Chronic
sleep disruption is regarded as a physiological stressor that can impair brain function217
and raises pro-inflammatory cytokines by inducing a functional alteration of the
proinflammatory cytokine response in monocytes, which is greater among females
compared to males. 218

3.4.6 Other correlates of CRP
Among individuals not experiencing infection, CRP concentrations may vary with
many additional factors.98 In adults, CRP has been found to be positively associated with
age113 and negatively associated with birth weight.114 Adult females have higher CRP than
males113,115 Furthermore, some component of variation in circulating levels of CRP may be
heritable: estimates of heritability between 30% and 50% have been suggested.116,117
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3.5 Physiology of Inflammation and Depression
Depression is a complex condition, and it is likely that alterations in multiple
interacting systems underlie its pathogenesis.118 Therefore, numerous hypotheses have
been proposed to elucidate its origins. One of these is the inflammatory hypothesis, initially
called the macrophage theory of depression,119 presently also known as the malaise or
cytokine theory of depression.120,121 This inflammatory hypothesis emphasizes the role of
psycho-neuroimmunological dysfunctions, which is based on several observations. The
first one of these observations noted is that subsets of patients with major depression have
an altered peripheral immune system, with impaired cellular immunity and increased
levels of pro-inflammatory cytokines, including IL-6 and CRP.122,123 Furthermore,
postmortem gene analyses in the prefrontal cortex of patients who had major depression
have suggested up-regulation of various pro and anti-inflammatory cytokines.124 It is now
known that cytokines can cross the blood-brain barrier and induce inflammation in the
central nervous system and can influence neurotransmitter metabolism, neuroendocrine
function and regional brain activity, all of which are relevant to depression.63

3.5.1 Cytokine Administration Induces Depression
It has been noted that chronic therapeutic administration of cytokines, mainly
interferon-alpha (INF-α) for hepatitis C virus infection or cancer, can lead to depressive
symptomatology in up to 50% of patients who will meet the criteria for major depression
within 3 months of starting therapy;125 up to 90% receiving this therapy will display at
least one or two significant depressive symptoms.126 Therefore, INF-α-induced depression
has been used as a model to identify the specific changes in the immune system that may
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play a role in the development of behavioral changes leading to depression.127 INF-α is a
cytokine released by the innate immune system in response to viral infections; it has been
shown to induce IL-6 production, which stimulates CRP production. Additionally, some
evidence indicates that INF-α induced depression can be prevented and/or treated using
selective serotonin reuptake inhibitor (SSRIs).125 Therefore, there is evidence supporting
the directionality of inflammation leading to depression.

3.5.2 Cytokines Alter Neurotransmitter Metabolism
Numerous human and laboratory animal studies have demonstrated that multiple
neurotransmitter systems, including monoamines, serotonin, dopamine, and glutamate, are
affected by acute and chronic administration of cytokines.121 Serotonin has been the most
studied neurotransmitter with regards to inflammation and depression. INF-α has been
shown to attenuate the expression of 5HT1A, a serotonin receptor.128 Patients treated with
INF-α have decreased serum serotonin, and this has been more pronounced in those who
developed depression.129 Moreover, INF-α -associated increases in cerebrospinal fluid
(CSF) levels of IL-6 have been inversely associated with the serotonin metabolite 5hydroxyindoleacetic acid (5-HIAA), indicating lowered brain serotonergic activity.130 The
exact pathway affected is not clear, but it is know that the enzyme indoleamine 2,3dioxygenase (IDO) is activated by various cytokines alone or in combination.131 IDO
catabolizes tryptophan, the primary amino acid precursor of serotonin, into kynurenine.
Evidence of a role of IDO in cytokine-induced depression comes from several studies that
demonstrated correlations between INF-α-induced depression and decreases in
tryptophan accompanied by an increase in kynurenine and/or the kynurenine to

25

tryptophan ratio.131 Although much of the attention regarding IDO was initially focused on
the depletion of tryptophan and therefore, of serotonin, several lines of evidence have
started to challenge this pathway, and have focused more on the presence of increased
kynurenine and its metabolites for immune-induced depression.131

3.5.3 Effects of Inflammation on Neurogenesis and Neurotrophic Factors
Pro-inflammatory cytokines can influence neuronal functioning through changes in
apoptosis, oxidative stress, and metabolic derangement, as well as by impairing processes
of synaptic plasticity and neurogenesis.120,132 In humans, treatment with INF-α has been
associated with reduced levels of peripheral brain-derived neurotrophic factor (BDNF),
which are known to correlate well with BDNF availability in the CNS.133,134 Furthermore
reduced BDNF during INF-α treatment has been found to correlate with increased
depression.134
Figure 1: Potential mechanisms linking inflammation to depression.
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3.6 Epidemiology of Inflammation and Depression in Women
Research on the association between inflammation and depression has mainly
focused in elderly populations, but recent studies have included younger adults, children,
and different at-risk populations, such as pregnant or post-partum women. The first large
cross-sectional study to analyze the association between CRP and depression in a
nationally representative sample using NHANES included 6,914 non-institutionalized men
and women ages 18-39 years old (women sample size: 3,760). 55 Employing the Diagnostic
Interview Schedule (DIS) depression questionnaire to assess depression, which was
categorized into recurrent depression and severe depression within the last year and
within their lifetime. Ford and colleagues found a higher proportion of women
experiencing lifetime depression (11.7% vs 5.7%) compared to men. CRP was
dichotomized at the limit of detection (0.21 mg/dL), and labelled as “low CRP” and “high
CRP”. Almost a third (27.3%) of women were found to have high CRP levels compared to
only 13% of men. A history of major depression was associated with elevated CRP level
(OR: 1.64, 95%CI 1.20, 2.24) in both men and women. When stratified by gender, no
significant associations were found between depression and inflammation in women (past
year depression OR=0.76, p=0.33; history of depression OR= 1.39, p=0.24). Among men,
CRP levels were significantly higher in those experiencing a recent episode of depression
(OR=3.00, 95% CI 1.39-6.48) and those with recurrent depression (OR= 3.55, 95% CI 1.558.14) compared to their non-depressed counterparts.55 Despite having a large, nationally
representative sample size, this study was limited by the low sensitivity of the CRP
concentration detected by their assay, as 74.1% of the population fell below the limit of
detection (0.21 mg/dL), therefore the study was forced to categorize CRP levels into
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low/high based on the limit of detection (low CRP: <0.21 mg/dL and high: >0.21 mg/dL). In
addition to the cross-sectional limitation of the study design, the severity of depression was
not determined since the depression questionnaire only assessed the presence of major
depression disorder in a yes/no manner, limiting the potential to assess the degree to
which inflammation may be contributing to depression.
In another study, Matthews et al. (2010) assessed the bi-directionality of the
relationship between depression and CRP in the prospective Study of Women’s Health
Across the Nation (SWAN) over a 7-year period.135 The Center for Epidemiological Studies
Depression scale (CES-D) was used to assess depressive symptoms during the previous
week in 1,781 women ages 42-52 years old on a yearly basis. Using multivariable
longitudinal linear mixed regression model (woman-specific), they found that initial higher
depression scores at time X predicted higher subsequent CRP levels and vice-versa over a
7-year period. After adjustment for BMI, physical activity, medications, and health
conditions, higher CRP levels at year X significantly predicted higher depression scores in
the subsequent year (p=0.03). Higher depressive symptoms also predicted higher CRP in
the following year, but this association was not significant (p=0.10). In other words, they
found that CRP remained a modest, yet statistically significant, predictor of subsequent
depressive symptoms one year later, whereas the reverse association (depression as
predictor of inflammation) only approached significance. Despite it being a strong study
with multiple measurements of each exposure and outcome, and an ethnically-diverse
population, this study was limited by its inclusion of only an older sample population of
women. This is an important study because it sheds light on the directionality of this
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association, suggesting that among women, inflammation is a predictor of depression, and
not the other way around.
Gimeno et al. (2008) assessed whether CRP predicted cognitive symptoms of
depression or whether the symptoms of depression predicted inflammatory markers in the
Whitehall II study in London.136 Participants consisted of office staff ages 35-55 from 20
different London-based civil service departments. Baseline measurements took place in
1991-1993, and follow-up assessment took place in 2002-2004 (mean follow-up was 11.8
years). They excluded those with CRP >10 mg/L and those who reported a cold or flu in the
2 weeks prior to assessments. The remaining sample size included 5,978 participants
(1,803 women) for baseline and 3,339 for follow-up (951 women). At baseline, women had
significantly higher levels of both CRP and cognitive symptoms of depression compared to
men (CRP: 0.91±3.2 vs 0.77±3.0 mg/L; p<0.001; Depression score: 1.17±1.9 vs 0.95±1.7;
p<0.001, respectively). However, in the cross-sectional analyses at baseline of
inflammation and cognitive symptoms of depression, CRP (β=-0.067, p=0.011) was
negatively associated with cognitive symptoms of depression among women, but not
among men (p for sex interaction=0.025). In longitudinal analyses of CRP and cognitive
depression score, the association was statistically significant for the whole group (β=0.046,
p=0.004). When the analysis was stratified by gender, men had a slight positive and
significant association between CRP and depression (β=0.058, p=0.002), but this was no
longer significant in women (β=0.02, p=0.522). It must be noted that 2,388 men were
included in this analyses, whereas only 951 women were included. Additionally, they
showed that cognitive symptoms of depression at baseline did not predict CRP levels at
follow-up (β= -0.013, p=0.341) for either gender.136
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Some of the limitations of this study include an older sample population (mean age
for women was 50.4±6.1 years) and no mention of menopausal status of the women,
allowing for the possibility that menopausal state could bias the results towards the null, as
younger women (including women with menstrual cycles) tend to have higher depression
rates. Furthermore, for the longitudinal analysis, the long follow-up time (11.8 years) could
actually be too long to be able to detect a true predictive association between inflammation
at baseline and depression at follow-up.
Overall, Ford et al found a significant association between lifetime history of major
depression and elevated CRP levels in a nationally representative sample of US adults with
a cross-sectional analysis.55 In longitudinal analysis, two studies found that inflammation
predicts depression, but that depression does not predict inflammation.135,136 There is
growing evidence that nutrition could be playing a very important role in both
inflammation and the development or severity of depression, and none of the previous
studies accounted for any biomarkers of nutritional status.
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CHAPTER 4
NUTRITIONAL STATUS: EMPHASIS ON VITAMINS D AND B6

4.1 Micronutrients of Interest - Introduction
Micronutrient status plays an important role in maternal and child health. Both
vitamin D and B6 are considered micronutrients with a surprisingly large prevalence of
insufficiency and deficiency in the female U.S. population, which can lead to increased risk
of disease. This chapter will review the epidemiology of each micronutrient in the U.S. with
an emphasis on women of reproductive age, followed by background information on
metabolism, transport, food sources, and assessment of each. The association between each
micronutrient and inflammation as well as depression will also be reviewed.

4.1.2 Epidemiology of Vitamin D Status in the US
According to the National Center for Health Statistics, in 2001-2006, one third of
individuals aged 1 year were at risk for vitamin D inadequacy or deficiency.141
Furthermore, a recent publication using NHANES data shows that mean serum 25-hydroxy
vitamin D (25-OHD) was lower in 2000-2004 compared to 1988-1994, suggesting a decline
in either consumption of vitamin-D containing foods, cutaneous vitamin D synthesis, or
both.141
For women of childbearing age, maternal vitamin D malnutrition imposes multiple
health impacts on both women and their offspring.142 Women with suboptimal vitamin D
status are at increased risk for pre-eclampsia and eclampsia, gestational diabetes, and
bacterial vaginosis.142 Furthermore, vitamin D deficiency during pregnancy or in the
postpartum period has been associated with increased risk of rickets, type 1 diabetes,
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allergies, asthma, and schizophrenia in the offspring as well as maternal depression.143 The
potential consequences of vitamin D deficiency in women of reproductive age is
particularly troublesome considering that a large proportion of this population within the
U.S. has suboptimal levels of circulating vitamin D. Recent estimates found that
approximately 78% of women have vitamin D insufficiency and 42% have vitamin D
deficiency.144 Additionally, these proportions vary by ethnicity: vitamin D levels are much
lower in non-Hispanic Blacks, followed by Hispanics, and non-Hispanic White females.
Eighty-six percent of African American women have vitamin D deficiency, followed by 60%
of Hispanic and 26% of non-Hispanic White women. With regards to insufficiency, 99%,
93% and 69% of non-Hispanic Blacks, Hispanics, and White women, respectively, have
suboptimal levels of circulating vitamin D. 159,219

4.2 Background on Vitamin D
Vitamin D is both a hormone and a vitamin, known to have many functions in health
maintenance and disease prevention. The term vitamin D refers collectively to the two
major nutritionally relevant forms: vitamin D3 or cholecalciferol, which is formed in the
skin following exposure to sunlight or ultraviolet light, and ergocalciferol or vitamin D2
which is obtained by irradiation of plants, phytoplankton, yeast, invertebrates, and fungi
containing ergosterol.145

4.2.1 Uptake of Dietary Vitamin D
Due to the fat-soluble nature of vitamin D, it is absorbed with other lipids in the
intestine, a process facilitated by bile and pancreatic lipase. Following absorption, vitamin
D is integrated into chylomicrons and enters the lymphatic system, which drains into the
32

main circulation. Lipoprotein lipase, particularly in adipose tissue, acts upon chylomicron
lipids and may result in a portion of the vitamin D being taken up by fat cells. This
observation suggests a mechanism whereby increased adiposity causes sequestering of
vitamin D and is related to lower vitamin D status. 220 Vitamin D sequestration in adipose
tissue is a nonspecific process, and these stores may not be actively used in periods of
need.220 After depletion of triacylglycerols, the cholesterol-rich chylomicron remnants,
which still contain a significant fraction of the absorbed vitamin D, are taken up by the
liver.

4.2.2 Endogenous Synthesis of Vitamin D
Most vitamin D in serum comes from endogenous production in human skin, from
the precursor, 7-Dehydrocholesterol (7-DHC). Following exposure to sunlight, 7-DHC in
the skin absorbs ultraviolet B (UVB) photons between the wavelengths of 290-320nm and
is converted to pre-vitamin D3.221 At normal body temperature, pre-vitamin D3 undergoes
thermal isomerization to form vitamin D3, which is more easily translocated from the skin
cells to the bloodstream. In circulation, vitamin D3 travels bound to a specific α1-globulin
known as vitamin D-binding protein (DBP), the major plasma carrier of all vitamin D
metabolites. This complex then travels to the liver, where vitamin D metabolism starts.
Toxic levels of vitamin D do not occur from prolonged sun exposure, which degrades into
many inactive forms, such such as lumisterol and tachysterol. 222

4.2.3 Metabolism of Vitamin D
Vitamin D, as either D2 or D3, is considered biologically inactive until it undergoes
two enzymatic hydroxylation reactions. Circulating vitamin D2 or D3 in chylomicron
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remnants, as well as vitamin DBP-bound vitamin D3 from endogenous synthesis, are first
taken up by the liver and hydroxylated by hepatic 25-hydroxylase (25-OH-ase) from the
CYP27A gene to form 25-hydroxycholecalciferol (25-OHD). 25-OHD then circulates in the
blood stream as a complex with DBP, and when the active form of vitamin D is required due
to decrease in serum calcium or phosphate, 25-OHD is further hydroxylated by 1αhydroxylase (CYP27B1) in the kidneys. 223 This second hydroxylation converts 25-OHD to
the biologically active form: 1,25-dihydroxyvitamin D (1,25-[OH]2D), also known as
calcitriol. The 1α-hydroxylase gene is also expressed in several extra-renal tissues, but its
contribution to the formation of the active form of vitamin D in these tissues is unknown.
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The enzymatic reaction producing 1,25-(OH)2D is tightly regulated by two

counteracting hormones: up-regulation by parathyroid hormone (PTH) and downregulation via fibroblast-like growth factor-23 (FGF23).225 This control of vitamin D
activation constitutes the basis of the vitamin D endocrine system that is central to
maintaining calcium and phosphate homeostasis. Following its synthesis in the kidney,
calcitriol binds to DBP to be transported to target organs. Catabolism of 1,25(OH)2D to
more polar and readily excretable inactive metabolites, 24,25(OH)2D and 1α, 24,25(OH)2D,
begins with the 24-hydroxylation of either 25-OHD or 1,25(OH)2D, respectively. Calcitriol
induces its own destruction by stimulating these enzymes.226

4.2.4 Assessment of Vitamin D Status
Both 25-OHD and 1,25(OH)2D levels can be measured in serum or plasma.227
However, circulating 25-OHD concentration is the best biomarker of vitamin D status
because it reflects both increases in vitamin D intake and cutaneous production of vitamin
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D3. Serum 25-OHD also has a longer half-life of approximately 15 days compared to the
shorter half-life of 4-6 hours for 1,25(OH)2D.168 Furthermore, serum 1,25(OH)2D
concentration is tightly controlled by PTH, calcium, and phosphate,168 and levels do not
typically decrease until vitamin D deficiency is severe. 228
The serum vitamin 25-OHD concentrations used to define deficiency, marginal
deficiency, normal ranges, and toxic levels are somewhat controversial. Table 1 shows the
Institute of Medicine (IOM)-proposed cut-offs for assessing vitamin D sufficiency,
deficiency, and toxicity using serum 25-OHD concentrations. While these cutoffs serve as
the more “traditional” reference guidelines, literature on the topic suggests that the optimal
serum concentration of 25-OHD is probably much higher than the recommended
concentration for adults. Table 2 shows the proposed alternate 25-OHD reference limits
considered “acceptable” by leading researchers in the field. 229,230

Table 1. Institute of Medicine (IOM) Rec 1
Table 1: Institute of Medicine (IOM) Recommended
Serum 25-Hydroxyvitamin D (25-OHD)

25-OHD level
(ng/mL)*

25-OHD Level
(nmol/L)**

Health Status

<12

<30

Associated with vitamin D deficiency, leading to
rickets in children and osteomalacia in adults

12 to 20

30 to 50

≥20

≥50

>50

<125

Generally considered inadequate for bone and
overall health in healthy individuals
Emerging evidence links potential adverse effect
to such high levels, particularly >150 nmol/L
(>60 ng/mL)

Source: Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for
Calcium and Vitamin D. Washington, DC. National Academy Press, 2010.
*Serum concentrations of 25-OHD are reported in both nanomoles per liter (nmol/L)
**1ng/mL = 2.496 nmol/L
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Table 2: Alternate Recommendation of Different Levels of Serum 25-OHD
25-OHD Level
(ng/mL)*

25-OHD Level
(nmol/L)**

Health Implication

<20

50

Deficiency

20-29.9

50-75

Insufficiency

≥30

>75

Sufficiency

>150

>374

Intoxication

Source: Holick, Michael F. Vitamin D Deficiency. N Engl J Med 2007; 357:266-281
*Serum concentrations of 25-OHD are reported in both nanomoles per liter
(nmol/L) and nanograms per milliliter (ng/mL).
**1ng/mL = 2.496 nmol/L

4.2.5 Factors Affecting Vitamin D Status
Many variables can affect cutaneous synthesis of vitamin D, making it a challenge to
estimate average 25-OHD levels produced by sun exposure in North America.231 Cutaneous
synthesis of vitamin D is affected by the amount of solar UVB radiation that reaches the
earth’s surface, which depends on latitude, season of the year, and time of the day of sun
exposure. At latitudes above 40o N below 40o S, the amount of vitamin D synthesized
between November and February is extremely low because vitamin-D producing UVB
photons pass through the ozone layer at an oblique angle, causing many to be absorbed by
the ozone. More UVB photons penetrate the ozone layer in the spring, summer, and fall
months because the sun is directly overhead. Studies suggest a seasonal change in serum
25-OHD concentrations between the winter nadir and the summer zenith of approximately
25 nmol/L.231
The cutaneous synthesis of vitamin D, and its contribution to serum vitamin D
levels, also depends upon the presence of 7-DHC in the skin. Aging, melanin pigmentation,

36

clothing, and use of sunscreen also affect cutaneous synthesis. 232 Aging decreases the
synthesis of 7-DHC in skin, thereby reducing the production of vitamin D3 by approximately
75% by age 70 years compared to younger adults. 232 The skin pigment melanin is a
natural sunblock that competes with 7-DHC for UVB photons, therefore, darker-skinned
persons require a much longer sun exposure in order to make the same amount of vitamin
D as lighter-skinned individuals.233 Using sunscreen and wearing clothing that completely
covers the body can also block UVB photons, reducing vitamin D synthesis. 240
Obesity can affect the amount of dietary vitamin D that reaches the liver. While in
chylomicrons, a portion of dietary vitamin D is sequestered in adipose tissue in a
nonspecific manner, and these stores may not be actively used in periods of need. This
suggests a mechanism whereby increased adiposity causes sequestering of vitamin D and is
related to lower vitamin D status. 220 Therefore, obese individuals may require higher
intakes of vitamin D to achieve serum concentrations of 25-OHD comparable to those
observed among lean individuals. For instance, Blum et al (2008) supplemented elderly
subjects with 700 IU daily for a year, and found that serum levels of 25-OHD were
approximately 10 nmol/L lower for every additional 15 kg of weight above “normal”. 235
Available literature demonstrates that serum 25-OHD levels increase in response to
increased vitamin D intake, although overall, it can be concluded that the relationship is
non-linear rather than linear. A summary of 16 human trials suggested the following
association between dietary vitamin D and 25-OHD concentration: for each additional 100
IU of vitamin D3, serum 25-OHD concentrations increased by 1 to 2 nmol/L.236 However,
this increase of serum 25-OHD differs based on the starting 25-OHD concentrations. Chung
et al (2009) confirmed the association between increasing doses of vitamin D and
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increasing net change in serum 25-OHD concentration in both adults and children, but
concluded that the dose-response relationships differ depending on the subjects’ baseline
serum 25-OHD levels (≤40 vs >40 nmol/L) and duration of the supplementation (≤3 vs >3
months).237 There is evidence that increasing serum 25-OHD level above approximately 50
nmol/L requires more vitamin D intake than does increasing serum 25-OHD levels when
the starting point is less than 50 nmol/L.238 Furthermore, there have been reports that the
rise in serum 25-OHD level for a given dose tends to stabilize by week 6 and does not vary
with age at least up to 80 years of age. 239

4.2.6 Dietary Sources & Recommended Dietary Allowance for Vitamin D
The dietary sources of vitamin D include food and dietary supplements. Very few
foods naturally contain vitamin D3. These include egg yolks and oily fish, such as salmon,
mackerel and herring and liver oils from cod, tuna and shark. 173 Sun-dried mushrooms
also contain some vitamin D2. In the United States, the foods fortified with vitamin D (D2 or
D3) include milk, breads and cereals, margarine, yogurts and cheeses, and some brands of
orange juice.173
In recent years, dietary supplements containing vitamin D have become more
common and have been more frequently consumed. 173 Traditionally, many supplements
have contained 400 IU per daily dose, but levels in supplements have been increasing and
can be found in the range of 1,000 to 5,000 IU of vitamin D3 per dose and even up to 50,000
IU of vitamin D2 per dose.173 Recent findings suggest that vitamin D3 may be more efficient
at increasing serum 25-OHD levels compared to vitamin D2.240
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The current recommended dietary allowance (RDA) is the daily dose that should
meet the nutritional needs of 98% of healthy individuals in the US for a specific nutrient.
The RDA for vitamin D represents a daily intake that is sufficient to maintain normal
calcium homeostasis and bone health in healthy individuals with minimal sun exposure.
RDAs for vitamin D vary by age and gender. For women of reproductive age (14-50yrs), the
RDA is set at 600 International Units (IUs) (15micrograms) per day.173

4.2.7 Biological Activities of Vitamin D
1,25(OH)2D is considered the biologically active hormonal form of vitamin D
responsible for carrying out most, if not all, of the biological functions of vitamin D. The
biological actions of 1,25(OH)2D involve regulation of gene expression at the
transcriptional levels and are mediated through binding to a vitamin D receptor (VDR),
located primarily in the nuclei of target cells. 241 Until recently, the main known role of
vitamin D was to control bone metabolism and calcium and phosphorus homeostasis. But
in the past decade, the VDR has been discovered in many tissues throughout the body (e.g.
gut, kidney, gonads, heart, muscle, brain, and skin), implying that 1,25(OH)2D may play a
role in these organs. Furthermore, the specific vitamin D-responsive elements (VDREs)
considered the hallmark of vitamin D action are present in a large number of human genes
involved in a wide range of roles, such as modulation of cell growth, 242 neuromuscular243
and immune function, including and reduction of inflammation, 244 to mention a few.
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4.3 Vitamin B6
4.3.1 Epidemiology of Vitamin B6 Status in the US
A recent cross-sectional study on vitamin B6 status in the US population found that
regardless of vitamin B6 supplementation, plasma Pyridoxal-5’phosphate (PLP) – the
principal biomarker of vitamin B6– of women of childbearing age was significantly lower
than those of comparably aged men. A fourth of women in the U.S. have insufficient vitamin
B6 levels as defined plasma PLP levels <20 nmol/L.137 Among oral contraceptive users,
seventy-five percent were found to have suboptimal vitamin B6 levels (Morris et al, 2008).
These statistics are worry-some considering that maternal vitamin B6 levels may affect the
neurological development of their offspring.138 Furthermore, clinical studies have shown
that suboptimal vitamin B6 status decreases probability of conception139 and increases risk
of pregnancy complications, including spontaneous abortions.140

4.3.2 Vitamin B6: Background
Vitamin B6 is a water-soluble vitamin that functions as a coenzyme in over 100
enzymatic reactions involved in the metabolism of amino acids, carbohydrates,
neurotransmitters and lipids.146 As of recently, it has also been coined a potent antioxidant
that effectively quenches reactive oxygen species.147 Vitamin B6 currently refers to a
collective of six biologically interconvertible 3-hydroxy-2-methylpyridine compounds:
pyridoxine (PN), pyridoxal (PL), pyridoxamine (PM) and their respective 5’-phosphates:
PNP, PLP and PM.148 In addition to the 6 forms of vitamin B6, there also is a glucoside form
of pyridoxine that exists in variable amounts in plant foods.149

40

The most abundant and biologically active form of vitamin B6 is PLP, serving as a
coenzyme in numerous biological processes that include tryptophan-niacin conversion,
heme synthesis, gluconeogenesis, neurotransmitter synthesis, and amino acid
metabolism.150 Given PLP’s wide range of functions, deficiency of vitamin B6 can have
serious and diverse physiologic effects, including microcytic anemia, seborrheic dermatitis,
epileptiform convulsions, depression, and confusion.148
Although vitamin B6 is widely available in food such as fortified cereal products,
fruits, vegetables, nuts, beans, legumes, and animal products, recent literature suggests that
a larger portion of the population than previously thought may be at risk for low vitamin B6
status, specifically women of childbearing age.137 This review will provide background on
vitamin B6, its sources, metabolism, assessment in humans, and its connection with
inflammation.

4.3.3 Dietary Sources, Intake & DRI for Vitamin B6
Vitamin B6 is widely available in foods such as whole grain products, meat, fish,
poultry and non-citrus fruits in the American diet. Other rich sources include highly
fortified cereals, beef liver, and other organ meats.148 The major forms in animal tissue are
the coenzyme species PLP and PMP. In most fruits, vegetables and cereal grains, a
significant fraction of vitamin B6 is pyridoxine-5’-β-D-glucoside, a form that is partially
available as a source of vitamin B6.146 Vitamin B compounds, particularly PL and PLP, are
light sensitive; furthermore large losses of food vitamin B6 can occur during heating and
leaching of the vitamin during food preparation.148
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The adequacy of vitamin B6 nutrition depends on the quantity of dietary B6
consumed as well as its bioavailability, defined as the extent of intestinal absorption and
metabolic utilization.146 Vitamin B6 is absorbed in the small intestine by a non-saturable
passive diffusion mechanism.148 The bioavailability of B6 supplements or fortified foods in
the form of pyridoxine is roughly 90%, whereas in the rest of non-fortified sources, it
depends on the form of B6; bioavailability of non-glucoside forms of the vitamin in food is
greater than 75% and the bioavailability of pyridoxine-5’-β-D-glucoside in food is about
half as much.146

4.3.4 Dietary Reference Intakes for Vitamin B6
The main criterion used in setting the estimated average requirement (EAR) for
vitamin B6 is plasma PLP value of at least 20 nmol/L.151 The EAR for vitamin B6 is 1.1 mg
per day for adults ages 19-50 years old, and the RDA is 1.3 mg/day or 20% more than EAR
to allow for variance in need.148 Data from NHANES 2001-2002 showed the median
vitamin B6 dietary intake of U.S. women (19 years or older) is 1.45 mg/day. Intake of
women ranges (5th to 95th percentile) from 0.79 to 2.51 mg/day. Recent evidence shows
that a higher RDA may be prudent, especially for women. Data from NHANES 2003-2004
suggests that a daily vitamin B6 intake of 3.0 to 4.9 mg/day is generally adequate to
maintain an acceptable plasma PLP concentration, but a large portion of women of
childbearing age, do not maintain adequate vitamin B6 status at that intake level.137

4.3.5 Vitamin B6 Metabolism
After consumption, the phosphorylated vitamers are dephosphorylated in the
intestinal mucosa, and are absorbed rapidly by carrier-mediated diffusion.152 Most of the
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absorbed non-phosphorylated B6 is taken up by the liver and metabolized to PLP, the major
co-enzymatic form.148 PN, PL, and PM are converted to their respective 5’-phosphate
derivatives by the enzyme PL kinase, which is present in all tissues, including erythrocytes.
Non-phosphorylated forms of vitamin B6 can move freely in and out of tissues, whereas
phosphorylation ensures metabolic trapping. Tissue concentrations of pyridoxal phosphate
are controlled by the balance between phosphorylation and de-phosphorylation.152 Free
pyridoxal either leaves the cells or is oxidized to 4-pyridoxic acid by aldehyde
dehydrogenase (which is present in all tissues) and also by hepatic and renal aldehyde
oxigenases.152 4-Pyridoxic acid is the inactive excretory metabolite, which is actively
secreted by the renal tubules.
At high intakes of vitamin B6, tissue-binding capacity may be exceeded and the free
PLP is rapidly hydrolyzed to the non-phosphorylated PL, which is released by the liver and
other tissues into circulation. However, product inhibition of the PNP oxidase by PLP
renders the relationship between PN intake and PLP concentration in tissues and plasma
non-linear.148

4.3.6 Vitamin B6 Transport and Turnover
Under normal conditions, most circulating vitamin B6 is present as PLP that is mainly
Schiff base-linked to proteins, primarily albumin in plasma and hemoglobin in
erythrocytes. Although 90% of vitamin B6 is plasma is present as PLP, the total is less than
0.1% of the total body vitamin B6.153 Estimates of total body vitamin B6 stores in healthy
adults range from approximately 400 µmol to 1,000 µmol (60 to 170 mg), and 80% to 90%
of this is in muscle, primarily bound to glycogen phosphorylase.148 The overall body half-
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life of vitamin B6 is estimated to be roughly 25 days, with an estimated daily fractional
turnover rate of less than 3%. However, this half-life could be longer given the slow
turnover of the large pool of B6 bound to glycogen phosphorylase.148

4.3.7 Assessment of Vitamin B6 Status
A variety of biochemical indicators have been used to assess vitamin B6 status. Even
though vitamin B6 status is most appropriately evaluated using a combination of direct (i.e.,
vitamin concentration in plasma or cells) and indirect (i.e., erythrocyte amino transferase
saturation by PLP or tryptophan metabolites),153 plasma or serum PLP may be the best
single indicator because it is a reflection of liver PLP and thus tissue stores.154 Circulating
PLP concentration is normally measured by an enzymatic assay using the apoenzyme form
of tyrosine decarboxylase or by high performance liquid chromatography.148
A plasma or serum PLP level of less than 20 nmol/L is considered to reflect
inadequate vitamin status in adults, although some support a threshold of 30 nmol/L for
assessing sufficiency.148 However, there is no definite consensus for a value that
unquestionably defines a deficient state of this nutrient.155 Plasma PLP increases
approximately 12 nmol/L for each 1 mg/day increase in vitamin B6 intake.137 Indicators
for assessing vitamin B6 status are shown in the table below (table 3).153
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Table 3: Vitamin B6 Biomarkers.

Source: McCormick, D. B. in Present Knowledge in Nutrition 1, 269–277 (International Life Sciences Institute, 2006).

4.3.8 Factors that Can Affect Vitamin B6 Status
There are several factors that have been shown to decrease plasma PLP status,
including smoking, certain medications, oral contraceptives or hormone replacement
therapy, pregnancy, renal failure, alcoholism and inflammation.197,198 Vitamin B6 deficiency
my result from the prolonged use of drugs that are carbonyl-trapping reagents, and can
form biologically inactive adducts with pyridoxal and pyridoxal phosphate.152 Such
compounds include penicillamine, the antituberculosis drug isoniazid, and the antiParkinsonian drugs benserazide and carbidopa.
Several studies have found smokers to have lower plasma PLP levels presumably
linked to smoker’s increased inflammation levels.137,157,158 With regards to alcohol intake,
despite alcoholism being associated with nutritional deficiency of B-vitamins, a recent
study found alcohol intake to be positively associated with higher plasma PLP in the Boston
Puerto Rican Health Study.157
Plasma PLP decreases during pregnancy more than can be accounted for by
increased blood volume, with the most significant drop in the third trimester.159 This
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reduction in plasma PLP may represent a normal physiological change in pregnant women
as there have been no reports of clinical symptoms of deficiency in pregnant women with
decreased status.159 There may be several reasons for this decrease, including fetal
sequestration of plasma PLP or a shift in maternal distribution in favor of erythrocytes over
plasma.153,160 However, Barnard and colleagues (1987) have shown that, despite the fall in
plasma PLP in pregnancy, the plasma concentration of PLP plus pyridoxal is unchanged.161
Renal failure and other conditions in which plasma alkaline phosphatase is elevated (i.e.,
pregnancy and metabolic bone disease) are associated with low plasma PLP and a
corresponding increase in pyridoxal.153
Obesity has also been noted to affect vitamin B6 status. In a cross-sectional study of
morbidly obese adults in Norway, several vitamins including plasma B6, vitamin C, vitamin
D and vitamin E, were found to be lower in morbidly obese men and women compared to
healthy controls.162 Given that obesity is a state of chronic low-grade inflammation, it
could be contributing to compromised B6 status via inflammation. Plasma PLP is also
affected by acute phase responses, such as in inflammation and infection.163 This
association will be further discussed in the following sections.

4.3.8.1 Estrogens and Vitamin B6 Status
The connection between vitamin B6 status and oral contraceptive use was first
noted by Rose in 1966, when increased urinary excretion of xanthurenic acid, kynurenine,
and 3-OH-kyurenine was observed following a tryptophan load test.164 Several studies
followed with similar findings, where supplementation with high doses of vitamin B6 in the
form of pyridoxine hydrochloride corrected the abnormal tryptophan metabolism in
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women taking OCs.165–167 Although these studies may appear as evidence of estrogeninduced vitamin B6 deficiency or depletion, when other indices of vitamin B6 nutritional
status were measured, they seemed to be unaffected by contraceptive use, suggesting an
effect on tryptophan metabolism, rather than on vitamin B6 nutritional status.152 These
studies led to a general consensus that estrogen disrupts tryptophan metabolism
independent of vitamin B6 status, rendering the tryptophan load test a poor indicator of
vitamin B6 status in OC users.168
Although the association between OC use and tryptophan metabolism is well
established, the potential effect of OC use on vitamin B6 status and requirements remains
controversial.169 In a recent large-scale population-based study performed in the U.S. using
the NHANES 2003-2004 cycle, plasma PLP concentration was found to be significantly
lower (<20 nmol/L) in 75% of OC users who were not supplementing with vitamin B6.137
Morris and colleagues also assessed current vitamin B6 intake and suggested that intakes
higher than the current RDA may be necessary to maintain adequate vitamin B6 status in
OC users.137 In another cross-sectional study in Italy, women who had not been taking OCs
for at least 12 months had significantly higher vitamin B6 levels compared to current OC
users.170 In a prospective studies of OC use and vitamin B6 status, an initial lowering of
plasma PLP levels was observed three months after start of OC use; however, plasma PLP
levels returned to pre-treatment levels by six months of OC use.171 These findings suggest
that the effects of OC use on vitamin B6 concentrations may be transient.
Although OC use may be associated with a reduction in plasma PLP levels, the
mechanism by which OC use may lower plasma PLP concentration is not well defined, but
some suggest that plasma PLP may redistribute into tissue in response to OC use.172
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Another possible explanation could be that OC use induces certain PLP-dependent
enzymes, such as tryptophan oxygenase, causing an increased need for the vitamin in
metabolism.172 A third explanation for the low plasma PLP concentrations observed in OC
users involves inflammation.169 OC use is associated with increased serum CRP
concentrations.67 Krintus and colleagues (2009) found three-fold higher CRP levels among
OC users compared to non-OC users.173 Furthermore, Williams and colleagues found
similar results in their study, which indicated that combined OC use was associated with
increased CRP levels in women independent of other factors, such as obesity.174

4.3.9 Biological Activities of Vitamin B6
The metabolically active vitamer is pyridoxal phosphate, which serves as a
coenzyme for over 100 reactions, primarily in amino acid metabolism, such as
aminotransferases, decarboxylases, aldolases, racemases and dehydratases.148 The
catabolism of nearly all amino acids involves transfer of their amino group to α-keto acids,
which requires PMP. Furthermore, decarboxylases are essential in the formation of many
hormones and neurotransmitters, such as serotonin, epinephrine, and dopamine, rendering
vitamin B6 essential for their synthesis. PLP is also a cofactor for mitochondrial δaminolevulinate synthase which catalyzes the first and rate-limiting step in heme
biosynthesis in the liver.148 The role of PLP in one-carbon metabolism may be especially
important in nucleic acid biosynthesis and immune system function.168 In addition, PLP
enzymes are also involved in lipid and carbohydrate metabolism, including in muscle
glycogen phosphorylase and sphingolipid synthesis and may modulate glucocorticoid
action.148 Figure 3 below shows a summary of the main metabolic actions of vitamin B6.153
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4.4 Nutrients related to Depression
4.4.1 Physiology of Vitamin D and Depression
Several biological mechanisms may explain the link between vitamin D deficiency
and depression. These proposed mechanisms are based on the presence of VDR and 1,αhydroxylase in the brain. First of all, calcitriol can cross the blood-brain barrier and is also
synthesized in the brain.246 Secondly, VDRs have been found in many areas of the human
brain, including the prefrontal cortex, hippocampus, cingulated gyrus, thalamus,
hypothalamus, and substantia nigra – all of which have been previously linked to the
physiology of depression. However, current experimental evidence does not fully satisfy
criteria to establish causality. 247
Vitamin D has the potential to regulate expression of many genes, including the
expression of neurotrophins, which regulate neural development and also function in the
adult brain. 248 Gene expression of three of the four neurotrophins present in mammalian
brains (NGF, BDNF, NT-3, and NT4/5), are affected by vitamin D.247 Vitamin D could be
playing an important role in the regulation of neurotransmission, neuroprotection,
neuroimmodulation, and nerve growth factor synthesis. 250 Therefore, a vitamin D
deficiency may be contributing to neuronal decline and disruption in neural
transmission.249
Another mechanism linking vitamin D to depression is vitamin D’s involvement in
the neuroendocrinological system by modulating glucocorticoid signaling.251
Glucocorticoid levels have been found to be higher in patients suffering from major
depressive disorder. A malfunction in glucocorticoid signaling and the release of cortisol
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may be a result of low vitamin D levels.251 However, the exact mechanism linking
glucocorticoids, vitamin D and depression remains unknown.
And lastly, since vitamin D is associated with higher levels of inflammatory
cytokines, and inflammation has been linked with depression, compromised vitamin D
status may be contributing to an inflammatory-induced depression. There is supporting
evidence for a modulatory effect of vitamin D both in vivo and in vitro on proinflammatory
cytokines. Firstly, treatment with vitamin D has resulted in decreased production of
proinflammatory cytokines (or increased production of anti-inflammatory cytokines) in a
variety of cell types including monocytes, microglia (an important source of
proinflammatory cytokines in the brain), keratinocytes, and endothelial cells, among
others.247 Furthermore several studies have found increased proinflammatory cytokine
levels in individuals with compromised serum vitamin D.
In summary, there are several mechanisms through which low vitamin D can be
contributing to depression and there is ample biological evidence to suggest an important
role for vitamin D in brain development and function, but the current experimental
evidence base does not yet fully satisfy causal criteria. 247

4.4.2 Epidemiology of Vitamin D and Depression
The largest cross-sectional study of vitamin D concentrations and depression in
adults in the US included 7,970 adults representing over 90 million US noninstitutionalized, civilian population, aged 15-39 from the NHANES III (1988-1994).252
Vitamin D was categorized into deficient (<50 nmol/L), insufficient (50-75 nmol/L), and
sufficient (>75 nmol/L). Depression was assessed using the Diagnostic Interview Schedule
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(DIS), and categorized into major depression, depression episodes longer than two years,
and current depression. The proportion of individuals with major depression did not vary
by vitamin D status (p=0.86). However, the proportion of individuals with vitamin D
deficiency was significantly higher among those who had experienced depression for over
two years compared to those who had not experienced depression for over two years
(24.7% vs 19.1%, p=0.039), and those with current depression compared to those without
depression (27.4% vs 14.5%, p=0.003). In multivariable logistic model, they found that
those with vitamin D deficiency have 1.85 times the odds of having current depression,
compared to individuals with sufficient vitamin D levels (OR=1.85, p=0.021), after
adjusting for age, gender, ethnicity, poverty income ratio, nutritional supplements,
medication use, geographical location, BMI and serum creatinine. Additionally, they
observed a higher prevalence of vitamin D deficiency in women, non-Hispanic Blacks,
persons living below poverty, non-supplement consumers, those with higher BMI, and in
those with current depression compared to their counterparts.252 A more recent secondary
analysis of NHANES 2005-2006 focused solely on women ages 20 and over to assess the
relationship between vitamin D and depression, using the same vitamin D assessment
method, but the depression assessment tool used in this cycle was the Patient Health
Questionnaire 9 (PHQ-9). None-the-less, they found a linear statistically significant
relationship between circulating 25-OHD and depression score (p=0.002) after controlling
for age, race, and education.175
Even though most of the available epidemiological studies have been unable to
establish causality due to their cross-sectional design, a randomized double-blind trial of
vitamin D supplementation and depression by Jorde et al (2008) provided important
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evidence for a possible causal relationship between vitamin D and depression. Participants
in the randomized clinical trial included 334 overweight and obese men and women ages
21 to 70 years old who were randomized to receive one of two doses of vitamin D (40,000
IU/week, 20,000 IU/week) or a weekly placebo. Serum vitamin D and depression (using
the Beck Depression Inventory) were assessed at baseline and at the end of the one year
period. Even though they did not find continuous 25-OHD to be significantly correlated
with depression scores at baseline, after participants were stratified by vitamin D status
(sufficient vs insufficient, or <40 vs ≥40 nmol/L), those with insufficient 25-OHD had
significantly higher total depression scores (6.0 vs 4.5, p<0.05) compared to those with
sufficient vitamin D concentration. 253 There was also a modest, yet significant decrease in
median total depression scores after 1 year of vitamin D supplementation with 40,000 IU
(median score: 4.5 to 3.0, p<0.01), with 20,000 IU/week (median score: 5.0 vs 4.0, p<0.01).
The placebo group did not have a significant decrease in depression score after 1 year
(median score: 4.0 vs 3.8, p>0.05). However, this study was limited to overweight and/or
obese individuals, and it is not clear whether these findings could be generalized to a
normal-weight population; furthermore, the median baseline depression scores were low
in this population, suggesting a very low number of clinically depressed participants. And
finally, the effect of vitamin D supplementation with 400 IU/day on depression was
evaluated in the Women’s Health Initiative, a large prospective study that included 36,282
post-menopausal women. They employed the Burnham scale and current antidepressant
use to assess depression status, which was assessed every two years.254 After 2 years
follow-up, those who were randomized to consume daily vitamin D/calcium supplements
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had an odds ratio of 1.16 (95% CI 0.86-1.56), suggesting that among this population, this
level of supplementation had no beneficial effects on depression.
Most epidemiological studies to date have been either cross-sectional or have had a
small range of depression scores, as the number of individuals with clinically-significant
depression have been small. The two studies that focused on a large female population did
not limit their study to females of reproductive age, which are known to have higher rates
of depression. Furthermore, very few have accounted for inflammation, which may be a
strong confounder, as vitamin D affects inflammation status, and that, in turn, is
contributing to the development of depression. To date, two studies have examined if the
association between vitamin D and depression is partially affected by CRP levels.222,223
Although both studies found an inverse association between circulating vitamin D levels
and depression, they did not find a significant difference in risk of depression among
subjects with low vitamin D and elevated CRP,222 nor did they find CRP to mediate the
association between vitamin D and depression. 223 However, these studies did not assess
whether the association between vitamin D and depression was symptom specific, nor did
they stratify by gender given that vitamin D and depression affect women
disproportionately.

4.4.3 Physiology of Vitamin B6 and Depression
Even though the exact pathway linking vitamin B6 to depression is not entirely
understood, two main theories/mechanisms have been proposed for the etiology of
depression involving vitamin B6 and tryptophan metabolism. The first mechanism involves
pyridoxal 5’-phosphate as a coenzyme in the tryptophan-serotonin pathway, and a lack of

53

B6 may theoretically cause depression by reducing serotonin levels.257 The second
mechanism involves vitamin B6 as a key player in the kynurenine pathway which is thought
to play an important role in the pathogenesis of inflammation-dependent depression. 258
A link between tryptophan metabolism and depression first became evident with
the development of serotonin reuptake inhibitor drugs, leading to the first theory, the
Monoamine/serotonin (5-HT) Theory of Depression, which involves an alteration in
tryptophan and other monoamine activities in the etiology of depression.259 Nevertheless,
a direct connection between changes in monoaminergic neurotransmission such as
serotonin and depression has not been definitely proven.258
The alternative hypothesis is based on a shift in the tryptophan metabolism from
serotonin synthesis to the generation of neuroactive metabolites, such as quinolinic acid
and kynurenic acid, by the kynurenine pathway. The balance between serotonergic and
kynurenine pathways is controlled by the expression of three rate-limiting enzymes that
convert tryptophan to kynurenine: indolamine 2,3 dioxygenase (IDO1), IDO2, and
tryptophan 2,3 dioxygenase (TDO2).258 The expression of these enzymes is tightly
regulated by the innate immune system. The Macrophage Theory of Depression, first
proposed in 1990, implicated elevated pro-inflammatory cytokines as a cause of
depression. 260 With the discovery that several pro-inflammatory cytokines induce the
expression of IDO1, the two theories were joined to form the new Kynurenine Theory of
Depression, which ties activation of the immune system to a shift in tryptophan metabolism.
261
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4.4.4 Epidemiology of Vitamin B6 and Depression
After it was first discovered that women taking oral contraceptives had
compromised vitamin B6 status in the early 1970’s, studies sought to explore possible
effects of vitamin B6 deficiency on female health. The link between vitamin B6 status and
depression was first observed in the late 1970’s when an inverse association was found
between pure pregnancy depression and serum B6 levels in 15 pregnant women. 262 This
was thought to be due to the high levels of estrogen during pregnancy, which changed the
brain metabolism increasing the need for pyridoxal 5’-phosphate. Furthermore, fetal
sequestration of vitamin B6 was thought to contribute to vitamin B6 deficiency in this
population, leading to depression in the perinatal period. That same year, Livingston and
colleagues (1978) carried out a more complex study where they assessed the vitamin B6
status of 40 non-pregnant women of reproductive age (control group), 30 pregnant
women, 20 postpartum non-depressed, and 24 postpartum depressed women, to see
whether vitamin B6 status differed by depression state and by pregnancy status. However,
they found no evidence for vitamin B6 deficiency in women suffering from postpartum
depression. 263
Several studies have looked at the association between vitamin B6 and depression in
the past decade, but the results have varied depending on whether vitamin B6 is measured
in plasma or in diet. Hvas and colleagues (2004) examined the association between
depression and vitamin B6 status using the Major Depression Inventory (MDI) and plasma
PLP in a small cross-sectional analysis of 140 individuals aged 19-92 years old.11 In this
study of mostly an elderly population (mean age= 75 years old), they found plasma PLP
concentration to be inversely associated with depression score after adjusting for age and
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gender (r= -0.25, p=0.002). Individuals with PLP concentration below 30 nmol/L were also
found to have higher depression scores compared to those with normal PLP levels after
adjustment for age and sex (p=0.02; 95%CI 1.2-9.4); however, this study was limited by
small sample size, older age of participants despite the range including adults aged 19 and
older, and limited number of participants with depression.
A study by Tucker and colleagues (2008) examined the association between both
dietary vitamin B6 and plasma PLP in 618 participants from the Massachusetts Hispanic
Elderly Study and a neighborhood based comparison group of 251 non-Hispanic Whites
living in Massachusetts.264 Depressive symptoms were assessed using the Center for
Epidemiologic Studies Depression Scale (CES-D) with the cutoff denoting depression set at
16 or higher. Dietary vitamin B6 was assessed using a semi-quantitative food frequency
questionnaire designed for this population. After adjusting for age, sex and ethnicity, they
found plasma PLP to be significantly associated with lower CES-D score in the total sample
(β= -0.12, p<0.05) and in non-supplement users (β= -0.14, p<0.05) as well as with
depression in the total sample (OR=0.74, 95% CI 0.56, 0.99, after adjustment for folate) and
in non-supplement users (OR= 0.71, 95% CI 0.52, 0.98). Furthermore, those who had
plasma PLP levels below 20 nmol/L had almost twice the likelihood of having high
depression score, compared to those with PLP levels above 20 nmol/L in the total sample
(OR= 1.74, 95%CI 1.02, 2.89) and in non-supplement users (OR= 1.78, 95% CI 1.03, 3.09).
However, even though total intake of vitamin B6 (dietary + supplements) was not
associated with depression score, dietary intake of vitamin B6 alone was inversely
associated with depression score in the total sample and in non-supplement users
(p<0.001).264 In this particular study, dietary intake of vitamin B6 was more strongly
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associated with depressive symptoms in an older cohort than total B6 intake or plasma PLP.
They determined that for each additional log unit of dietary vitamin B6 intake, there was a
40% reduction of high depressive symptomatology in this cohort. In the most recent study,
higher plasma PLP was significantly associated with a decreased prevalence of depression
(p-trend: 0.03) among 422 adults ages 21-67 years old in Japan.232 In cross-sectional
analyses, they found that the odds of depression were 46% lower among those in tertiles
two and three (PLP >25.5 nmol/L; OR: 0.54, 95% CI 0.31, 0.94 and OR: 0.54, 95% CI 0.30,
0.96, respectively) compared to those in the lowest tertile of PLP (range: 8.1 to 25.5
nmol/L) after adjusting for age, gender, office, smoking, alcohol intake, physical activity, job
position, marital status, history of cancer, cardiovascular disease, or mental disease, dietary
vitamin B12 intake, serum folate and homocysteine concentration, and depression score at
baseline. However, this association was no longer significant in longitudinal analyses.
Intervention studies with vitamin B6 supplementation on depression have been
hard to interpret because most have either focused on supplementation with vitamin B
complex.265,266 or have studied the effect of supplemental vitamin B6 on other aspects of
mental health, such as pre-menstrual syndrome267 or anxiety or depression in
schizophrenic patients268 or in post-stroke patients. 238 A more recent study by Almeida
and colleagues (2014) found that even though supplemental B vitamins (including 25 mg of
vitamin B6/day) did not increase anti-depressant efficacy in adults taking citalopram, it did
enhance and sustain antidepressant response over 1 year, suggesting a potential for the a
change in treatment guidelines of depression to incorporate B-vitamins.269 Little is known
about the role of vitamin B6 in the development and severity of depression in adults,
especially in women of reproductive age, who are at increased risk of depression.
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The studies examining dietary vitamin B6 alone have yielded controversial results
regarding the association between vitamin B6 intake and depression. 270,271 However, those
assessing plasma vitamin B6 and depression have consistently shown an inverse
association between plasma PLP and depression scores11,232,240 Studies on vitamin B6 and
depression to date have been mostly limited by small sample size, age of population
(mostly elderly), heterogeneity in the measure of depression, lack of assessment of possible
confounders and none have taken inflammation into account.

4.5 Nutrients Related to Inflammation
The influence of infection-related inflammation on micronutrient status was first
recognized in the 1960s by Scrimshaw et al, when changes in concentrations of circulating
minerals and vitamins, including vitamin D, were observed following infection.176 Several
decades later, the association between nutrition and inflammation remains an important
research topic. A recent study attempting to shed light on the association between
inflammation and nutritional status examined the relationship between c-reactive protein
and micronutrient concentrations cross-sectionally in a cohort of 2,000 persons from the
Scottish Trace Element and Micronutrient Reference Laboratory between 2001 and
2011.177 C-reactive protein was categorized into 6 groups ranging from the lower limit of
detection to over 80 mg/L. With the exception of vitamin E and copper, all micronutrients
tested (vitamins A, D, B6, and C) showed similar significant trends of decreasing plasma
concentrations as CRP concentrations increased.177 However, due to the cross-sectional
nature of this study, directionality could not be demonstrated. Even though the
mechanisms for each of these associations may differ, the effects of inflammation on
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micronutrient status can be, in part, mediated by pro-inflammatory cytokines that suppress
hepatic production of many carrier proteins, increasing capillary permeability, and
promoting sequestration of some micronutrients into the liver and other organs.178 There
is also the possibility of reverse causation if individuals are sick and have systemic
inflammation, their appetite may be diminished274 leading to limited dietary intake, and
consequently, compromised micronutrient status.
Many different micronutrient biomarkers have been studied with regards to
inflammation, such as iron, vitamin A, vitamin E, selenium, copper, omega-3 fatty acids
among others, but vitamin B6 and vitamin D are of special interest in light of inflammation
and depression. Serum and plasma biomarkers of both of these vitamins are reduced in an
inflammatory state, and a deficiency of both micronutrients has been associated with
depression. It is of special interest to study these biomarkers in a female population of
reproductive age, because both vitamin D and B6 deficiencies are highly prevalent in this
group, and they are essential for healthy pregnancy outcomes. The following sections will
provide a review of the literature on each of these vitamins with regards to inflammation.

4.5.1 Physiology of Vitamin D and Inflammation
There is considerable evidence for a modulatory effect of vitamin D treatment on
proinflammatory cytokines both in vitro and in vivo. The vitamin D receptor has been
identified in peripheral lymphocytes, macrophages, and thymus tissue.179 The biological
actions of vitamin D are mediated by its binding to a high-affinity vitamin D receptor that
acts as a ligand-activated transcription factor. Cell-based and animal studies have
suggested that vitamin D influences inflammation by modulating the expression of several
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cytokine genes controlled by the VDR. Vitamin D and its analogues inhibit production of
proinflammatory cytokines (or increase production of anti-inflammatory cytokines) in a
variety of cell types, including monocytes,180 microglia,181 keratinocytes,182 endothelial
cells,183 and human benign prostatic hyperplastic cells.184 In addition to mediating the
release of specific cytokines, vitamin D also increases the expression of cytokine
receptors.275 Vitamin D promotes proliferation of immunosuppressive regulatory T cells
towards a T-helper 2 type profile, which has an anti-inflammatory effect.185 VDR knock-out
mice have higher levels of proinflammatory cytokines and are more susceptible to
inflammatory diseases such as inflammatory bowel disease compared to normal mice.186
In humans, vitamin D studies conducted in subjects with a wider range of serum vitamin D
levels have shown variable results regarding the association of vitamin D and inflammatory
cytokines. The following section summarizes recent studies on human populations.

4.5.2 Epidemiology of vitamin D and Inflammation
Low vitamin D status has been associated with increased risk for chronic disease in
which inflammation is an underlying component.187 Even though most studies have
examined the association between vitamin D status and inflammation in adults with acute
or chronic illnesses, a few recent studies have examined the association between vitamin D
status and CRP in healthy adults.188 Three recent cross-sectional studies evaluating the
association between serum vitamin D and c-reactive protein found an inverse association
in adults without acute illness.189–191 However, the available literature is conflicting. Three
recent cross-sectional studies found no association between serum vitamin D and CRP192–
194

and two recent randomized clinical trials also found no association between vitamin D
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supplementation and circulating CRP levels.195,196 However, a meta-analysis of ten
randomized clinical trials of vitamin D supplementation found a significant inverse
association between serum vitamin D levels and circulating hs-CRP.197
Given the inconsistent results in the literature, Amer and Qayyam employed singleknot spline regression at the median of serum vitamin D concentration to evaluate the
shape of the association between inflammation and both low and high vitamin D levels in
NHANES adults. Study participants (15,167 men and women) were divided into two
groups: low vitamin D group (those with 25-OHD < 21 ng/mL) and high vitamin D group
(those with 25-OHD ≥ 21 ng/mL). Mean CRP values in the lower and higher 25-OHD were
2.2 and 1.7 mg/L, respectively.189 In univariate spline linear regression model among those
in the low vitamin D group, CRP decreased as the serum 25-OHD level increased (p<0.001).
However, in the high vitamin D group, an increase in 25-OHD was not associated with any
statistically significant decrease in the CRP level (95%CI -0.11, 0.001; p=0.07). In
multivariable linear regression, this inverse association seen between vitamin D and CRP in
the low vitamin D group (< 21ng/mL) remained unchanged (p<0.001). However, in the
high vitamin D group, the association between CRP and vitamin D reversed in multivariable
regression, and CRP was positively associated with vitamin D levels.189 These results shed
light on the potential interactions and mechanisms at play in the association between
circulating vitamin D levels and inflammation. It is possible that vitamin D supplementation
among healthy subjects with baseline vitamin D levels ≥21 ng/mL might not have
additional effects on systemic inflammation. A second study using restricted spline
regression 86 found a U-shaped association between 25(OH)-vitamin D and CRP among
healthy adults, with a nadir between 52-62 nmol/L (21-25 ng/mL), suggesting that below
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these levels, 25(OH)-vitamin D may have an anti-inflammatory effect, but above these
levels vitamin D may have a pro-inflammatory effect.
In order to discern the association between vitamin D status, supplementation, and
its effect on inflammation, Chen et al (2014) completed a meta-analysis of ten randomized
controlled trials including a total of 924 participants. They found that vitamin D
supplementation significantly decreased the circulating CRP level by 1.08 mg/L (95%CI 2.13, -0.03). Furthermore, after subgroup analysis, they found a higher reduction of CRP by
2.21 mg/L (95%CI -3.50,-0.92) among participants with baseline CRP level ≥5mg/L.
Additionally, their analysis revealed that baseline CRP level, supplemental dose of vitamin
D and intervention duration together may be attributed to the heterogeneity across
studies.197 They concluded that vitamin D supplementation was indeed beneficial for the
reduction of circulating CRP, but the results of studies should be interpreted with caution.
The current literature suggests the mechanism by which vitamin D may influence
inflammation may be more complex, and perhaps only those with very low vitamin D status
may benefit from vitamin D supplementation. However, more research is needed to shed
light on dosage required and vitamin D status adequate for improving inflammatory state.

4.5.3 Physiology of Vitamin B6 and Inflammation
In addition to functioning as a cofactor in a wide variety of enzymes involved in
macronutrient metabolism and in neurotransmitter synthesis, vitamin B6 plays a critical
role in both the innate and adaptive immune responses.198 Vitamin B6 is required for the
production of cytokines,199 which are among the primary mediators of inflammation, as
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well as for the proliferation and activation of lymphocytes that characterize the
inflammatory response.200,201
There are several hypotheses regarding the underlying mechanism for the
association between low plasma PLP and inflammation. One hypothesis suggests that low
dietary intake of vitamin B6 confers increased risk of inflammation; however, in most
studies of inflammatory conditions such as rheumatoid arthritis (RA) where plasma PLP
levels are low, vitamin B6 intakes correlate poorly with plasma PLP concentration.202
Despite lower plasma PLP levels, RA patients have normal measures of other indicators of
vitamin B6 status, such as erythrocyte aspartate transaminase (EAST) activity coefficient
and erythrocyte PLP concentration,202 suggesting a functional deficiency rather than a
frank deficiency.
A second hypothesis suggests increased vitamin B6 requirements during
inflammation are due to catabolism of vitamin B6. In the study by Chiang et al (2003),
urinary excretion of 4-pyridoxic acid, which is a measure of vitamin B6 metabolism, was not
correlated with plasma PLP in RA patients, suggesting that low plasma PLP in this
condition is not due to increased metabolism of vitamin B6.202 However, this idea remains
in debate, as a new study by Ulvik and colleagues revealed that there was an increase in
vitamin B6 catabolism during inflammation by assessing the substrate product ratio in
plasma (pyridoxic acid to the addition of PL + PLP).277 This new approach to assess vitamin
B6 catabolism may provide new insights into the potential mechanisms underlying the
association between plasma vitamin B6 and inflammation.
It appears the lower plasma PLP observed in inflammatory conditions is not linked
to dietary inadequacy or to vitamin B6 deficiency in most cases, but rather is due to
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metabolic phenomena inherent to inflammation.271 Among NHANES participants, the
prevalence of low plasma PLP (<20nmol/L) is approximately 2.5 times higher in
individuals with higher CPR (>10 mg/L) compared to those with CPR levels ≤3mg/L. 278
These data suggest there is a higher need tor plasma PLP by the immune system during
active inflammation.
Current evidence points to the third hypothesis: that the inverse association
between plasma PLP and inflammation is the result of mobilization of plasma PLP to sites
of active inflammation for use by the PLP-dependent enzymes that play a role in the
inflammatory response. 279 Because the PLP in muscle is phosphorylated, it is not easily
released; thus, when there is an increased demand for PLP during inflammation or when
intake is low, PLP is supplied by liver and plasma stores. This evidence comes from a study
with an animal model of RA, which found that during bouts of inflammation, PLP levels fell
in liver and plasma, but not in other tissues. 205 Hence, plasma PLP concentration would be
highly susceptible to a sudden increase in PLP demand during an immune response. 271
This third hypothesis proposes that the lower plasma PLP levels observed during
inflammation are due to the mobilization of PLP to the site of inflammation for degradation
of tryptophan via the kynurenine pathway, metabolism of immunomodulatory
sphingolipids, and the proliferation of immune cells.271 Degradation of tryptophan
through the indoleamine 2,3-dioxygenase (IDO) pathway is a hallmark of inflammation.271
Tryptophan metabolism through the kynurenine pathway includes two vitamin B6dependent enzymes. These studies suggest that impaired vitamin B6 status in inflammation
is not solely caused by either lower intake, malabsorption or excessive catabolism of the
vitamin, but may be a result of metabolism mechanisms inherent to the inflammatory
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process. The sequestration of PLP in the sites of inflammation may appear to be the most
convincing hypothesis to date, but further studies are needed to rule out the remaining
hypotheses and confirm the latter.

4.5.4 Epidemiology of Vitamin B6 and Inflammation
A number of population studies have shown that low plasma vitamin B6 levels are
associated with typical chronic inflammatory diseases, such as rheumatoid arthritis and
inflammatory bowel diseases,203 and are inversely related to markers of inflammation.163
However, this association seems to be affected by several factors, such as OC use, age, and
dietary supplementation.
The first large study to investigate this association was carried out over a decade
ago. Using the Framingham Heart Study cohort, Friso and colleagues examined the
association between plasma PLP levels and CRP in 891 older adults.156 They found those
with high CRP levels (≥6 mg/L) had significantly lower PLP levels (36.5 vs 55.8 nmol/L, pvalue<0.001) than individuals with low CRP values. Only 6.4% (n=57) of the study
population had high CRP as defined by the cut-point used. Vitamin B6 intake did not differ
between the CRP groups (2.4 vs 2.1 mg/day, p-value>0.2), therefore the lower PLP levels in
one group were not due to diminished intake.156
A larger, more recent cross-sectional study using the National Health and Nutrition
Examination survey evaluated the relationship between both vitamin B6 intake and plasma
PLP concentrations and serum CRP in 2,686 adults representative of the adult U.S.
population.204 They investigated whether the vitamin B6 requirement is affected by
inflammation by determining the vitamin B6 intake associated with minimal prevalence of
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vitamin B6 inadequacy in different serum CRP categories. Vitamin B6 intake was assessed
using two 24-hour diet recalls as well as from supplement use data. Those who were
diabetic, pregnant, lactating, taking hormones or steroidal anti-inflammatory drugs were
excluded. They found female gender, current smoking, and low albumin to be positively
associated with higher inflammation and vitamin B6 deficiency (<20 nmol/L). After
multivariable adjustment for demographics, smoking, BMI, alcohol use, antioxidant vitamin
status, intakes of protein and energy, and serum concentrations of creatinine and albumin,
high vitamin B6 intake was associated with protection against high CRP levels (>10 mg/L)
compared with those with low CRP (≤3 mg/L). However, plasma PLP ≥20 nmol/L
compared with <20 nmol/L was inversely related to serum CRP independently of B6 intake
(p<0.001). Higher vitamin B6 intakes were found to be protective against inflammation,
with higher vitamin B6 intakes associated with maximum protection against vitamin B6
inadequacy in the presence of inflammation.204 This study confirmed the association
between inflammation and low plasma PLP concentration, but challenged the notion that
vitamin B6 intake is unrelated to inflammation. From these studies, it appears that
suboptimal vitamin B6 status can be corrected via supplementation, but the amount of
vitamin B6 intake needed to protect against vitamin B6 inadequacy may be elevated in the
presence of inflammation.272 Vitamin B6 supplementation with 50 mg/day of pyridoxine for
30 days may correct vitamin B6 deficiency,275 but higher levels (100mg/day) may be
needed to improve inflammation among individuals with high inflammation levels, such as
rheumatoid arthritis patients.276
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CHAPTER 5
RESEARCH GAP & PURPOSE OF THE STUDY

Depression is the leading cause of disease burden among women of reproductive
age. This population is at increased risk for both vitamin D and vitamin B6 deficiencies
compared to men, as has been shown by previous NHANES analyses. Additionally, this
population has been repeatedly shown to have higher inflammation levels compared to
men. This is particularly interesting given that inflammation has been linked to the
development and severity of depression since the early 1990s. Given all the evidence
linking vitamin D and B6 to inflammation in numerous animal and population-based
studies, it is surprising to see how little is known about how these factors may be
connected, and how they may be contributing to depression severity or symptomatology. It
is of special interest to find new avenues for depression prevention and treatment due to
the low response rate of antidepressants.
What was once coined the “macrophage theory of depression” may now be the basis
for how low-grade inflammation could be contributing to compromised micronutrient
status, and how the interaction between these factors could be an underlying cause for the
depression seen in women of reproductive age. This knowledge gap prevents our
understanding to what extent correcting micronutrient status and inflammation might be a
simple, economic, and effective component of a prevention strategy aimed at reducing the
risk of developing depression.
The primary objective in the proposed study was to assess how inflammation is
related to depression, while accounting for micronutrients numerous lifestyle and
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behavioral factors, such as body mass index, leisure-time physical activity, sleep, and oral
contraceptive use. Our study also considered different types of depressive symptoms, such
as affective and somatic, in addition to individual depression symptoms, to determine how
inflammation, vitamin D and B6 concentrations may be interacting and contributing to
different dimensions of depression. The study findings shed light on potential mechanisms
linking nutritional status and inflammation to different aspects of depression and
depression severity. Findings may be used to create new approaches that include targeting
nutritional status to prevent, treat, and help manage depression among women of
reproductive age.

5.1 Specific Aims and Hypotheses by Manuscript Title
5.1.2 Study #1: Inflammation is associated with depression symptomatology among
women of reproductive age from NHANES 2005-2008
Our working hypothesis for this aim is that elevated inflammation is positively associated
with depression in women of reproductive age. Our experimental approach was to
investigate the association between high-sensitivity C-reactive protein (hs-CRP) and sum
depression scores, as well as individual symptoms and depression subtypes measured with
the PHQ-9 to determine the extent to which inflammation is associated with increased
depression. We also explored which lifestyle and behavioral factors affected this
association through moderation or mediation pathways in post-hoc analysis.

5.1.2.1 Specific Aim #1:
To assess the association hs-CRP and different dimensions of depression among nonpregnant women of reproductive age from NHANES 2005-2008.

5.1.2.2 Hypothesis #1a:
Among women of reproductive age, hs-CRP will be positively associated with depression
score and depression severity as determined by the PHQ-9.
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5.1.2.3 Hypothesis #1b:
Among women of reproductive age, the association between inflammation and depression
will depend on the nature of the symptoms.
5.1.3 Study #2. Does inflammation influence the association between vitamin B6 and
depression in non-pregnant women ages 15-44 from NHANES 2005-2008
Our working hypothesis for this aim is that elevated hs-CRP is modifying the association
between vitamin B6 levels and depression in women of reproductive age. Our experimental
approach was to investigate the association between vitamin B6 levels and depression
scores among women with high and low inflammation levels to determine the extent to
which inflammation influences the association between vitamin B6 status and different
dimensions of depression.
5.1.3.1 Specific Aim #2:
To assess the association between vitamin B6 concentrations and different dimensions of
depression, stratified by CRP categories, in women of reproductive age from NHANES
2005-2008.
5.1.3.2 Hypothesis #2a:
Among women of reproductive age, hs-CRP will be inversely associated with serum vitamin
B6 status.
5.1.3.3 Hypothesis #2a:
Among women of reproductive age, depression will be inversely associated serum vitamin
B6 status, and this association will be strongest among women with elevated hs-CRP
concentrations.
5.1.4 Study #3. Do inflammation or lifestyle factors influence the association between
vitamin D status and depression in non-pregnant women ages 15-44 from
NHANES 2005-2008
Our working hypothesis for this aim is that inflammation modifies the association between
vitamin D status and depression in women of reproductive age. Our experimental approach
was to investigate the association between vitamin D categories and depression scores
measured with the PHQ-9 among women with high and low CRP levels to determine the
extent to which hs-CRP influences the association between vitamin D and different
dimensions of depression symptomology. We also explored which lifestyle and behavioral
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factors affected this association through moderation or mediation pathways in post-hoc
analysis.
5.1.4.1 Specific Aim #3:
To assess whether inflammation modifies the association between vitamin D and
depression in non-pregnant women of reproductive age from NHANES 2005-2008.
5.1.4.2 Hypothesis #3a:
Among women of reproductive age, serum vitamin D status will be inversely association
with depression.
5.1.4.3 Hypothesis #3b:
Among women of reproductive age, the association between vitamin D status and
depression depends on inflammation.
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CHAPTER 6
STUDY DESIGN AND METHODS

6.1 Study Design and Population
We examined cross-sectional data from the 2005-2008 National Health and
Nutrition Examination Survey (NHANES), which is national survey from the National
Center for Health Statistics of the Centers for Disease Control and Prevention (CDC),
designed to assess the health and nutritional status of the U.S. population. NHANES
employs a complex, multistage, probability sampling design to select individuals
representative of the civilian, non-institutionalized population, with oversampling of
special sub-populations, such as racial and ethnic minorities. Detailed descriptions of the
survey design and procedures are available at the study website.277
Briefly, approximately 5,000 people are surveyed each year via in-person interviews
and physical examinations. The interview, which is conducted in participants’ homes,
includes demographic, socioeconomic, dietary, and health-related questions; the
examination component is comprised of medical, dental, and physiological measurements,
as well as laboratory tests, which take place in specially-designed and equipped mobile
examination centers (MEC) that travel throughout the country. The National Center for
Health Statistic’s Institutional Review Board has reviewed and approved the NHANES
protocol. 282
Participants were eligible for our study if they were women of reproductive age
(15-44 years old) who were not pregnant. From the initial sample of 2,609 eligible women,
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we excluded those who were taking anti-inflammatory medications, including NSAIDs
(n=70), those with acute inflammation denoted by CRP levels above 10 mg/L (n=201)277
and those with missing data for either depression (n=506) or inflammation (n=104).
Depression data for those younger than 18 years was not publicly available; therefore, our
age range was restricted to women ages 18-44 years old. Women who reported current
antidepressant use were additionally excluded (n=135).

6.2 Exposure Assessment
Fasting whole blood samples were collected during the medical examination.
Venipuncture was performed using standard phlebotomy techniques by NHANES-trained
personnel. Serum specimens were frozen at -20 degrees Celsius until biomarker
assessment at varying laboratories designated by the Center for Disease Control. Further
detailed instructions on specimen collection and processing can be found at NHANES
website.21 A brief description for each biomarker assessment is provided below.
Serum hs-CRP was assayed at the University of Washington Medical Center. Hs-CRP
was quantified by latex-enhanced nephelometry using a Dade Behring Nephelometer II
analyzer System (Dade Behring Diagnostics Inc, Somerville NJ). Monoclonal antibodies
were used to detect serum CRP, and N rheumatology standard SL was used to standardize
against the World Health Organization’s International Reference Preparation of CRP. This
high-sensitivity assay allowed for a minimum detection of 0.2 mg/L and does not have a
maximum reportable limit. Further details can be found on the website. 277 CRP was
modeled as three categories: no inflammation (CRP<1mg/L), low inflammation (CRP
between 1-3 mg/L) and mid-high inflammation (CRP between 3-10 mg/L), following
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guidelines for increased risk of cardiovascular disease set forth by the American Heart
Association. 278
Serum specimens for pyridoxal 5’-phosphate (PLP) were processed, stored and
shipped to the Division of Environmental Health Laboratory Sciences, National Center for
Environmental Health, Centers for Disease Control and Prevention in Atlanta, Georgia.
Briefly, serum PLP, the main bioactive form of vitamin B6, was measured using reversephase high performance liquid chromatography (HPLC) analysis using fluorometric
detection at 325nm excitation and 425nm emission. Quantitation of PLP was based on
analyte peak area interpolated against a five-point calibration curve from aqueous
standards. This HPLC assay has a lower limit of detection compared to the enzymatic assay
used in previous NHANES cycles (0.3 vs 10 nmol/L). 277 Serum PLP was also divided into
categories indicating vitamin B6 deficiency (PLP <20nmol/L), insufficiency (PLP 20 to 29.9
nmol/L) and sufficiency (PLP ≥30 nmol/L) following previously used cut-offs for vitamin
B6 status. 277
Measurements of serum 25(OH) vitamin D were performed with the DiaSorin RIA
kit (Stillwater, MN) for NHANES 2001-2006, and with liquid chromatography-tandem mass
spectrometry (LC-MS/MS) method for NHANES 2007-2008. 279 In order to use vitamin D
data from these two different methods, NHANES converted the vitamin D data from 20012006 assayed with the RIA method to equivalent 25(OH)D measurements from a
standardized LC-MS/MS method using regression analysis. This was done to allow
researchers to use vitamin D data that are equivalent to 25(OH)D measurements assayed
with LC-MS/MS method. 279 Serum vitamin D was primarily categorized into variables
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indicating vitamin D deficiency (<50nmol/L), insufficiency (50 to 75 nmol/L) and
sufficiency ( >75 nmol/L) following previously used cut-offs for vitamin D status.165,280

6.2.1 Laboratory Quality Assurance and Monitoring
The NHANES quality control and quality assurance protocols meet the 1988 Clinical
Laboratory Improvement Act mandates at all the locations. Quality control measures and
device calibrations were performed daily for all laboratory procedures.277

6.3 Depression Assessment
The Patient Health Questionnaire-9 (PHQ-9)281 was administered during the MEC
interview to assess depressive symptom severity over the past two weeks. Based on the
diagnostic criteria for major depressive disorder in the Diagnostic and Statistical Manual
Fourth Edition (DSM-IV), the PHQ-9 employs a 4-point scale (0=not at all, 1= several days,
2= more than half the days, 3= nearly every day) to determine the frequency with which
respondents experienced the following nine symptoms of major depressive disorder:
anhedonia, depressed mood, sleep disturbance, fatigue, appetite changes, low self-esteem,
concentration problems, psychomotor retardation/agitation, and suicidal ideation. Total
depression scores range from 0 to 27, and scores of 10 or higher indicative of clinical
depression.282 The PHQ-9 has been shown to be a reliable and valid questionnaire as
indicated by its high internal consistency and good sensitivity (88%) and specificity (88%)
for identifying cases of major depressive disorder in community samples.283–285
In addition to the total depression score, we calculated somatic and cognitive-affective
depression subscale scores. The somatic depression subscale was calculated by adding the
scores for frequency of somatic depression symptom from the PHQ-9 (sleep disturbance,
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fatigue, appetite changes, and psychomotor retardation/agitation) and the cognitiveaffective subscale score was calculated adding the scores for non-somatic symptoms
(anhedonia, depressed mood, low self-esteem, concentration problems and suicidal
ideation).287 While previous factor analyses supported a one-factor model with all nine
items,288,289 recent confirmatory factor analyses have found that subscales of depression
dimensions may provide a better fit to the data.290,291 It has also been argued that given the
heterogeneity of symptoms for depression, individual symptoms should be analyzed.29 We
included a separate analysis for individual depressive symptoms, coded as continuous
variables (scores ranging from 0-3) and as binary variables. To dichotomize the variable,
those items with responses “more than half the days” and “nearly every day” indicated the
presence of the symptom.292,293

6.4 Covariate Assessment
We considered as possible covariates a selected set of demographic, lifestyle, and
socioeconomic factors available through data collected during the demographic or
household section of the NHANES questionnaire. The National Center for Health Statistics
(NCHS) standard definitions for ethnicities were used, and ethnicities were categorized as
non-Hispanic whites, non-Hispanic blacks, Mexican-Hispanics, other Hispanics, and other
race. Educational attainment was measured as the highest completed grade of school
regardless of age, and categorized into four levels: less than high school, high school
equivalent, some college, and college graduate or above. The smoking assessment for
respondents aged 18-19 years (MEC) was not identical to that for respondents aged 20+
years (household interview). For respondents aged 20+ years, we classified as current
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smokers those who reported smoking at least 100 cigarettes during their lifetime and
reported that they now smoke cigarettes every day or some days. For respondents ages 1819 years, we classified as current smokers those who reported smoking 15 or more day in
the last 30 days. To determine a smoking dose from current smokers, we classified those
who reported smoking <15 days per month or “some days” as medium dose smoking, and
those who smoked more than 15 days per month or “every day” as high dose smokers. To
create the alcohol groups, we used data obtained during the alcohol use interview at the
MEC and calculated the drinks per day as suggested by Case and Stewart.294 Alcohol
consumption, which was only available for participants of legal drinking age (21 and older),
was categorized into abstainer, one or fewer drinks/day and more than one drink per day.
Leisure-time physical activity (LTPA) was assessed by asking participants about their
involvement in 48 specific recreation activities of moderate or vigorous intensity.
Frequency was first multiplied by the duration in hours and divided by 4.3 to obtain hours
of LTPA per week. To calculate MET hrs/week, each activity was multiple by its MET level
per NHANES physical activity codes.295 Participants were then categorized into quartiles of
physical activity. Sleep duration was assessed by asking participants how many hours of
sleep they usually get on a weekday/workday, and those who reported sleeping 12 or more
hours were labeled as sleeping 12 hours/night. Oral contraceptive use was determined by
self-report of current use, with “past” or “never” users classified as not currently using oral
contraceptives (OC). Body mass index (BMI) (calculated as kg/m2) was computed from
height and weight measurements and categorized into four standard categories:
underweight (BMI<18.5 kg/m2), normal weight (18.5 ≤ BMI<25), overweight (25≤
BMI<30) and obese (BMI≥30 kg/m2).
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6.5 Statistical Analysis Plan
The complex survey design used for NHANES data collection was incorporated into
all data analyses using the “svy” command with appropriate weighting in Stata 12.0
(StataCorp LP, College Station, TX). Detailed information on the procedures for taking into
account survey sampling weights have been described elsewhere.296
Descriptive statistics were calculated for the overall sample using frequency
distributions for categorical variables and means and standard errors for continuous
variables. Natural logarithmic transformations were performed on hs-CRP, PLP, and
vitamin D to normalize the distribution, and their geometric means and 95% confidence
intervals are presented. Bivariate analyses were carried out for each covariate and each
exposure as well as outcome using weighted ANOVAs, Chi square tests and 2-sample t-test
as appropriate. In linear regression models, all covariates that changed the estimated
coefficient for the primary predictor of interest by more than 10% were retained in the
multivariable model. In addition, known risk factors for depression were retained in the
model as well as those that were associated with both the predictor and the outcome.
To examine whether each exposure was more strongly related with certain
depression symptoms, we conducted a series of linear regression analyses involving total
depression score, somatic depression score, and non-somatic depression score as well as
each individual depression symptom as outcome. A similar series of logistic regression
analyses was also completed for dichotomous individual depressive symptoms. For all the
individual depression symptoms, we also adjusted for the remaining depression symptom
scores to account for any potential overlap between different symptoms and reduce the
probability of Type I error. Logistic regression analyses were carried out for depression
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PHQ-9 score of 10 or greater. The command “mfpigen” was used to assess all possible
interactions among variables in the full models.
For each study, several lifestyle variables were assessed as potential mediators by
running Sobel mediation tests and the Preacher and Hayes test of indirect effects to
quantify their effects on any observed relationships between exposure and
depression.297,298 Effect modification was assessed by stratified regression analyses and by
including multiplicative interaction terms in the multivariable analysis. Final model fit was
assessed using goodness of fit tests. All linear and logistic regression estimates were
weighted using NHANES sample weights, which account for the complex survey design,
survey nonresponse, and post-stratification. All analyses were considered significant at an
alpha of 0.05.
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CHAPTER 7
“THE ASSOCIATION BETWEEN C-REACTIVE PROTEIN AND DEPRESSIVE SYMPTOMS
AMONG WOMEN OF REPRODUCTIVE AGE IS MODERATED BY BODY MASS INDEX”

7.1 Abstract
Depression is the leading cause of disability world-wide, and women in their
childbearing years make up the largest group of Americans with depression. Recent
evidence indicates that inflammation is associated with depression, and this relationship
may differ by gender and by depression symptoms. We conducted a secondary data
analysis to evaluate the association between c-reactive protein (CRP) and different
dimensions of depressive symptomatology in non-pregnant women ages 18-44 years from
the cross-sectional National Health and Nutrition Examination Survey (NHANES) 20052008. Depression scores were calculated based on the Patient Health Questionnaire-9
(PHQ-9) and categorized into total depression, somatic and non-somatic depression. High
depression score (PHQ-9≥10) was also used as an outcome, as were individual symptoms
of depression. High-sensitivity CRP was quantified by latex-enhanced nephelometry. To
account for NHANES’ complex survey design sample, we incorporated the sampling
weights to analyze 1,489 observations. CRP was positively related to total (p=0.006),
somatic (p=0.01) and non-somatic depression scores (p=0.01) in unadjusted models.
However, in the multivariable adjusted models, CRP was positively associated with
depression scores (total depression, p=0.001; somatic depression, p=0.001; non-somatic
depression, p=0.007) only among those who were underweight (BMI<18.5 kg/m ). BMI
2

accounted for 44.8% of the association between CRP and total depression scores (p<0.05).

79

When individual depression symptoms were examined, BMI was negatively associated
with abnormal appetite score among women with no inflammation (CRP<1mg/L), but BMI
was positively associated with appetite score among those with moderate inflammation
(CRP 3-10mg/L). BMI appears to play a role in the association between inflammation and
depression symptoms among women. Further research is needed determine whether
changes in biomarkers of inflammation predict changes in specific dimensions of
depression in this population, and whether lifestyle modification can be used to prevent
depression or as adjuvant treatment for depression among women.

7.2 Introduction
Depression is common in the United States, with approximately 16% of adults
experiencing clinical depression at some point in their lives.1 Women are two- to threetimes more likely than men to experience depression.2,3 Depression is a multifaceted
phenomenon with a large range of symptoms, and different subtypes of depression have
been proposed based on specific combinations of symptoms.4 Research into the etiology of
depression needs to account for the heterogeneous nature of the condition and requires
developing methods to characterize and objectively assess the severity of depression and
to classify depression into its different subtypes.5 In order to address the issue of symptom
diversity, subtypes of depressive symptoms have been proposed based on specific
combination of symptoms. Somatic depression, characterized by sleep disturbance, fatigue,
or changes in appetite, has been found to be more prevalent in females compared to
males,6 and other evidence suggests that gender differences may account for heterogeneity
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in depression symptoms and that the involvement of inflammation in the etiology of
depression may be affected by lifestyle factors.7
Several observational studies reported that increases in inflammatory biomarkers
are associated with increased risk for depression; however, conflicting findings exist
regarding the directionality of the association, and the underlying mechanisms are not fully
understood. Recent research has specifically focused on the association between high
sensitivity c-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor α (TNFα), and other markers of systemic inflammation and depression.8,9 However, very few
studies have investigated depression subtypes, including somatic and
cognitive/affective,6,10–14 and no studies have examined whether the association between
inflammation and depression among women is symptom-specific. Individual depression
symptoms differ in their biological correlates, which underscores the heterogeneous nature
of depression and may explain the lack of progress in validating depression diagnoses with
biomarkers.15 Assessing the association between inflammation and specific symptoms
offers opportunities to investigate potential biological factors that may be related to
specific syndromes but may be masked by aggregate scoring; individuals with similar total
depression scores often have drastically different clinical conditions.16 The analysis of
individual symptoms could reveal patterns that are currently missed.
The purpose of this study was to further explore the relationship between
inflammation and depression among U.S. reproductive-age women and to determine
whether CRP, a marker of inflammation, is associated with depression subtypes or
individual symptoms of depression among this population. Our goal was to determine
whether serum CRP levels in the low-grade inflammation range are associated with
81

particular subtypes of depressive symptoms among 1,489 women, aged 18-44 years, from
the National Health and Nutrition Examination Survey (NHANES) 2005-2008 and to assess
whether body mass index (BMI) and other lifestyle factors potentially modify this
association.

7.3 Methods
7.3.1 Study Design and Study Population
We analyzed cross-sectional data from the 2005-2008 National Health and Nutrition
Examination Survey (NHANES), which is a national survey from the National Center for
Health Statistics of the Centers for Disease Control and Prevention (CDC), designed to
assess the health and nutritional status of the U.S. population. NHANES employs a complex,
multistage, probability sampling design to select persons representative of the civilian,
non-institutionalized population, with oversampling of special sub-populations, such as
racial and ethnic minorities. Detailed descriptions of the survey design and procedures are
available at the NHANES website.16
Briefly, approximately 5,000 people are surveyed each year via in-person interviews
and physical examinations. The interview, which is conducted in participants’ homes,
includes demographic, socioeconomic, dietary, and health-related questions; the
examination component is comprised of medical, dental, and physiological measurements,
as well as laboratory tests, which take place in specially-designed and equipped mobile
examination centers (MEC) that travel throughout the country. The National Center for
Health Statistic’s Institutional Review Board has reviewed and approved the NHANES
protocol.
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Participants were eligible for our study if they were women of reproductive age
(15-44 years old) who were not pregnant. From the initial sample of 2,609 eligible women,
we excluded those who were taking anti-inflammatory medications, including NSAIDs
(n=70); those with acute inflammation denoted by CRP levels above 10 mg/L (n=201);17
those reporting antidepressant use (n=135) and those with missing data for either
depression (n=506) or inflammation (n=104). Depression data for those younger than 18
years was not publicly available; therefore, our age range was restricted to women ages 1844 years old. The remaining sample contained 1,489 observations.

7.3.2 Assessment of Depression Status
The Patient Health Questionnaire-9 (PHQ-9)18 was administered during the MEC
interview to assess depressive symptom severity over the past two weeks. Based on the
diagnostic criteria for major depressive disorder in the Diagnostic and Statistical Manual
Fourth Edition (DSM-IV), the PHQ-9 employs a 4-point scale (0=not at all, 1= several days,
2= more than half the days, 3= nearly every day) to determine the frequency with which
respondents experienced the following nine symptoms of major depressive disorder:
anhedonia, depressed mood, sleep disturbance, fatigue, appetite changes, low self-esteem,
concentration problems, psychomotor retardation/agitation, and suicidal ideation. Total
depression scores range from 0 to 27, and scores ≥10 represent clinically significant
depressive symptoms.18 The PHQ-9 has been shown to be a reliable and valid
questionnaire as indicated by its high internal consistency and good sensitivity (88%) and
specificity (88%) for identifying cases of major depressive disorder in community
samples.19–21
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In addition to the total depression score, we calculated somatic and cognitiveaffective depression subscale scores. The somatic depression subscale was calculated by
adding the scores for frequency of somatic depression symptom from the PHQ-9 (sleep
disturbance, fatigue, appetite changes, and psychomotor retardation/agitation), and the
cognitive-affective subscale score was calculated adding the scores for non-somatic
symptoms (anhedonia, depressed mood, low self-esteem, concentration problems and
suicidal ideation).10 While previous factor analyses supported a one-factor model with all
nine items,22,23 recent confirmatory factor analyses have found that subscales of depression
dimensions may provide a better fit to the data.24,25 Some also argue that given the
heterogeneity of symptoms for depression, individual symptoms should be analyzed.15 We
also included a separate analysis for individual depressive symptoms, coded as continuous
variables (scores ranging from 0-3) and as binary variables. To dichotomize the variable,
those items with responses “more than half the days” and “nearly every day” indicated the
presence of the symptom.26,27

7.3.3 C-Reactive Protein
Fasting whole blood samples were collected during the medical examination.
Venipuncture was performed using standard phlebotomy techniques by NHANES-trained
personnel. Serum specimens were frozen at -20 degrees Celsius until biomarker
assessment at the University of Washington Medical Center. Serum high-sensitivity CRP
was quantified by latex-enhanced nephelometry using a Dade Behring Nephelometer II
analyzer System (Dade Behring Diagnostics Inc, Somerville NJ). Monoclonal antibodies
were used to detect serum CRP, and N rheumatology standard SL was used to standardize
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against the World Health Organization’s International Reference Preparation of CRP. This
high-sensitivity assay allowed for a minimum detection of 0.2 mg/L and does not have a
maximum reportable limit. Further details can be found on the website.16 Given that hsCRP was not normally distributed, it was converted to its natural logarithm to improve
normality. In additional analyses, CRP was modeled as three categories: no inflammation
(CRP<1mg/L), low inflammation (CRP between 1-3 mg/L) and moderate inflammation
(CRP between 3-10 mg/L), following guidelines for increased risk of cardiovascular disease
set forth by the American Heart Association.17

7.3.4 Covariates and Confounders
We considered as possible covariates a selected set of demographic, lifestyle, and
socioeconomic factors available through data collected during the demographic or
household section of the NHANES questionnaire. The National Center for Health Statistics
(NCHS) standard definitions for ethnicities were used, and ethnicities were categorized as
non-Hispanic whites, non-Hispanic blacks, Mexican-Hispanics, other Hispanics, and other
race. Educational attainment was measured as the highest completed grade of school
regardless of age, and categorized into four levels: less than high school, high school
equivalent, some college, and college graduate or above. The smoking assessment for
respondents aged 18-19 years (MEC) was not identical to that for respondents aged 20+
years (household interview). For respondents aged 20+ years, we classified those who
reported smoking at least 100 cigarettes during their lifetime and reported that they now
smoke cigarettes every day or some days as current smokers. For respondents ages 18-19
years, we classified those who reported smoking 15 or more day in the last 30 days as
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current smokers. To create the alcohol groups, we used data obtained during the alcohol
use interview at the MEC and calculated the drinks per day as suggested by Case and
Stewart.13 Alcohol consumption, which was only available for participants of legal drinking
age (21 and older), was categorized into abstainer, one or fewer drinks/day and more than
one drink per day. Oral contraceptive use was determined by self-report of current use,
with “past” or “never” users classified as not currently using oral contraceptives (OC).
Body mass index (BMI), leisure-time physical activity (LTPA), and sleep duration
have been associated with both C-reactive protein and depression7,28,29 and were examined
as potential mediators/confounders of the relationship between CRP and depressive
symptoms. BMI (kg/m2) was computed from height and weight measurements and
categorized into four standard categories: underweight (BMI<18.5 kg/m2), normal weight
(18.5 ≤ BMI<25), overweight (25≤ BMI<30) and obese (BMI≥30 kg/m2). LTPA was
assessed by asking participants about their involvement in 48 specific recreation activities
of moderate or vigorous intensity. Frequency was first multiplied by the duration in hours
and divided by 4.3 to obtain hours of LTPA per week. To calculate MET hrs/week, each
activity was multiplied by its MET level according to NHANES physical activity codes.30
Participants were then categorized into quartiles of physical activity. Sleep duration was
assessed by asking participants how many hours of sleep they usually get on a
weekday/workday; those who reported sleeping 12 or more hours were labeled as
sleeping 12 hours/night.
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7.3.5 Data Analysis
The complex survey design used for NHANES data collection was incorporated into
all data analyses using the “svy” command with appropriate weighting in Stata 12.0
(StataCorp LP, College Station, TX). Detailed information on the procedures for taking into
account survey sampling weights have been described elsewhere.31
Descriptive statistics were calculated for the overall sample using frequency
distributions for categorical variables and means and standard errors for continuous
variables. Because hs-CRP was logarithmically transformed when analyzed as a continuous
variable, geometric means (antilogarithms of the transformed means) and their 95%
confidence intervals are presented. Bivariate analyses were carried out for each covariate
and log-transformed hs-CRP and CRP categories as well as for covariates and total
depression, somatic/non-somatic depression and binary depression variables, using
weighted ANOVAs, Chi square tests and 2-sample t-tests, as appropriate. In linear
regression analyses, all covariates that changed the estimated coefficient for the primary
predictor of interest by more than 10% were retained in the multivariable model. In
addition, known risk factors for depression, such as smoking and education levels, were
retained in the model as were risk factors were associated with both the predictor and the
outcome (e.g. BMI, LTPA, OC use).
To examine whether hs-CRP was more strongly related to certain depression
symptoms, we conducted a series of linear regression analyses involving total depression
score, somatic depression score, and non-somatic depression score as well as each
individual depression symptom as outcome. Individual symptom analysis was repeated via
logistic regression for dichotomous symptoms. For all the individual depression symptoms,
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we also adjusted for the remaining depression symptom scores to account for any potential
overlap between different symptoms. Logistic regression analyses were carried out for
depression PHQ-9 score of 10 or greater. Model adequacy was assessed using goodness of
fit tests.
BMI, LTPA and sleep were assessed as potential mediators by running Sobel
mediation tests and the Preacher and Hayes test of indirect effects to quantify the effects of
BMI, LTPA, and sleep on any observed relationships between hs-CRP and depression.32,33
Effect modification was assessed by stratified regression analyses and by including
multiplicative interaction terms in the multivariable analyses.

7.4 Results
Description of Study Cohort. The mean age of the 1,489 women included in our
sample was 31.7 years. The majority of women were white (63.5%), married or living with
a partner (60.4%,) did not use oral contraceptives (80.8%), reported an average of seven
hours of sleep per night, and were nonsmokers (76.3%). Almost eight percent (n=132) of
our sample reported moderate to severe depression symptoms indicative of clinically
significant depression, denoted by a score of 10 or higher on the PHQ-9 (Table 4).
In bivariate analysis, depression scores were positively associated with BMI (ptrend <0.02 for all) and negatively associated with education (p<0.001) and with LTPA
(p<0.001). Depression score was higher for both somatic and non-somatic subtypes for
women who were not currently taking oral contraceptives (p=0.05 and p=0.01,
respectively) and for smokers (p<0.001 for all). Women with high depression scores slept
less (6.1 vs 7.0 hours/night, p<0.001) compared to those with low depression scores. The
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prevalence of depression was significantly higher among women who were separated or
divorced, who smoked, and those who reported the lowest levels of LTPA. The prevalence
of a high depression score was lower among women who reported current oral
contraceptive use compared to non-OC users (4.5% vs 8.0%, p=0.09; Table 4).
Just over a quarter of women (27.8%) had hs-CRP levels between 3-10 mg/L,
indicative of moderate inflammation. CRP was positively associated with BMI, with
moderate inflammation being much more prevalent among obese (55.4%) or overweight
(27.0%) women compared to normal weight (13.8%) or underweight women (6.6%;
p<0.001). We found a negative association between educational attainment and hs-CRP
(p<0.001). Hs-CRP levels were higher in oral contraceptive users compared to non-users
(2.1 vs 1.1 mg/L, p<0.001), and only 21% of current users had hs-CRP levels <1mg/L
compared to 43.3% of non-contraceptive users (p<0.001). Those in the lower quartile of
LTPA had higher circulating hs-CRP concentration compared to the rest of the quartiles
(p=0.05), with some evidence of an LTPA dose response (p for trend=0.02). CRP
concentration did not vary by age, smoking status or marital status (Table 5).
Association of hs-CRP with depression. In univariate linear regression, hs-CRP was
positively associated with total depression score (β: 0.32, p=0.006), somatic depression
score (β:0.17, p=0.01) and non-somatic depression score (β:0.14, p=0.01). After adjustment
for demographics and behavioral characteristics, hs-CRP remained statistically significantly
associated with all three depression scores, although the betas and p values were
somewhat attenuated. Upon further adjustment for sleep duration, BMI and LTPA, the
association of hs-CRP with total depression and depression subtypes was attenuated and
no longer significant (Table 6).
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To determine which depression symptoms were associated with hs-CRP, we first
estimated bivariate associations, and found that hs-CRP was significantly higher among
those experiencing trouble sleeping (1.70 vs 1.24 mg/L, p=0.009) or those with abnormal
appetite (1.85 vs 1.24, p<0.001) (Table 8). We also estimated linear and logistics regression
models for continuous and dichotomized symptoms. In linear regression analyses of
individual depression symptoms, hs-CRP was significantly associated with sleep
disturbance, abnormal appetite, psychomotor abnormalities (somatic symptoms) and with
anhedonia, depressed mood, and trouble concentrating (non-somatic symptoms).
However, after adjustment for age, race/ethnicity, marital status, education, smoking,
sleep, BMI and LTPA, as well as mutual adjustment for remaining depression symptoms,
these associations were no longer significant (Table 9). In univariate logistic regression,
hs-CRP was significantly associated with sleep disturbances (OR:1.32 p=0.01) and
abnormal appetite (OR:1.42, p<0.001) (Table 10). After adjustment for age, ethnicity,
education, marital status, smoking, OC use, LTPA, sleep duration, and BMI, as well as
mutual adjustment for the remaining depressive symptom score, a one standard deviation
increase in log-transformed CRP was significantly associated with a 31% higher odds of
sleep disturbance (OR: 1.31, p=0.05), and marginally associated with an 82% higher odds
of suicidal ideation (OR: 1.82%, p=0.06). No other significant associations remained.
To examine BMI as a potential modifier of the hs-CRP-depression association, we
first ran the linear regression model adjusting for BMI, which attenuated the association
between hs-CRP and total depression as well as the association with subtypes of
depression (Table 7). This addition did not change the direction of the association.
Adjustment for BMI did not change the direction of the association. Addition of an
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interaction term between continuous BMI and continuous hs-CRP into the multivariable
model did not result in any significant changes (not shown). To further assess how BMI
may be influencing the association between hs-CRP and depression, we carried out a series
of linear regressions using each one of the nine depression symptoms from the PHQ-9
questionnaire as the main outcome (Table 9). This analysis revealed the following
symptoms of somatic depression to be affected by addition of the interaction term for BMI
and CRP: fatigue (β:-0.26, p=0.07) and changes in appetite (β: -0.23, p=0.02). The
interaction terms for continuous BMI x CRP for these two symptoms were significant
(p=0.04 and p=0.02, respectively). To better understand how the outcome of changes in
appetite may relate to BMI and CRP, we plotted this interaction with predictive margins to
visualize the score for abnormal appetite for those with no inflammation, low
inflammation, and mid-high inflammation (using the mean CRP for each category) based on
BMI levels. We found that among those with CRP levels below 1 mg/L, BMI was negatively
associated with abnormal appetite score, but among those with CRP levels between 3-10
mg/L, BMI was positively associated with predicted appetite score (Figure 3).
Furthermore, we stratified our analysis by BMI category and found that after
adjustment in our final model, an increase in one standard deviation of log transformed hsCRP was associated with an increase in total depression score (β:1.60, p=0.001), somatic
(β:1.07, p=0.001), and non-somatic depression score (β:0.49, p=0.007) only among those
who were underweight. This association was not significant in any other BMI category
(Table 7).
To assess whether BMI, LTPA or sleep were potential mediators or confounders of
the association between hs-CRP and depression, we ran a series of Sobel tests and Preacher
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and Hayes tests of indirect effects with total depression score, somatic depression score
and non-somatic depression score as the main outcomes (Figure 2). For total depression,
44.8% of the total effect was significantly mediated by BMI (p<0.05); for somatic
depression, 43.8% of the total effect was mediated by BMI (p<0.05) and for non-somatic
depression, 45.8% of the total effect was mediated by BMI (p=0.09). LTPA also attenuated
the association between hs-CRP and depression variables, but these indirect effects were
not statistically significant (all p>0.09). For total depression, the standardized CRP effect
size was reduced by 16.9% (p=0.03) upon addition of sleep to the model; for somatic
depression, the effect size was reduced by 20.7% (p=0.03), and for non-somatic depression,
it was reduced by 12.4% (p=0.05). We also conducted analyses to test hs-CRP x sleep
(p>0.16 for all) and hs-CRP x LTPA (p>0.20 for all) interactions for the full models for total
depression, somatic and non-somatic depression, all of which were not significant.
In univariate logistic regression, an increase in one standard deviation in logtransformed hs-CRP was associated with an 18% increase in the odds of having depression,
and this was borderline significant (OR: 1.18, 95% CI 0.98, 1.41, p=0.07) (data not
shown). No significant interactions were evident in logistic regression analyses.
Association between Sleep and Physical Activity and Depression. Sleep duration was
inversely associated with total depression score (β:-0.41, p<0.001), somatic depression
score (β:-0.31, p<0.001) and non-somatic depression score (β:-0.11, p=0.04) in the final,
multivariable linear regression model (data not shown). In multivariable logistic
regression, sleeping more than seven hours was associated with a 53% lower odds of
having high depression score (OR:0.47, p=0.005). LTPA was inversely associated with total
depression, somatic and non-somatic depression in multivariable linear regression as well
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in multivariable logistic regression (data not shown). Being in the lowest quartile of LTPA
was significantly associated with higher total depression score (β:1.4, p<0.001), somatic
depression score (β:0.82, p=0.001) and non-somatic depression score (β:0.58, p=0.001). In
multivariable logistic regression, the relative odds of a high depression score (OR: 2.8,
p=0.01) was significantly higher among women in the lowest quartile of LTPA compared to
those with more activity.

7.5 Discussion
In this large representative sample of reproductive age US women, we found that hsCRP was positively associated with total depression, somatic depression, and non-somatic
depression after adjustment for demographic and behavioral characteristics.
However, these associations were attenuated and were no longer significant after
adjustment for BMI, sleep, and LTPA, suggesting that the association between inflammation
and depression may be mediated or confounded by these lifestyle factors. Although
previous studies have also reported an association between higher levels of inflammatory
biomarkers such as hs-CRP and increased depressive symptoms,8,14,34–37 our study is the
first to investigate how these lifestyle factors may influence the association between
inflammation and various dimensions of depression among women of reproductive age.
Body mass index significantly attenuated the association between CRP and depression
among women in our analysis, and this finding is consistent with, and expands upon the
result of a recent analysis by Liu et al (2014), where CRP was significantly associated with
depression among men, but not among women after adjustment for BMI.7 We observed a
similar pattern among our sample of women of reproductive age, suggesting that BMI, a
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proxy for adiposity, partially explained the association observed between CRP and total
depression score in unadjusted models. Adipose tissue functions as a key endocrine gland,
releasing adipokines, which can have pro- or anti-inflammatory activities, depending on
the adipose storage site.38 Pro-inflammatory adipokines, such as leptin and IL-6, are
upregulated in proportion to adipose tissue and increase transcription of hs-CRP.39
Compared to men, women generally have greater body fat content,40 which is associated
with higher BMI and higher leptin levels. BMI may be masking the association between CRP
and depression given that adiposity is associated with higher inflammation and, in some
studies, predicts future depression.41 However, given that our study is cross-sectional, and
depression has also been found to predict weight gain through emotional eating and weight
gain,42 we cannot rule out the possibility that BMI may be operating as a mediator instead
of a confounder.
Although the association between obesity and depression seems clearly established,
conflicting evidence remains regarding the shape of the relationship between body weight
and depression when considering the full range of BMI, including those who are
underweight.43–45 Some suggest the relationship between body weight and depression is Ushaped, with those who are underweight and overweight or obese having higher odds of
depression.7 We observed a positive association between CRP and depression scores,
evident only among those who were underweight (BMI <18.5 kg/m2), suggesting that BMI
modifies the CRP-depression association. It is possible that inflammation originating from
non-adipose tissue is strongly related to depression among those with lower levels of
adiposity. Among those with higher levels of adiposity, adipokine-derived inflammation
may be attenuating this association. These results are consistent with recent findings from
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a cross-sectional analysis of the relationship between log-transformed CRP and depression
scores among an elderly Chinese population, where Qin et al. (2017) found that CRP was
significantly associated with total depression score, somatic depression score, and nonsomatic depression score among underweight individuals after adjustment for age, sex,
education, marital status, smoking, and alcohol consumption.46 Similarly, they did not
observe any significant association between CRP and any type of depression in their full
sample after adjustments or in the normal, overweight, or obese BMI categories.
Additionally, they found a lower prevalence of depression among those in the higher BMI
categories, whereas we found that the prevalence of depression increased with increasing
BMI. This inverse association between BMI and depression is not a new phenomenon
among Asian populations, as obesity may be thought to protect middle-aged and elderly
Chinese against depression.47 Given the demographic and cultural differences between
these two populations, the similarities in results need to be examined further to determine
whether different mechanisms are involved.
Previous studies indicate that inflammation is more strongly related to somatic
symptoms of depression.6,11,13,14,25 We did not see a significant difference between CRP and
somatic vs non-somatic depression scores. However, when analyzing individual symptoms
of depression, CRP was significantly associated with sleep disturbances and changes in
appetite. Previous studies have also reported that CRP is significantly associated with
sleep disturbances26,27 and appetite changes,27 in addition to other somatic symptoms
(fatigue and low energy) after adjustment for age, gender, ethnicity and the sum of
remaining depression symptoms. In some cases,26,27 the associations between CRP and
additional symptoms of depression could be due to including participants with acute
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inflammation (CRP>10 mg/L) as well as including men and women in the analysis. One of
the studies27 found that, relative to the lowest quartiles, those in the highest quartile of CRP
(range: 3.31-157.50 mg/L) have higher odds of all the somatic symptoms they assessed;
these relationships were not significant among lower quartiles of CRP. In support of
immune-to-brain-pathways, sleep disturbance is one of the sickness symptoms found to be
mediated by increases in circulating pro-inflammatory cytokines.48 Therefore, our finding
that inflammation was associated with higher odds of sleep disturbance, even after
adjustment for sleep and other potential confounders, is consistent with previous
studies,28,49 and adds to the evidence that sleep disturbances may be one of the primary
manifestations of inflammation-associated depression, which may be more evident among
women even at lower inflammation levels.
The occurrence of appetite change was the only other somatic symptom associated with
inflammation, although this relationship showed evidence of effect modification by BMI.
BMI was negatively associated with abnormal appetite score among those with CRP levels
below 1mg/L, but was positively associated with predicted appetite score among those
with CRP levels between 3-10mg/L. These findings suggest that baseline inflammation
levels can affect how BMI is associated with appetite changes, and BMI can either be
protective or increase the risk of experiencing this somatic symptom of depression.
However, interpretation can be challenging due to the ambiguity in the question used to
assess changes in appetite (“Over the past two weeks, how often have you been bothered by
poor appetite or overeating?”), which asks about both negative or positive changes in
appetite that could relate to either melancholic/typical depression (characterized by
decreased appetite and weight loss) or to atypical depression (characterized by overeating
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and weight gain). Some evidence indicates that atypical depression is more strongly
associated with inflammation and BMI than is melancholic depression.50
From a physiologic perspective, endocrine changes in adipose-related hormones can
partially explain how inflammation may be related to changes in appetite among
individuals with different BMI levels. Leptin, an adipocyte-derived hormone also serves as
a feedback signal to control energy intake and regulate hunger.51 Increased leptin signaling
associated with weight gain or excess adipose tissue increases energy expenditure and
suppresses food intake, whereas decreased leptin signaling elicits anabolic activities by
reducing energy expenditure and increasing food intake.51 Leptin levels are proportional
to fat mass, but sustained high levels can lead to leptin resistance, which is a hallmark of
obesity. Elevated CRP levels can also lead to leptin resistance.52 Therefore, leptin may play
a more influential role in controlling changes in appetite and weight, but among those with
elevated CRP, hunger and appetite regulation through leptin may be compromised if leptin
resistance is present. A recent study53 found that rats treated with a leptin receptor
antagonist showed depressive-like symptoms accompanied by peripheral inflammation,
demonstrating that leptin resistance can induce an obesity phenotype in healthy rats that is
characterized by immune changes and depressive like behaviors. These observations
support the idea that comorbid obesity and depressive illness develop are a joint response
to changes in peripheral endocrine and metabolic environment.
Our results are consistent with findings that show an inverse association between
regular physical activity and serum concentration of inflammatory markers, suggesting
that physical activity may have anti-inflammatory properties.54,55 The most sedentary
women in our analysis had slightly higher mean hs-CRP levels, and LTPA was inversely
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associated with total depression. These findings agree with previous suggestions of
physical activity as a prevention or treatment for depression.56,57 Although little to no LTPA
appeared to increase the odds of depression in this cross-sectional study, we cannot rule
out a possible reverse causation, where those with high depression scores are more
sedentary. Suarez et al (2013) found that high depression scores may inhibit the antiinflammatory effects of LTPA.29
Our study has important strengths, including a large, diverse sample of women
representative of the US population, the use of a validated, multidimensional depressive
symptom measure, and the testing of multiple candidate mediators such as BMI, physical
activity, and sleep. We also adjusted for sleep duration to avoid potential confounding by
conditions such as sleep apnea or insomnia. Furthermore, we excluded those who are
currently taking antidepressants to prevent nondifferential misclassification of outcome,
given that some of the common side effects of antidepressants reported by patients are the
very symptoms that are used to measure depression, such as insomnia, hypersomnia,
agitation, restlessness, fatigue, somnolence, weight gain or weight loss, and decreased or
decreased appetite.58 This overlap of antidepressant side-effects and depression symptoms
provides a compelling reason for analyzing symptoms separately from total depression
scores.15
Our study also has important limitations. First, due to the cross-sectional nature of
NHANES study design, we were unable to determine the directionality of the association
between hs-CRP and depression symptoms. It is reasonable to speculate that the impact of
depression may affect inflammation-reducing activities, such as healthy eating or exercise,
and may lead to increased adiposity through weight gain. Prospective studies are
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warranted to establish directionality and experimental models are needed to understand
causality. The lack of additional markers of inflammation can also be considered a
limitation; however, CRP is considered the best marker of systemic inflammation.59 In
healthy young adults CRP is relatively stable, with a median concentration of around 0.8
mg/L, a 90th percentile of around 3 mg/L and a 99th percentile of approximately 10 mg/L.60
We excluded those with CRP levels higher than 10 mg/L, in order to avoid spurious
associations between depression and acute inflammation due to current infections.
Although CRP levels tend to remain stable in the general population, they can vary
significantly across the menstrual cycle, as reported by Gaskins et al (2012), who observed
a larger portion of women with CRP levels above 3 mg/L during menses compared to other
phases of the menstrual cycle.61 There is evidence that inflammation markers are
associated with menstrual symptoms and PMS,62 so it may also help to standardize CRP
measurements to menstrual cycle phase in reproductive aged women. In addition,
depending on the phase of the menstrual cycle our participants were currently in when
they were interviewed, their symptoms of depression as measured by the PHQ-9 may have
been higher or lower if they experienced pre-menstrual syndrome. These issues of
misclassification of exposure or outcome may have biased our results towards the null.
Data on menstrual cycle phase would have allowed us to discern whether depression
symptoms were related to hormonal changes or PMS. And finally, this survey from a noninstitutionalized population may represent only less severe depression, because those who
may be experiencing severe depression may either be institutionalized or
disproportionately chose not to participate in the survey. Therefore, our results might not
be generalizable to women with severe depression or major depressive disorder.
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7.6 Conclusion
In summary, we found that the relationship between CRP and depressive symptoms
varies by BMI; among those who are underweight, CRP was positively associated with
depressive symptoms. Furthermore, the relationship between inflammation and changes in
appetite and sleep disturbance may underlie previous findings that somatic depression is
more prevalent among women. The current study expands our understanding of how
systemic inflammation may contribute to depression symptoms among women of
reproductive age. Understanding how inflammation and BMI may affect depression
symptoms among women can help identify potential novel treatment avenues that may
benefit from changes in lifestyle to promote greater efficacy and remission.
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Table 4: Distribution of covariates by depression in women of reproductive age from NHANES 2005-2008 (N=1489)
Total
Population
N
Total population sample
C-reactive protein (mg/L)*
Age, years (mean, SE)
Sleep per night, hours (mean, SE)
Body Mass Index (kg/m2)
less than 18.5
18.5 to 24.9
25-29.9
30 or greater
p-trend
Marital Status
Single/Never Married
Married/with partner
Divorced/Separated/Widowed
Education
Less than Highschool
Highschool or GED
Some college
College graduate
p-trend
Race/Ethnicity
Non-Hispanic White
Mexican Hispanic
Other Hispanic
Non-Hispanic Black
Other Race
Oral Contraceptive use
Not currently using
Currently using
Smoke
Not current smokers

%

1489
1.3
31.7
6.9

1.2, 1.4
0.3
0.1

49
593
423
422

3.5
44.4
26.3
25.9

Total PHQ-9 Score
(range 0-27)
Mean

SE

2.9

0.1
----

2.5
2.6
3.0
3.4

0.5
0.1
0.3
0.3

p-value

--

Somatic
Depression Score
(range 0-12)
Mean

SE

1.8

0.1
----

1.6
1.7
1.9
2.1

0.3
0.1
0.2
0.1

0.06

29.2
60.4
10.2

3.0
2.7
4.0

0.2
0.1
0.5

369
354
482
284

15.6
20.6
36.0
27.8

4.1
3.5
2.9
2.0

0.3
0.3
0.2
0.2

1.9
1.7
2.4

0.1
0.1
0.3

2.4
2.1
1.8
1.4

0.2
0.2
0.1
0.1

2.8
3.2
3.6
3.4
2.9

0.2
0.2
0.4
0.3
0.3

80.8
19.2

3.0
2.3

0.1
0.3

1126

76.3

2.5

0.1

0.1
----

0.9
1.0
1.1
1.4

0.2
0.1
0.1
0.1

1.8
1.9
2.1
2.1
1.7

0.1
0.1
0.2
0.1
0.2

0.1
0.2

1.6

0.1

<0.001

1.0
1.0
1.7

0.1
0.1
0.3

1.7
1.4
1.1
0.6

0.1
0.2
0.1
0.1

Yes
%

N

%

p-value

1357
1.3
31.7
7.0

92.5
1.2, 1.4
0.3
0.1

13
2
1.6
32
6.1

7.5
1.3, 1.9
0.8
0.2

-0.09
0.48
<0.01
0.43

47
543
385
380

97.1
93.3
91.5
91.4

2
50
38
42

2.9
6.7
8.5
8.6

508
718
131

93.6
93.5
83.5

45
65
22

6.4
6.5
16.5

317
317
446
276

86.0
89.1
93.0
97.9

51
37
36
8

14.0
10.9
7.0
2.1

508
336
122
315
76

92.9
92.5
89.4
89.7
96.2

49
28
19
33
3

7.1
7.5
10.6
10.3
3.8

1118
201

92.0
95.5

11
3
12

8.0
4.5

1057

95.3

69

4.7

2E-04

<0.001

<0.01

<0.001
0.27
1
1.3
1.5
1.3
1.2

0.1
0.1
0.2
0.1
0.1

0.26

0.01
1.2
0.8

0.1
0.2

0.9

0.1

<0.001
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--

No
N

0.01
0.08

0.05
1.9
1.5

p-value

0.08

<0.001
0.37

0.01
1231
213

1.1

<0.001

<0.01
0.27
63.5
10.2
6.6
12.6
7.2

SE

0.02
0.15

<0.001

557
364
141
348
79

--

Mean

0.13

0.01
0.12
553
783
153

p-value

High Depression Score
(PHQ-9 score ≥10)

Non-Somatic
Depression Score
(range 0-15)

0.09

<0.001

<0.01

Current smokers
324
23.7
4.4
0.4
2.7
0.2
1.8
0.2
263
83.4
61
16.6
Alcohol Consumption
0.57
0.63
0.81
none
386
24.3
2.8
0.2
1.8
0.1
1.1
0.1
351
92.5
35
7.6
<1 drink/day
901
75.0
3.0
0.2
1.9
0.1
1.1
0.1
818
92.4
83
7.6
>1 drink/day
10
0.7
4.4
2.0
2.4
1.0
2.0
1.0
6
75.8
4
24.2
p-trend
0.47
0.43
0.56
Leisure Time Physical Activity
<0.001
<0.001
<0.001
Q1 (0-64 MET minutes/week)
386
25.1
4.2
0.3
2.5
0.2
1.7
0.2
321
84.5
65
15.5
Q2 (65-594 MET min/week)
302
24.8
2.5
0.2
1.6
0.1
0.9
0.1
283
95.2
19
4.9
Q3 (595-1560 MET min/week)
270
23.9
2.3
0.2
1.6
0.1
0.8
0.1
258
96.3
12
3.7
Q4 (>1560 MET min/week)
321
26.3
2.2
0.3
1.4
0.2
0.8
0.1
306
95.9
15
4.1
p-trend
<0.001
<0.001
<0.001
Weighted regression and t-tests for continuous depression scores and design-based Pearson chi square for categorical depression variables. *Geometric mean and 95%
CI for ln-transformed CRP.
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0.24

<0.01

Table 5: Distribution of covariates by inflammation (hs-CRP) in women of reproductive age
from NHANES 2005-2008 (N=1,489)
hs-CRP*
Geometric
mean
Total population sample
Depression Score (PHQ-9)
Age, years (mean, SE)
Sleep per night, hours (mean, SE)
Body Mass Index (kg/m2)
less than 18.5
18.5-24.9
25-29.9
30 or greater
p-trend
Marital Status
Single/Never Married
Married/Living with partner
Divorced/Separated/Widowed
Education
Less than High school
High school or GED
Some college
College graduate
p-trend
Race/Ethnicity
Non-Hispanic White
Mexican Hispanic
Other Hispanic
Non-Hispanic Black
Other Race
Oral Contraceptive use
Not current user
Current user

CRP<1mg/L

hs-CRP Category
1<CRP<3mg/L
3<CRP<10mg/L

95% CI

p-value

N

%

N

%

N

%

p-value

1.3

1.16, 1.42
----

--

553
2.6
31.9
7.1

38.7
0.2
0.4
0.1

492
2.9
31.9
6.9

33.6
0.2
0.6
0.1

444
3.4
32.6
6.8

27.8
0.3
0.4
0.1

-<0.05
0.42
0.05
<0.001

0.5
0.8
1.6
3.0

0.33, 0.78
0.66, 0.87
1.9, 1.75
2.63, 3.40

32
336
137
48

72.6
56.6
31.6
10.5

12
172
171
135

20.9
29.6
41.3
34.1

5
85
115
239

6.5
13.8
27.0
55.4

<0.001

<0.001
0.10
1.3
1.3
1.5

1.14, 1.47
1.10, 1.43
1.27, 1.79

0.66
221
283
49

38.8
39.6
32.6

175
260
57

34.3
32.4
38.2

157
240
47

29.2
27.8
29.2

0.005
1.6
1.5
1.3
1.0

1.35, 1.95
1.24, 1.71
1.12, 1.47
0.88, 1.23

0.002
122
128
176
126

30.5
36.5
36.1
48.00

117
119
165
91

34.3
32.2
35.9
31.3

129
107
141
67

35.2
31.4
28.0
20.7

216
118
52
126
41

39.3
31.6
36.1
34.8
52.6

195
121
47
105
24

34.7
34.2
30.3
30.3
31.6

146
125
42
117
14

26.1
34.2
33.7
34.9
15.8

501
42

43.3
21.0

394
82

31.7
40.8

336
89

25.0
38.2

<0.001
0.009
1.3
1.6
1.4
1.5
0.8

1.10, 1.44
1.33, 1.99
0.99, 2.09
1.33, 1.71
0.58, 1.10

1.1
2.1

1.02, 1.27
1.73, 2.49

0.05

<0.001
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<0.001

Smoke

0.13

Not a current smoker

1.3

1.12, 1.40

Current smoker

1.4

1.22, 1.62

Alcohol Consumption

0.49
425

39.5

369

32.9

332

27.7

109

35.7

114

36.1

101

28.2

0.09

0.02

None

1.6

1.29, 1.91

121

33.9

120

29.8

145

36.3

<1 drink/day

1.2

1.09, 1.37

339

39.8

318

34.8

244

25.3

>1 drink/day

1.4

0.73, 2.64

3

33.2

5

52.2

2

14.6

p-trend

0.04

Leisure Time Physical Activity

0.05

0.03

Q1 (0-64 MET min/week)

1.5

1.33, 1.78

116

29.4

144

38.7

126

32.0

Q2 (65-594 MET min/week)

1.1

0.88, 1.42

126

44.7

90

30.0

86

25.3

Q3 (595-1560 MET min/week)

1.2

1.01, 1.39

113

43.3

84

33.3

73

23.4

Q4 (>1560 MET min/week)

1.2

1.05, 1.37

125

40.8

110

34.5

86

24.8

p-trend

0.02

*ln-transformed hs-CRP, with geometric means and 95% confidence intervals. Weighted regression and t-test for continuous hsCRP and chi square test for categorical CRP.
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Table 6: Association of total depression score and depression subtypes with
inflammation in women of reproductive age from NHANES 2005-2008 (n=1489)
Depression defined as:
Total PHQ-9 score
(range 0-27)
Per 1 S.D. increase
in hs-CRP:
Unadjusted Model
Model 1
Model 2

β
(95% CI)

p-value

0.32
(0.10, 0.54)
0.24
(0.02, 0.46)

0.006

0.11
(-0.16, 0.37)

0.43

0.03

Somatic
Depression score
(range 0-12)
β
(95% CI)

p-value

0.17
(0.04, 0.30)
0.13
(0.006, 0.26)

0.01

0.06
(-0.11, 0.22)

0.48

0.04

Non-somatic
Depression score
(range 0-15)
β
(95% CI)

p-value

0.14
(0.04, 0.25)
0.11
(0.002, 0.22)

0.01

0.05
(-0.08, 0.18)

0.42

0.05

Model 1 adjusted for age, race/ethnicity, education, marital status, smoking and oral contraceptive use. Model 2
includes those variables adjusted in Model 1 plus sleep, leisure-time physical activity and body mass index
categories.
Figure 2: Linear regression analysis assessing mediators/confounders of the relationship between hs-CRP and (a) total
depression score, (b) somatic depression score and (c) non-somatic depression score among of reproductive age from NHANES
2005-2008.
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Table 7: Association of total depression score and depression subtypes with inflammation in
women of reproductive age from NHANES 2005-2008 stratified by Body Mass Index categories
Depression defined as:
Somatic
Non-somatic
Total PHQ-9 score
Depression score
Depression score
(range 0-27)
(range 0-12)
(range 0-15)
Per 1 S.D. increase
in hs-CRP:
BMI <18.5 kg/m2
Unadjusted
Adjusted
BMI 18.5-24.9 kg/m2
Unadjusted
Adjusted

β
(95% CI)
0.51
(-0.08, 1.10)
1.60
(0.74, 2.47)

p-value
0.09

0.27
(-0.18, 0.73)
1.07
(0.47, 1.66)

0.001

0.15
(-0.18, 0.49)
0.01
(-0.34, 0.36)

0.36

0.13
(-0.39, 0.64)
0.15
(-0.55, 0.86)

0.62

0.20
(-0.41, 0.80)
0.29
(-0.40, 0.98)

0.51

β
(95% CI)

0.95

p-value
0.23
0.001

0.08
(-0.16, 0.32)
-0.03
(-0.23, 0.16)

0.51

0.06
(-0.22, 0.35)
0.06
(-0.35, 0.47)

0.65

0.12
(-0.25, 0.49)
0.24
(-0.12, 0.60)

0.52

0.72

β
(95% CI)
0.24
(-0.10, 0.57)
0.49
(0.15, 0.84)

p-value
0.16
0.007

0.08
(-0.06, 0.21)
0.05
(-0.14, 0.24)

0.27

0.06
(-0.20, 0.32)
0.09
(-0.24, 0.43)

0.64

0.08
(-0.23, 0.39)
0.03
(-0.34, 0.41)

0.60

0.60

BMI 25-29.9 kg/m2
Unadjusted
Adjusted
BMI ≥30 kg/m2
Unadjusted
Adjusted

0.66

0.40

0.77

0.19

0.58

0.85

Adjusted models include age, race/ethnicity, marital status, education, smoking, oral contraceptive use, physical
activity, sleep and continuous body mass index.
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Table 8: Distribution of c-reactive protein and CRP categories by dichotomized individual depression symptoms among women
C-Reactive Protein Categories
Serum hs-CRP*
<1 mg/L
1-3mg/L
3-10 mg/L
Mean
95% CI
p-value
N
%
N
%
N
%
p-value
Trouble sleeping**
0.009
0.07
No
1.24 (1.1, 1.4)
492 91.4 421
86.1
380 86.3
Yes
1.70 (1.4, 2.1)
61
8.7
71
13.9
64
13.7
Fatigue
0.31
0.56
No
1.27 (1.1, 1.4)
464 85.1 418
85.4
360 82.4
Yes
1.41 (1.2, 1.7)
89
14.9 74
14.6
84
17.6
Abnormal appetite**
<0.001
<0.001
No
1.24 (1.1, 1.4)
508 93.2 454
93.2
388 86.3
Yes
1.85 (1.6, 2.2)
45
6.8
38
6.8
56
13.7
Moving or speaking too slow or too fast
0.09
0.35
No
1.28 (1.2, 1.4)
539 98.2 475
96.9
427 96.6
Yes
1.75 (1.3, 2.5)
14
1.8
17
3.1
17
3.4
Anhedonia
0.35
0.10
No
1.28 (1.2, 1.4)
526 96.4 459
94.2
418 95.3
Yes
1.4
(1.1, 1.8)
27
3.6
33
5.8
26
4.7
Depressed mood
0.17
0.39
No
1.27 (1.1, 1.4)
516 95.3 463
94.2
407 92.7
Yes
1.56 (1.2, 2.0)
37
4.7
29
5.8
37
7.3
Low self-esteem
0.27
0.48
No
1.27 (1.2, 1.4)
527 96.0 467
94.7
414 94.1
Yes
1.56 (1.1, 2.2)
26
4.0
25
5.3
30
5.9
Trouble concentrating
0.18
0.19
No
1.27 (1.2, 1.4)
530 96.2 472
96.7
418 93.9
Yes
1.66 (1.1, 2.4)
23
3.8
20
3.3
26
6.1
Suicidal ideation
0.29
0.31
No
1.28 (1.2, 1.4)
545 99.4 488
99.6
436 98.8
Yes
1.83 (0.9, 3.7)
8
0.6
4
0.4
8
1.2
Weighted t-tests and design-based Pearson chi square for categories of CRP. *Natural log transformed hs-CRP. **Significant trend test for weighted proportions.
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Table 9: Linear regression of total depression score and individual depression symptoms with hs-CRP in women of
reproductive age from NHANES 2005-2008
Somatic Depression Symptoms
Total PHQ-9 score
Per 1 S.D.
increase
in hs-CRP:
Unadjusted
Model 1
Model 2

β
(95% CI)
0.38
(0.14, 0.62)
0.15
(-0.11, 0.42)
-0.27
(-0.99, 0.46)

p-value
0.003
0.25
0.46

Model 3

--

Per 1 S.D.
increase
in hs-CRP:

Anhedonia
β
p-value
(95% CI)
0.03
0.02
(0.006, 0.06)
0.01
0.63
(-0.02, 0.04)
-0.008
0.91
(-0.14, 0.13)
-0.003
0.83
(-0.03, 0.02)

Unadjusted
Model 1
Model 2
Model 3

Sleep disturbance
β
(95% CI)
0.06
(0.002, 0.11)
0.04
(-0.02, 0.10)
0.09
(-0.16, 0.34)
0.03
(-0.02, 0.08)

Fatigue*

Abnormal appetite*

β
β
p-value
p-value
(95% CI)
(95% CI)
0.04
0.02
0.51
0.07
0.001
(-0.04, 0.08)
(0.03, 0.11)
0.21
0.01
0.72
-0.009
0.73
(-0.06, 0.09)
(-0.06, 0.04)
0.46
-0.27
0.07
-0.23
0.02
(-0.55, 0.02)
(-0.41, -0.04)
0.27
-0.0004
0.99
-0.02
0.25
(-0.06, 0.06)
(-0.07, 0.02)
Non-somatic Depression Symptoms
Depressed mood
Low Sef-esteem
Trouble concentrating
β
β
β
p-value
p-value
p-value
(95% CI)
(95% CI)
(95% CI)
0.04
0.05
0.03
0.17
0.04
0.01
(0.001, 0.07)
(-0.01, 0.07)
(0.009, 0.07)
0.002
0.92
0.01
0.66
0.02
0.26
(-0.04, 0.05)
(-0.04, 0.06)
(-0.01, 0.05)
0.06
0.53
-0.08
0.41
-0.07
0.30
(-0.13, 0.24)
(-0.26, 0.11)
(-0.20, 0.06)
-0.01
0.56
-0.001
0.96
0.01
0.47
(-0.04, 0.02)
(-0.04, 0.04)
(-0.02, 0.04)
p-value

Psychomotor
abnormalities
β
p(95% CI)
value
0.03
0.03
(0.003, 0.05)
0.01
0.44
(-0.02, 0.04)
0.03
0.52
(-0.07, 0.14)
0.007
0.69
(-0.03, 0.04)
Suicidal Ideation
β
p(95% CI)
value
0.008
0.18
(-0.004, 0.02)
0.01
0.17
(-0.005, 0.03)
0.04
0.16
(-0.02, 0.09)
0.01
0.22
(-0.006, 0.03)

β= standardized beta coefficient for increase in 1 standard deviation in log-transformed hs-CRP. Model 1 is adjusted for age, race/ethnicity, marital status, education,
smoking, oral contraceptive use, sleep, antidepressant use, leisure-time physical activity, and body mass index. Model 2 is model 1 plus an interaction term for
BMIxCRP. Model 3 is additionally adjusted for the sum of the remaining depression items (mutually adjusted associations). *Interaction term for BMIxCRP is statistically
significant
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Table 10: Logistic regression of association of total depression score and individual depression symptoms with
hs-CRP in reproductive-aged women from NHANES 2005-2008
High depression
score
Per 1 S.D.
increase
in hs-CRP:
Unadjusted
Model 1
Model 2

Unadjusted
Model 1
Model 2

Sleep disturbance

Fatigue

Abnormal appetite

Psychomotor
abnormalities

OR
(95% CI)

p-value

OR
(95% CI)

p-value

OR
(95% CI)

p-value

OR
(95% CI)

p-value

OR
(95% CI)

p-value

1.18

0.07

1.32

0.01

1.1

0.31

1.42

<0.001

1.31

0.11

(0.98, 1.41)

(1.07, 1.62)

--

1.23

(0.91, 1.32)
0.07

(0.98, 1.5)
--

1.31

0.94

(1.21, 1.67)
0.64

(0.73, 1.22)
0.05

1.03

1.36

(0.94, 1.85)
0.002

(1.12, 1.64)
0.88

0.91

1.12

0.61

(0.72, 1.73)
0.53

(1.01, 1.71)
Anhedonia

Per 1 S.D.
increase
in hs-CRP:

Somatic Depression Symptoms

(0.71, 1.48)
(0.68, 1.22)
Non-somatic Depression Symptoms
Trouble
Depressed mood
Low Self-esteem
concentrating

1.03

0.90

(0.62, 1.73)
Suicidal Ideation

OR
(95% CI)

p-value

OR
(95% CI)

p-value

OR
(95% CI)

p-value

OR
(95% CI)

p-value

OR
(95% CI)

p-value

1.10

0.36

1.19

0.18

1.19

0.29

1.25

0.20

1.37

0.33

(0.90, 1.34)
0.88

0.28

(0.92, 1.54)
1.02

0.90

(0.86, 1.64)
0.99

0.97

(0.88, 1.79)
1.11

0.60

(0.72, 2.61)
1.13

0.74

(0.70, 1.11)
0.91
(0.67, 1.24)

(0.74, 1.40)
0.55

0.99
(0.69, 1.42)

(0.67, 1.48)
0.94

1.19
(0.74, 1.92)

(0.74, 1.66)
0.46

1.14
(0.78, 1.66)

(0.54, 2.34)
0.49

1.82

0.06

(0.97, 3.40)

Model 1 is mutually adjusted for the sum of other depressive symptoms. Model 2 is model 1 plus age, race/ethnicity, marital status, education, smoking, oral contraceptive use, sleep
duration, leisure-time physical activity, and body mass index.

109

Figure 3: The effect of BMI on abnormal appetite score (item 5 of the PHQ-9) for women
with no inflammation (CRP=0.4 mg/L), low and moderate inflammation (CRP=1.9mg/L and
CRP=5.6mg/L, respectively).
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CHAPTER 8
“THE ASSOCIATION BETWEEN SERUM PYRIDOXAL 5’-PHOSPHATE AND DEPRESSION
VARIES BY INFLAMMATION AND DEPRESSION SYMPTOMS AMONG WOMEN OF
REPRODUCTIVE AGE FROM NHANES 2005-2008”

8.1 Abstract
Depression is the leading cause of disease burden in U.S. women of reproductive
age. Inflammation is associated with depression, yet the mechanism for this association
remains unclear. Vitamin B6 status is reportedly compromised during inflammation and
has been linked to depression. In secondary data analyses, we evaluated the association
between vitamin B6 status, inflammation, and depression in 1,489 non-pregnant women
(18-44 yrs) from NHANES 2005-2008. Depression scores were calculated based on the
Patient Health Questionnaire-9 (PHQ-9) and categorized into total depression, somatic and
non-somatic depression. High depression score (PHQ-9 ≥10) was also used as an outcome,
as were individual symptoms of depression. Vitamin B6, as serum pyridoxal-5'phosphate
(PLP), was categorized as deficient (<20 nmol/L), insufficient (20-29.9 nmol/L) or normal
(≥30 nmol/L). Low inflammation was defined as a C-reactive protein (CRP) concentrations
between 1-3 mg/L and moderate inflammation as CRP between 3-10 mg/L. Overall, 7.5%
of women had a high depression score, but this proportion varied by inflammation and
vitamin B6 status. When stratified by CRP categories, the prevalence of depression was
higher among those with vitamin B6 deficiency (21%) than among those with vitamin B6
insufficiency (10%) or those with normal vitamin B6 status (5%), although this trend was
only significant among those with moderate inflammation (p-trend=0.02). A similar trend
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of increased depression with lower vitamin B6 concentration was observed among women
with CRP levels between 1-3 mg/L, but not among those with CRP <1 mg/L. In
multivariable models including individual depression symptoms, PLP levels below 30
nmol/L were associated with higher odds of experiencing suicidal ideation (OR: 7.33,
p=0.01 and OR: 3.5, p=0.06 for B6 deficiency and insufficiency, respectively) and depressed
mood (OR: 3.12, p=0.004 for B6 insufficiency). Among those with elevated CRP, vitamin B6
deficiency was associated with a higher score for psychomotor abnormalities (p=0.02).
Understanding the mechanism linking inflammation and vitamin B6 to various dimensions
of depression could lead to new approaches to prevent and treat depression.

8.2 Introduction
Depression is common in the United States; approximately 16% of adults experience
clinical depression at some point in their lives.1 Women are two- to three-times more
likely than men to experience depression,2,3 and among women, depression is the leading
source of disease burden.2–4 Numerous risk factors for depression have been identified,
among them vitamin B6 deficiency.5–8 Population-based studies estimate that a quarter of
U.S. women of childbearing age have suboptimal vitamin B6 concentrations, and the
prevalence may be even higher among women currently taking oral contraceptives (78%).9
In addition to a potential link with depression, these numbers are alarming considering
that suboptimal maternal vitamin B6 status has been shown to adversely affect other health
outcomes, including conception rates10 and pregnancy complications such as spontaneous
abortions,11 and may affect the neurological development of the offspring.12
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Serum pyridoxal 5’-phosphate (PLP), the bioactive form of vitamin B6, serves as a
coenzyme in numerous metabolic reactions, including the tryptophan-serotonin pathway,
and a lack of vitamin B6 may lead to depression by reducing serotonin levels.13 Studies
examining dietary vitamin B6 alone have yielded conflicting results regarding the
association between vitamin B6 intake and depression.14,15 However, studies assessing
serum PLP and depression have consistently shown an inverse association.6–8 To date,
most studies of vitamin B6 and depression have been limited by small sample size, use of an
elderly population, heterogeneity in the measures of depression, or failure to account for
inflammatory biomarkers. Inflammation is an important consideration because, in addition
to functioning as a cofactor in neurotransmitter synthesis, vitamin B6 plays an important
role in the production of cytokines, the primary mediators of inflammation.16 Lower serum
PLP concentrations are associated with inflammation,17,18 which may not necessarily be
linked to dietary vitamin B6 inadequacy in some cases, but rather could be due to metabolic
phenomena inherent to inflammation.19 During inflammation, tryptophan metabolism
shifts from serotonin synthesis to generation of neuroactive metabolites, such as quinolinic
acid and kynurenic acid, through the kynurenine pathway.20 This shift in utilization of
vitamin B6 could potentially contribute to depression. To date, no studies have investigated
how inflammation may affect the association between vitamin B6 status and depression.
The purpose of this study was to further explore the relationship between vitamin
B6 status and depression among U.S. reproductive-age women and to determine whether
high sensitivity C-reactive protein (hs-CRP), a marker of inflammation, modifies the
association between vitamin B6 and depression subtypes or individual symptoms of
depression among reproductive-age women.
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8.3 Methods
8.3.1 Study Design and Study Population
We analyzed cross-sectional data from the 2005-2008 National Health and Nutrition
Examination Survey (NHANES), which is national survey from the National Center for
Health Statistics of the Centers for Disease Control and Prevention (CDC), designed to
assess the health and nutritional status of the U.S. population. The NHANES employs a
complex, multistage, probability sampling design to select persons representative of the
civilian, non-institutionalized US population, with oversampling of special sub-populations,
such as racial and ethnic minorities. Detailed descriptions of the survey design and
procedures are available at the NHANES website.21
Briefly, approximately 5,000 people are surveyed each year via in-person interviews
and physical examinations. The interview, which is conducted in participants’ homes,
includes demographic, socioeconomic, dietary, and health-related questions; the
examination component is comprised of medical, dental, and physiological measurements,
as well as laboratory tests, which take place in specially-designed and equipped mobile
examination centers (MEC) that travel throughout the country. The National Center for
Health Statistic’s Institutional Review Board has reviewed and approved the NHANES
protocol.
Participants were eligible for our study if they were women of reproductive age
(15-44 years old) who were not pregnant. From the initial sample of 2,609 eligible women,
we excluded those with missing data for either depression (n=506) or serum pyridoxal 5’phosphate (n=7). Depression data for individuals younger than 18 years old was not
publicly available; therefore, our age range was restricted to women ages 18-44 years old.
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Also excluded were women with acute inflammation denoted by CRP levels above 10 mg/L
(n=201),22 those who were taking anti-inflammatory medications, including NSAIDs
(n=70), and those who reported current antidepressant use (n=135). The remaining
sample contained 1,489 women.

8.3.2 Assessment of Depression Status
The Patient Health Questionnaire-9 (PHQ-9)23 was administered during the MEC
interview to assess depressive symptom severity over the past two weeks. Based on the
diagnostic criteria for major depressive disorder in the Diagnostic and Statistical Manual
Fourth Edition (DSM-IV), the PHQ-9 employs a 4-point scale (0=not at all, 1= several days,
2= more than half the days, 3= nearly every day) to determine the frequency with which
respondents experienced the following nine symptoms of major depressive disorder:
anhedonia, depressed mood, sleep disturbance, fatigue, appetite changes, low self-esteem,
concentration problems, psychomotor retardation/agitation, and suicidal ideation. Total
depression scores range from 0 to 27, with scores of 10 or higher indicative of clinical
depression.24 The PHQ-9 has been shown to be a reliable and valid questionnaire as
indicated by its high internal consistency and good sensitivity (88%) and specificity (88%)
for identifying cases of major depressive disorder in community samples.25–27
In addition to the total depression score, we calculated somatic and cognitiveaffective depression subscale scores. The somatic depression subscale was calculated by
adding the scores for frequency of somatic depression symptom from the PHQ-9 (sleep
disturbance, fatigue, appetite changes, and psychomotor retardation/agitation) and the
cognitive-affective subscale score was calculated adding the scores for non-somatic
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symptoms (anhedonia, depressed mood, low self-esteem, concentration problems and
suicidal ideation).28 While previous factor analyses supported a one-factor model with all
nine items,29,30 recent confirmatory factor analyses have found that subscales of depression
dimensions may provide a better fit to the data.31,32 Some have also argued that given the
heterogeneity of symptoms for depression, individual symptoms should be analyzed.33 We
included a separate analysis for individual depressive symptoms, coded as continuous
variables (scores ranging from 0-3) and as binary variables. To dichotomize the variable,
those items with responses “more than half the days” and “nearly every day” indicated the
presence of the symptom.34,35

8.3.3 Serum Pyridoxal 5’-Phosphate
Fasting whole blood samples were collected during the medical examination.
Venipuncture was performed using standard phlebotomy techniques by NHANES trained
personnel. Serum specimens were processed, stored and shipped to the Division of
Environmental Health Laboratory Sciences, National Center for Environmental Health,
Centers for Disease Control and Prevention in Atlanta, Georgia. Further detailed
instructions on specimen collection and processing can be found at NHANES website.21
Briefly, serum PLP, the main bioactive form of vitamin B6, was measured using reversephase high performance liquid chromatography (HPLC) analysis using fluorometric
detection at 325nm excitation and 425nm emission. Quantitation of PLP was based on
analyte peak area interpolated against a five-point calibration curve from aqueous
standards. This HPLC assay has a lower limit of detection compared to the enzymatic assay
used in previous NHANES cycles (0.3 vs 10 nmol/L).21 Given that PLP was not normally
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distributed, PLP measures were converted to their natural logarithm to improve normality.
Serum PLP was also divided into categories indicating vitamin B6 deficiency (PLP
<20nmol/L), insufficiency (PLP 20 to 29.9 nmol/L) and sufficiency (PLP ≥30 nmol/L)
following previously used cut-offs for vitamin B6 status.36–38

8.3.4 Covariates and Confounders
We considered as possible covariates a selected set of demographic, lifestyle, and
socioeconomic factors using responses to the demographic and household sections of the
NHANES questionnaire. The National Center for Health Statistics (NCHS) standard
definitions for ethnicities were used; ethnicities were categorized as non-Hispanic whites,
non-Hispanic blacks, Mexican-Hispanics, other Hispanics, and other race. Educational
attainment was measured as the highest grade of school completed, and categorized into
four levels: less than high school, high school equivalent, some college, and college graduate
or above. The smoking assessment for respondents aged 18-19 years (MEC) was not
identical to that for respondents aged 20+ years (household interview). For respondents
aged 20+ years, we classified those who reported smoking at least 100 cigarettes during
their lifetime and reported that they now smoke cigarettes every day or some days as
current smokers. For respondents ages 18-19 years, we classified as current smokers those
who reported smoking 15 or more day in the last 30 days. To create the alcohol groups, we
used responses to the alcohol use interview at the MEC and calculated the drinks per day as
suggested by Case and Stewart.39 Alcohol consumption, which was only available for
participants of legal drinking age (21 and older), was categorized into abstainer, one or
fewer drinks/day and more than one drink per day. Leisure-time physical activity (LTPA)
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was assessed by asking participants about their involvement in 48 specific recreation
activities of moderate or vigorous intensity. Frequency was first multiplied by the duration
in hours and divided by 4.3 to obtain hours of LTPA per week. To calculate MET hrs/week,
each activity was multiplied by its MET level per NHANES physical activity codes.40
Participants were then categorized into quartiles of physical activity. Sleep duration was
assessed by asking participants how many hours of sleep they usually get on a
weekday/workday, and those who reported sleeping 12 or more hours were labeled as
sleeping 12 hours/night. Oral contraceptive use was determined by self-report of current
use, with “past” or “never” users classified as not currently using oral contraceptives (OC).
Body mass index (BMI) and high-sensitivity C-reactive protein (CRP) have been
associated with both vitamin B6 levels and depression9,17,41,42 and were examined as
potential confounders/mediators of the relationship between PLP and depression. BMI
(kg/m2) was computed from height and weight measurements and grouped into four
standard categories: underweight (BMI<18.5 kg/m2), normal weight (18.5 ≤ BMI<25),
overweight (25≤ BMI<30) and obese (BMI≥30 kg/m2). High-sensitivity c-reactive protein
was quantified using latex-enhanced nephelometry using a Dade Behring Nephelometer
(Dade Behring Diagnostics Inc, Somerville, NJ). CRP was classified into three categories:
those with no inflammation (CRP <1 mg/L), low inflammation (CRP 1-3 mg/L) and
moderate inflammation (CRP 3-10 mg/L) following previously used guidelines.22

124

8.3.5 Data Analysis
The complex survey design used for NHANES data collection was incorporated into
all data analyses using the “svy” command with appropriate weighting in Stata 12.0
(StataCorp LP, College Station, TX). Detailed information on the procedures for taking into
account sampling weights have been described elsewhere.43
Descriptive statistics were calculated for the overall sample using frequency
distributions for categorical variables and means and standard errors for continuous
variables. Because both PLP and hs-CRP were logarithmically transformed when analyzed
as continuous variables, geometric means (antilogarithms of the transformed means) and
their 95% confidence intervals are presented for serum PLP and hs-CRP. Bivariate analyses
were carried out for each covariate and ln-transformed PLP and vitamin B6 categories as
well as for covariates and total depression, somatic/non-somatic depression and binary
depression variables, using weighted ANOVAs, Chi square tests and 2-sample t-test as
appropriate. T-tests and chi-square tests were performed to assess crude differences in
PLP and vitamin B6 status by individual depressive symptom. Adjusted analyses were
performed using multivariable linear regression. In linear regression models, all covariates
that changed the estimated coefficient for the primary predictor of interest by more than
10% were retained in the multivariable model. In addition, known risk factors for
depression were retained in the model as well as those that were associated with both the
predictor and the outcome.
To explore variation in the association of vitamin B6 status with dimensions of
depression, we conducted a series of linear regression analyses in which total depression
score, somatic depression score, non-somatic depression score and each individual
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depression symptom served as an outcome variables. A similar series of logistic regression
analyses was also completed for dichotomized individual depressive symptoms. For all the
individual depression symptoms, we adjusted for the remaining depression symptoms to
account for any potential overlap between different symptoms and to reduce the
probability of type I error. Logistic regression analyses were also carried out for depression
PHQ-9 score of 10 or greater. The command “mfpigen” was used to assess all possible
interactions among variables in the full models.
C-reactive protein and BMI were assessed as potential mediators or effect modifiers
by running mediation tests, stratifying regression analyses, and by including multiplicative
interaction terms in the multivariable analysis. To quantify the effects of CRP and BMI on
any observed relationships between vitamin B6 status and depression, we carried out Sobel
mediation tests and Preacher and Hayes bootstrap tests of indirect effects.44,45 All linear
and logistic regression estimates were weighted using NHANES sample weights, which
account for the complex survey design, survey nonresponse and post-stratification.

8.4 Results
Description of Study Cohort. The characteristics of the 1,489 women who comprised
our final sample are shown in table 11. The mean age of our sample was 31.7 years. The
majority of women were white (63.5%), married or living with a partner (60.4%,), did not
use oral contraceptives (80.8%), reported an average of seven hours of sleep per night, and
were nonsmokers (76.3%). Almost eight percent (n=132) of women in our sample
reported moderate to severe depression symptoms indicative of clinically significant
depression, denoted by a score of 10 or higher on the PHQ-9 (Table 11).
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In bivariate analysis, depression scores were positively associated with BMI (ptrend <0.02) and hs-CRP (p-trend<0.02) and negatively associated with education
(p<0.001) and LTPA (p<0.001) (Table 12). Depression scores were higher for both somatic
and non-somatic subtypes among women who were not currently taking oral
contraceptives (p=0.05 and p=0.01, respectively) compared to OC users and for smokers
(p<0.001) compared to non-smokers. Women with high depression scores slept less (6.1
vs 7.0 hours/night, p<0.001) compared to those with low depression scores. The
prevalence of depression defined as a PHQ-9 score of 10 or greater was significantly higher
among women who were separated or divorced compared to women who were
married/living together with partner or who were single/not married; for those who
smoked compared to non-smokers; and those who reported the lowest levels of LTPA
compared to the rest of the LTPA quartiles. The prevalence of a high depression score was
lower among women who reported current oral contraceptive use compared to non-OC
users (4.5% vs 8.0%, p=0.09).
Approximately one third of women (32%) had suboptimal vitamin B6 levels and
10% percent had biochemical evidence of vitamin B6 deficiency (PLP<20 nmol/L). Serum
PLP was negatively associated with BMI (p-trend <0.001), CRP levels (p-trend <0.001), and
smoking dose (p-trend<0.001), and positively associated with LTPA (p-trend <0.001) and
education (p-trend<0.001). Those with vitamin B6 deficiency slept less than those with
insufficient and sufficient vitamin B6 levels (p=0.003). Vitamin B6 concentration did not
vary by age or oral contraceptive use (Table 12).
Association of PLP with depression scores. Mean serum PLP was lower among women who
had high depression scores compared to those who had low depression scores (34.4 vs
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47.1 nmol/L, p=0.004), and total depression score was higher for women who had vitamin
B6 deficiency compared to those who had insufficiency or sufficiency (4.4 vs 3.2 vs 2.6
points, respectively; p=0.003). In univariate analyses, vitamin B6 deficiency was associated
with a higher total depression score (β: 1.7, p=0.001), somatic depression score (β: 0.99,
p<0.001), and non-somatic depression score (β: 0.72, p=0.02). These associations were
attenuated and no longer significant after adjustment for demographics, lifestyle and
behavioral factors (data not shown).
To assess whether inflammation affects the association between vitamin B6 status
and depression, we first visualized the relationship using bar graphs (Figure 4). Depression
scores tended to increase with increasing CRP level, especially among those with vitamin
B6 deficiency (p-trend=0.04). When stratified by CRP categories (<1 mg/L, 1-3 mg/L and 310 mg/L), the prevalence of depression was highest among those with vitamin B6
deficiency, followed by those with vitamin B6 insufficiency; however, this trend was only
significant among those with moderate inflammation (CRP levels 3-10 mg/L ; ptrend=0.02), and borderline significant among those with low inflammation (p-trend=0.07)
(Figure 5). A similar pattern was found in linear regression models stratified by CRP levels.
Vitamin B6 deficiency was associated with higher total depression score (β: 1.48, p=0.01
and β:2.52, p=0.01) and somatic depression score (β:0.93, p=0.008; β:1.33, p=0.004)
among those with low or moderate inflammation, but not among those with CRP levels
below 1 mg/L in unadjusted analyses. Once again, adjustment for covariates completely
attenuated these results (data not shown).
To assess whether BMI or CRP were potential mediators or confounders of the
association between PLP and depression, we ran a series of Sobel mediation tests followed
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by bootstrap analysis for the Preacher and Hayes test of indirect effect.44,45 For total
depression score, 7.9% of the total effect was significantly mediated by CRP (p=0.045)
(Figure 6); BMI also attenuated the association between PLP and depression variables. For
total depression, the standardized PLP effect size was reduced by 10.8% upon addition of
BMI to the model (p=0.02); the effect of PLP on somatic and non-somatic depression was
also reduced by 9% and 13.5%, and these mediations were significant (p=0.03 and p-0.04,
respectively).
To determine which depression symptoms were associated with vitamin B6 status,
we estimated the bivariate associations, and then fit a series of linear and logistic
multivariable models for continuous and dichotomized symptoms. In bivariate analysis,
PLP was significantly lower among those experiencing most symptoms of depression,
except for moving or speaking too slow or too fast (p=0.13). The prevalence of vitamin B6
deficiency was significantly higher among those experiencing most individual depression
symptoms, except for low self-esteem (p=0.25) and trouble concentrating (p=0.17) (Table
13). In linear regression with individual depression symptoms, vitamin B6 deficiency was
significantly associated with a higher score for most of the symptoms of depression
(sleeping problems β: 0.30, p=0.001; fatigue β: 0.33, 0.001, abnormal appetite β: 0.27,
0.002; anhedonia β:0.18, p=0.03; depressed mood β: 0.22, p=0.008; low self-esteem β: 0.12,
p=0.05; suicidal ideation β: 0.07, p=0.05), but these associations were attenuated after
mutual adjustment and adjustment for demographics, behavioral, and lifestyle factors.
Compared to somatic symptoms, vitamin B6 deficiency was associated with fewer nonsomatic symptoms in unadjusted analysis among those with low inflammation levels
(anhedonia, low self-esteem) and moderate inflammation (depressed mood and suicidal
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ideation) in unadjusted analysis (data not shown). In univariate logistic regression with
dichotomized individual symptoms of depression, vitamin B6 deficiency was significantly
associated with all somatic symptoms (Table 14), and some non-somatic symptoms (Table
15). In the fully adjusted models, those with vitamin B6 deficiency had much higher odds of
experiencing suicidal thoughts (OR: 7.33, 95% CI 1.59-33.9), and those with vitamin B6
insufficiency had three times the odds of experiencing depressed mood (OR: 3.12, 95% CI
1.49-6.52) after adjustments.
High depression score was only associated with vitamin B6 deficiency in unadjusted
analyses (data not shown). There were no significant interactions between any variables
and vitamin B6. When stratified by CRP level, vitamin B6 deficiency was only crudely
associated with higher odds of high depression score among those with CRP levels between
1-10 mg/L (data not shown).

8.5 Discussion
In this large representative sample of reproductive age women, we found that
suboptimal vitamin B6 levels were associated with several dimensions of non-somatic
depression, including depressed mood and suicidal ideation. When considering
inflammation, the association of vitamin B6 deficiency with a higher score for the somatic
symptom of psychomotor agitation was observed among women with moderate
inflammation. Although previous studies have reported an association between lower
vitamin B6 status and increased depressive symptoms,6–8,15 our study is the first to examine
how inflammation may influence the association between vitamin B6 status and various
dimensions of depression among women of reproductive age.
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A role for suboptimal vitamin B6 levels in depression is supported by three previous
studies. The first, conducted in an elderly Danish population, found that plasma PLP
concentration was inversely associated with depression score after adjusting for age and
gender.6 A second study examined the association between plasma PLP in an elderly
population from the Boston Puerto Rican Study. They found that plasma PLP was inversely
associated with depression scores (β: -0.12, p<0.05), with vitamin B6 deficiency (PLP< 20
nmol/L) associated with an almost doubling of the odds of depression in multivariable
models (OR: 1.74, 95% CI 1.02, 2.89).7 In the most recent study, higher plasma PLP was
significantly associated with a decreased prevalence of depression (p-trend: 0.03) among
422 adults ages 21-67 years old in Japan.8 In cross-sectional analyses, they found that the
odds of depression were 46% lower among those in tertiles two and three (PLP >25.5
nmol/L; OR: 0.54, 95% CI 0.31-0.94 and OR: 0.54, 95% CI 0.30-0.96, respectively)
compared to those in the lowest tertile of PLP (range: 8.1 to 25.5 nmol/L), after adjusting
for numerous covariates (age, gender, office, smoking, alcohol intake, physical activity, job
position, marital status, history of cancer, cardiovascular disease, or mental disease, dietary
vitamin B12 intake, serum folate and homocysteine concentration, and depression score at
baseline). However, the association between PLP and depression was no longer significant
in longitudinal analyses. 8
Our results for total depression scores and high depression were only significant prior
to adjustments for sociodemographic, behavioral, and lifestyle factors, suggesting that
these covariates play a role in the relationship between vitamin B6 and depression. Because
of the cross-sectional design of NHANES, we cannot determine whether higher PLP levels
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are protective against depression or whether depression somehow leads to lower vitamin
B6 levels.
When investigating the association between PLP and different subtypes of depression,
we found that vitamin B6 deficiency (PLP <20 nmol/L), but not B6 insufficiency (20 <PLP
<30 nmol/L), was significantly associated with both higher somatic and non-somatic
depression scores in unadjusted analysis. This grouping of depression symptoms into
subtypes, although shown to be a better fit for data in factor analysis than the total sum
score of depression symptoms,28 may still be masking the association between vitamin B6
deficiency and specific symptoms of depression. Previously, vitamin B6 was associated with
depression among a Japanese population, but the association only reached statistical
significance when using a higher depression cut-off point of 19 instead of the usual cut-off
point of 16 in the Center for Epidemiological Studies Depression screener (CES-D).8 It is
possible that low vitamin B6 levels are only associated with more severe cases of
depression. In our analysis using dichotomized symptoms of depression, vitamin B6
deficiency was associated with higher odds of experiencing suicidal thoughts, a symptom
typically experienced by those with severe cases of depression (with PHQ-9 score of 15 or
higher).46 Furthermore, compared to women without suicidal thoughts, those experiencing
suicidal ideation also had the lowest mean serum PLP level of all the groups (21 vs 46.3
nmol/L, p<0.001). However, given the wide confidence intervals in regression analyses,
these results should be interpreted with caution, and a larger study with more cases of
depression may be necessary to get a more precise estimate of effect of vitamin B6
deficiency on symptoms of severe depression.
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Although the pathway linking vitamin B6 to depression is not entirely understood, a role
of vitamin B6 in tryptophan metabolism has been suggested. Vitamin B6, as PLP, serves as a
coenzyme in the tryptophan-serotonin pathway, and some suggest that a lack of vitamin B6
may cause depression by reducing serotonin levels.13 In addition, vitamin B6 also serves as
a key player in the kynurenine pathway, which is thought to play an important role in the
pathogenesis of inflammation-dependent depression.20 The shift in PLP metabolism to the
kynurenine pathway from its role in tryptophan-to-serotonin would result in lowered
serotonin levels, but the second pathway would also coincide with heightened circulating
inflammatory biomarkers. After stratifying by different levels of CRP, in unadjusted models,
vitamin B6 deficiency was associated with most dimensions of depression among those
with some degree of inflammation (denoted by CRP >1 mg/L), but not among those with no
inflammation (CRP <1mg/L). However, after adjustment for demographic, behavioral and
lifestyle factors, most of these associations were attenuated and no longer significant,
except for psychomotor retardation/agitation. Vitamin B6 deficiency was associated with a
higher score for psychomotor abnormalities (β: 0.14, p=0.02) among those with elevated
CRP (3-10mg/L) compared to those with normal PLP levels. Some evidence indicates that
inflammation may be related more to somatic symptoms of depression,47 which are more
pronounced in women than in men, rather than to non-somatic (affective) symptoms.48
These findings suggest that PLP may play a role in the activation of muscle synergy, which
is presumed to be modulated by neural command signals.49 Pyridoxine is a cofactor in the
metabolism and production of many neurotransmitters involved in regulation of mobility,
including serotonin, dopamine, and gamma-aminobutyric acid (GABA).50 Vitamin B6
deficiency may contribute to impaired motor performance given PLP’s indirect role in
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neural control of movement. It is possible that this motor impairment may be heightened
in the context of very low PLP levels and an additional trigger, such as the presence of
inflammation, but no studies to date have examined this possibility. Studies are needed to
investigate the kinetics and regulation of vitamin B6 vitamers and enzymes in different
compartments in the presence of inflammation.51
Our results suggest that CRP may act as an effect modifier in the association
between vitamin B6 status and depression. This conclusion is supported by our finding that
the crude association between vitamin B6 deficiency and depression was only evident
among those who have CRP levels above 1 mg/L, and it was more pronounced among those
with CRP levels above 3 mg/L. The question remains as to whether inflammation leads to
low PLP levels or whether low PLP levels enhance inflammation, but both scenarios would
probably be associated with higher depression scores.
There is evidence supporting an inflammation-to-vitamin B6 deficiency pathway,
since induced vitamin B6 deficiency did not lead to subsequent inflammation among a
group of healthy adults who underwent a 28-day vitamin B6 restriction study.52 Although
we cannot determine directionality of depression with either vitamin B6 or inflammation in
this cross-sectional study, we found the prevalence of depression (PHQ-9 score of 10 or
higher) did not vary significantly based on CRP levels (p=0.15). However, the prevalence of
depression did vary by vitamin B6 status, with a higher prevalence among those with lower
B6 levels (15.4% among those with B6 deficiency, 8.8% for B6 insufficiency and 5.9% among
those with normal B6 status, respectively, p=0.004). Although events of depression did not
vary significantly by CRP in this population, when stratified by CRP, the prevalence of
depression was mostly evident among those with higher levels of CRP and suboptimal B6
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status. If inflammation depletes circulating PLP levels due to increased demand for B6 for
the kynurenine pathway, then inflammation-reducing treatments may result in improved
vitamin B6 levels, and consequently, improved serotonin levels, which would theoretically
translate to lowered rates of depression. Many selective serotonin reuptake inhibitors
(SSRI) possess anti-inflammatory properties, and this is thought to be one of the
mechanisms by which SSRIs alleviate depression symptoms.53
We limited our study to biomarkers of vitamin B6 because studies examining dietary
vitamin B6 have yielded controversial findings on the association between vitamin B6 and
depression.14,15,54 However, those assessing circulating PLP concentrations and depression
have consistently shown an inverse association between plasma PLP and depression
scores. A possible reason for these inconsistencies may be the low correlation between
dietary vitamin B6 intake and plasma PLP that has been consistently observed in various
studies.7,8,55–58 Several non-dietary factors can affect circulating PLP concentration,
including body mass index, inflammation, smoking, and oral contraceptive use.9,56,59,60 In
our study, we controlled for all of these variables. Vitamin B6 supplements, on the other
hand, are positively correlated with circulating PLP levels,9,56,58 confirming that suboptimal
vitamin B6 status can be corrected via supplementation, but the amount of vitamin B6
intake needed to protect against vitamin B6 inadequacy may be elevated in the presence of
inflammation.17 Vitamin B6 supplementation with 50 mg/day of pyridoxine for 30 days
may correct vitamin B6 deficiency,61 but higher levels (100 mg/day) may be needed to
resolve inflammation among individuals with high inflammation levels, such as rheumatoid
arthritis patients.62 Longitudinal studies are needed to determine whether vitamin B6
supplementation alters inflammation and affects depression symptomatology or severity.
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Understanding these relationships will help to determine to what degree vitamin B6
supplementation could protect against inflammation-associated depression.
Almost a fifth of our sample reported current OC use, and contrary to previous
studies,9,63 oral contraceptive use was not related to a higher prevalence of vitamin B6
deficiency or depression in our sample. Current OC users had a slightly lower mean
depression score and lower prevalence of depression, which is also contrary to recent
findings from a large population-based study in the Netherlands, where OC use was
associated with increased risk of depression.63 Our findings are in agreement with a recent
randomized controlled trial that found OCs were associated with improvements in
depression among young women in the premenstrual phase.64 The prevalence of vitamin
B6 deficiency was 8.3% among OC users, compared to 11% among non-users (p=0.53), and
this is much lower than the calculations from Morris et al (2008) from NHANES 2003-2004
where up to 78% of current OC users had vitamin B6 deficiency.9 This could be due to more
routine vitamin B6 supplementation in OC users or analytical changes in PLP assessment
between the NHANES 2003-2004 and more recent cycles, where the previously used
enzymatic assay was changed to an HPLC method, which has a higher sensitivity.21 Two
more recent studies also failed to observe higher rates of vitamin B6 deficiency among OC
users.58,65
Our study has important strengths, including a large, diverse sample of women
representative of the US population, the use of a validated, multidimensional depressive
symptom measure, and the testing of multiple candidate mediators/confounders. We also
adjusted for sleep duration to avoid potential confounding by conditions such as sleep
apnea or insomnia. Furthermore, we excluded those who were currently taking
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antidepressants to prevent nondifferential misclassification of outcome, given that some of
the common side effects of antidepressants reported by patients are the very symptoms
that are used to measure depression, such as insomnia, hypersomnia, agitation,
restlessness, fatigue, somnolence, weight gain or weight loss, and decreased or decreased
appetite.66 This overlap of antidepressant side effects and depression symptoms provides
a compelling reason for analyzing symptoms separately from total depression scores.33
Our study also has important limitations. First, due to the cross-sectional nature of
the NHANES study design, we were unable to determine the directionality of the
association between PLP and depression symptoms. Both directions are plausible. Of the
three previous studies on PLP and depression, no significant prospective associations were
found between PLP and depression. One study,8 however, observed lower depression
scores after three years among those with better baseline vitamin B6 status (both PLP and
dietary), suggesting that vitamin B6 may decrease the risk of depression, rather than low
vitamin B6 level is the result of depression. Additionally, vitamin B6 can also act as an
antioxidant,67 so it is possible that adequate nutritional status and optimal vitamin B6 levels
could be protective against depression by reducing oxidative stress that may be associated
with inflammation-associated depression. And finally, this survey from a noninstitutionalized population may only capture those with less severe depression, because
those with severe depression may either be institutionalized or disproportionately unlikely
to participate in the survey. Therefore, our results might not be generalizable to women
with severe depression or major depressive disorder.
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8.6 Conclusion
In summary, vitamin B6 deficiency may be associated with symptoms experienced
among those with more severe cases of depression in this population, such as suicidal
ideation. When stratified by inflammation, we observed a pattern of increasing effect size
for vitamin B6 deficiency on individual somatic symptom scores with increasing CRP levels,
which was not evident for non-somatic symptoms. Although these patterns were only
observed in crude analyses, it remains possible nonetheless that inflammation may affect
vitamin B6 levels via the shift in PLP from the tryptophan-serotonin pathway to the
kynurenine pathway, and these two coexisting conditions may be contributing to somatic
symptoms rather than cognitive/affective symptoms of depression. Inflammation and
compromised vitamin B6 status may play important roles in the manifestation of
depression, but longitudinal studies are needed to better understand how vitamin B6 or
inflammation may affect the development or severity of depression symptoms. The
heterogeneity of depression also warrants further research based on symptoms in order to
identify potential treatments that may focus on vitamin B6 status for patients with different
dimensions of depression.
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Table 11: Distribution of covariates by depression in women of reproductive age from NHANES 2005-2008 (N=1,489)
Total
Population

Total population sample
Serum PLP (nmol/L)**
Age, years (mean, SE)
Sleep per night, hrs (mean,
SE)
Body Mass Index (kg/m2)
less than 18.5
18.5 to 24.9
25-29.9
30 or greater
p-trend
Inflammation Categories
hs-CRP <1 mg/L
hs-CRP 1-2.99 mg/L
hs-CRP 3-10 mg/L
p-trend
Marital Status
Single/Never Married
Married/with partner
Divorced/Separated/Widowed

Education
Less than High school
High school or GED
Some college
College graduate
p-trend
Race/Ethnicity
Non-Hispanic White
Mexican Hispanic
Other Hispanic

N
1489

%

Total PHQ-9 Score
(range 0-27)
Mean
2.9

SE
0.1

46.3
31.7

43.2,
49.6
0.3

---

6.9

0.1

--

pvalue

--

Somatic
Depression Score
(range 0-12)
Mean
1.8

SE
0.1

3.5
44.4
26.3
25.9

2.5
2.6
3.0
3.4

0.5
0.1
0.3
0.3

38.7
33.6
27.8

2.6
2.9
3.4

0.2
0.2
0.3

1.6
1.7
1.9
2.1

0.3
0.1
0.2
0.1
0.02

1.7
1.8
2.1

0.1
0.1
0.1
0.02

29.2
60.4
10.2

3.0
2.7
4.0

0.2
0.1
0.5

369
354
482
284

15.6
20.6
36.0
27.8

4.1
3.5
2.9
2.0

0.3
0.3
0.2
0.2

63.5
10.2
6.6

2.8
3.2
3.6

0.2
0.2
0.4

0.2
0.1
0.1
0.1
0.009

1.0
1.1
1.4

0.1
0.1
0.1
0.01

0.1
0.1
0.3

2.4
2.1
1.8
1.4

0.2
0.2
0.1
0.1
<0.001

1.8
1.9
2.1

0.1
0.1
0.2

47.1
31.7

%
92.5
44.0,
50.5
0.3

7.0

N
132

p-value

34.4
32.3

%
7.5
27.8,
42.5
0.8

0.1

6.1

0.2

<0.001
0.43

47
543
385
380

97.1
93.3
91.5
91.4

2
50
38
42

2.9
6.7
8.5
8.6

509
446
402

94.2
91.6
91.3

44
46
42

5.8
8.5
8.7

1.0
1.0
1.7

0.1
0.1
0.3

508
718
131

0.1
0.2
0.1
0.1
<0.001

93.6
93.5
83.5

45
65
22

6.4
6.5
16.5
<0.001

317
317
446
276

86.0
89.1
93.0
97.9

51
37
36
8

14.0
10.9
7.0
2.1

508
336
122

92.9
92.5
89.4

49
28
19

7.1
7.5
10.6

0.27
1
1.3
1.5

0.1
0.1
0.2

0.004
0.48

<0.001

<0.001
1.7
1.4
1.1
0.6

--

0.15

0.08

0.37
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N
1357

Yes

0.05

<0.001

<0.001
0.27
557
364
141

0.9
1.0
1.1
1.4

0.15

<0.001

--

No

0.08

0.08

1.9
1.7
2.4

p-value

-0.13

0.001
0.12
553
783
153

SE
0.1
---

--

0.005
0.05
553
492
444

--

Mean
1.1

---

0.06
49
593
423
422

pvalue

High Depression Score
(PHQ-9 score ≥10)

Non-Somatic
Depression Score
(range 0-15)

0.26

Non-Hispanic Black
Other Race
Smoke
Not current smokers
Current smokers
Leisure Time Physical
Activity
Q1 (0-64 MET min/week)
Q2 (65-594 MET min/wk)
Q3 (595-1560 MET min/wk)
Q4 (>1560 MET min/wk)
p-trend
Oral Contraceptive use
Not currently using
Currently using

348
79

12.6
7.2

3.4
2.9

0.3
0.3

1126
324

76.3
23.7

2.5
4.4

0.1
0.4

2.1
1.7

0.1
0.2

1.6
2.7

0.1
0.2

<0.001

25.1
24.8
23.9
26.3

4.2
2.5
2.3
2.2

0.3
0.2
0.2
0.3

80.8
19.2

3.0
2.3

0.1
0.3

0.9
1.8

0.1
0.2

2.5
1.6
1.6
1.4

0.2
0.1
0.1
0.2

0.1
0.2

89.7
96.2

33
3

10.3
3.8

1057
263

95.3
83.4

69
61

4.7
16.6

<0.001

<0.001
1.7
0.9
0.8
0.8

0.2
0.1
0.1
0.1

<0.001
0.05
1.9
1.5

315
76
<0.001

<0.001

<0.001
0.01
1231
213

0.1
0.1

<0.001

<0.001
386
302
270
321

1.3
1.2

<0.001
321
283
258
306

84.5
95.2
96.3
95.9

65
19
12
15

15.5
4.9
3.7
4.1

1118
201

92.0
95.5

113
12

8.0
4.5

<0.001
0.01
1.2
0.8

0.1
0.2

0.09

Weighted regression and t-tests for continuous depression scores and design-based Pearson chi square for categorical depression variables
* ln-transformed PLP, presenting geometric means and
95% CI.
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Table 12:Distribution of covariates by vitamin B6 (Pyridoxal 5'-Phosphate) variables in women of
reproductive age from NHANES 2005-2008 (N=1,489)
Deficiency
(PLP<20
nmol/L)

Serum PLP*
Mean

95% CI

p-value

N

%

Serum PLP Category
Insufficiency Sufficiency
(PLP 20(PLP≥30
29.9)
nmol/L)
N

%

N

%

46.0
42.9, 49.4
-183 10.7 327
21.3
972 68.0
Total population
4.4
0.4
3.2
0.3
2.6
0.2
Depression Score (PHQ-9)
-Sleep duration(hr), mean(SE)
-6.6
0.1
6.8
0.1
7.0
0.1
2
Body Mass Index (kg/m )
<0.001
less than 18.5
44.9
33.5, 60.1
6
11.5
11
26.9
32
61.6
18.5 -24.9
53.4
48.1, 59.3
58
8.8
110
17.7
421 73.5
25-29.9
44.8
40.7, 49.3
53 11.1
84
17.7
285 71.2
30 or greater
36.8
33.7, 40.3
66 13.6 121
30.3
233 56.1
p-trend
<0.001
Inflammation Categories
<0.001
hs-CRP <1 mg/L
54.6
50.0, 59.6
40
6.3
94
16.5
415 77.2
hs-CRP 1-3 mg/L
42.7
30.0, 47.9
69 12.1 114
23.4
307 64.5
hs-CRP 3-10 mg/L
39.8
35.3, 44.8
74 15.1 119
25.5
250 59.4
p-trend
<0.001
Education
<0.001
Less than Highschool
36.5
32.7, 40.8
57 16.9
82
23.0
229 60.2
Highschool or GED
42.1
38.7, 45.8
49 13.6
87
24.8
214 61.7
Some college
46.0
42.8, 49.4
52
9.3
108
21.9
320 68.9
College graduate
56.3
42.8, 49.4
24
6.8
50
17.1
209 76.2
p-trend
<0.001
Race/Ethnicity
0.008
Non-Hispanic White
48.1
43.0, 53.9
75 10.7 118
21.0
361 68.3
Mexican Hispanic
41.3
38.7, 44.0
34
9.5
79
23.1
251 67.4
Other Hispanic
47.6
42.9, 52.8
11
5.3
30
23.4
98
71.3
Non-Hispanic Black
38.3
35.0, 42.0
55 16.1
88
24.6
204 59.4
Other Race
48.8
41.7, 57.2
8
8.1
12
13.6
58
78.3
Smoke
<0.001
Not a current smoker
50.4
46.7, 54.4
107 7.7
238
19.8
775 72.5
Yes
34.6
30.6, 39.1
75 20.6
78
26.0
170 53.4
Leisure Time Physical
Activity
<0.001
Q1 (0-64 MET minutes/week)
39.5
35.4, 43.9
59 13.9
92
24.6
231 61.5
Q2 (65-594 MET minutes/week)
45.1
41.0, 49.5
37 12.0
54
6.5
211 71.5
Q3 (595-1560 MET minutes/wk)
48.8
42.8, 55.6
27
7.4
58
22.1
184 70.5
Q4 (>1560 MET minutes/week)
60.3
52.9, 68.7
20
3.9
68
19.1
231 77.1
p-trend
<0.001
Oral Contraceptive use
0.10
not a current user
45.6
42.6, 48.8
152 11.0 266
21.3
807 67.8
current user
52.9
44.4, 62.9
23
8.3
48
20.2
141 71.5
*natural log transformed serum PLP and 95% Confidence Intervals. Weighted ANOVA and linear regression
for p-trend for continuous serum PLP; Weighted Pearson chi-square for categorical PLP.
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p-value

--0.003
0.003
0.003

0.0001

0.0007

0.07

<0.001

0.0003

0.53

Figure 4: Higher depression scores are evident among those with vitamin B6 deficiency,
and an increasing trend is statistically significant as CRP levels increase. P-trend is
significant for increasing depression score as CRP increases only among those with vitamin
B6 deficiency (p-trend=0.04)

Figure 5: Prevalence of depression is highest among those with higher CRP levels, and
decreases with improving vitamin B6 status. Chi square results are only significantly
different for higher prevalence of depression with decreasing vitamin B6 concentrations
among women with elevated CRP (p=0.02), but not among women with CRP 1-3mg/L
(p=0.07) or CRP <1mg/L (p=0.92)
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Figure 6: Linear regression analysis assessing mediators/confounders of the relationship between PLP and (a) total depression
score, (b) somatic depression score and (c) non-somatic depression score among women of reproductive age from NHANES
2005-2008
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Table 13:Distribution of serum pyridoxal 5'-phosphate and vitamin B6 categories by individual depression symptoms
among women of reproductive age from NHANES 2005-2008 (N=1,489)
Deficiency

Serum PLP*
Mean
Trouble sleeping**
No
Yes
Fatigue**
No
Yes
Abnormal appetite**
No
Yes
Moving or speaking too slow or too fast
No
Yes
Anhedonia
No
Yes
Depressed mood**
No
Yes
Low self-esteem
No
Yes
Trouble concentrating
No
Yes
Suicidal ideation
No
Yes

95% CI

47.9
34.2

44.5, 51.5
28.9, 40.3

47.3
39.6

43.9, 51.1
34.1, 46.0

47.2
35.6

44.2, 50.4
29.2, 43.4

46.4
36.1

43.2, 49.8
26.3, 49.6

46.6
36.4

43.4, 50.0
28.7, 46.2

47.2
30.7

43.9, 50.7
27.1, 34.8

46.6
36.1

43.6, 49.8
29.4, 44.3

46.6
35.8

43.3, 50.1
28.6, 44.8

46.3
21.0

43.3, 49.5
14.8, 29.8

(PLP<20
nmol/L)

p-value
<0.001

Serum PLP Category
Sufficiency
Insufficiency
(PLP≥30
(PLP 20-29.9)

nmol/L)

N

%

N

%

N

%

148
35

77.3
22.7

280
47

86.2
13.2

860
112

90.6
9.5

140
43

76.1
23.9

271
56

83.5
16.5

826
146

86.2
13.8

156
27

82.2
17.8

297
30

89.9
10.1

891
81

93.1
6.9

171
12

93.9
6.1

319
8

98.3
1.7

945
27

97.6
2.4

166
17

90.1
9.9

309
18

95.7
4.3

922
50

96.1
3.9

161
22

88.2
11.8

297
30

90.4
9.6

922
50

96.3
3.7

169
14

92.7
7.3

308
19

94.2
5.8

925
47

95.7
4.3

172
11

92.1
7.9

310
17

96.1
3.9

932
40

96.3
3.7

178
5

97.4
2.6

321
6

99.0
1.0

963
9

99.7
0.3

p-value
0.0005

0.03

0.04

0.003

0.002

0.13

0.03

0.04

0.02

<0.001

0.0001

0.006

0.25

0.04

0.17

<0.001

0.002

Weighted t-tests and design-based Pearson chi square for categories of plasma PLP. *ln-transformed PLP. **Significant trend test for weighted proportions.
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Table 14: Logistic regression analysis of the association of individual somatic depressive symptoms
(dichotomous) with serum pyridoxal 5'-phosphate in women (n=1,489)
Somatic Depression Symptoms
Sleeping problems
OR
(95% CI)

p-value

Fatigue

Abnormal appetite

Psychomotor
abnormalities

OR
(95% CI)

pvalue

OR
(95% CI)

pvalue

OR
(95% CI)

pvalue

1.96
(1.33, 2.90)
1.24
(0.73, 2.11)
ref

0.001

2.94
(1.68, 5.13)
1.53
(0.86, 2.72)
ref

<0.001

2.63
(1.04, 6.65)
0.71
(0.27, 1.83)
ref

0.04

0.96
(0.58, 1.58)
0.68
(0.31, 1.48)
ref

0.85

0.79
(0.25, 2.57)
1.11
(0.60, 2.07)
ref

0.69

2.02
(0.45, 9.09)
0.21
(0.03, 1.34)
ref

0.35

Unadjusted Model
PLP <20nmol/L
PLP 20-29.9
PLP ≥30 nmol/L
Adjusted Model
PLP <20nmol/L
PLP 20-29.9
PLP ≥30 nmol/L

2.82
(1.68, 4.72)
1.45
(0.89, 2.37)
ref

<0.001

1.60
(0.52, 4.90)
1.10
(0.63, 1.94)
ref

0.40

0.13

0.73

0.42

0.32

0.14

0.73

0.46

0.10

Adjusted model includes age, ethnicity, smoking, oral contraceptive use, sleep duration, physical activity, body mass
index, CRP and mutually adjusted for the sum of the remaining depression items.
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Table 15: Logistic regression analysis of the association of individual non-somatic depressive symptoms (dichotomous) with
serum pyridoxal 5'-phosphate in women (n=1,489)
Non-somatic Depression Symptoms
Anhedonia

Unadjusted Model
PLP <20nmol/L
PLP 20-29.9
PLP ≥30 nmol/L
Adjusted Model
PLP <20nmol/L

Depressed mood

Low self-esteem

Trouble
concentrating

Suicidal ideation*

OR
(95% CI)

pvalue

OR
(95% CI)

pvalue

OR
(95% CI)

pvalue

OR
(95% CI)

pvalue

OR
(95% CI)

pvalue

2.71
(1.31, 5.61)
1.12
(0.49, 2.57)
ref

0.009

3.46
(1.78, 6.73)
2.76
(1.70, 4.48)
ref

0.001

1.74
(0.93, 3.25)
1.36
(0.67, 2.75)
ref

0.08

2.21
(0.92, 5.29)
1.05
(0.45, 2.45)
ref

0.07

8.46
(1.94, 36.86)
3.32
(0.85, 12.92)
ref

0.006

0.79

<0.001

0.38

0.91

0.08

0.29
0.08
1.22
0.76
0.49
0.34
0.68
0.56
7.33
0.01
(0.07, 1.18)
(0.33, 4.52)
(0.11, 2.19)
(0.18, 2.60)
(1.59, 33.9)
PLP 20-29.9
0.53
0.17
3.12
0.004
1.05
0.92
0.76
0.62
3.50
0.06
(0.21, 1.32)
(1.49, 6.52)
(0.39, 2.83)
(0.24, 2.37)
(0.93, 13.1)
PLP ≥30 nmol/L
ref
ref
ref
ref
ref
Adjusted model includes age, ethnicity, smoking, oral contraceptive use, sleep duration, physical activity, body mass index, CRP and
mutually adjusted for the sum of the remaining depression items. *Suicidal ideation not adjusted for education due to collinearity.
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CHAPTER 9
“VITAMIN D, DEPRESSION, AND INFLAMMATION AMONG WOMEN OF
REPRODUCTIVE AGE FROM NHANES 2005-2008”

9.1 Abstract
Depression is the leading cause of disability world-wide, and women in their
childbearing years make up the largest group of Americans with depression. Recent
evidence indicates that vitamin D deficiency, which is more prevalent among
women, may be associated with mood and depression, but much remains unknown
concerning how inflammation, lifestyle and behavioral factors may influence this
association. We conducted a secondary data analysis to evaluate the effects of
inflammation, sleep, oral contraceptive use and body mass index on the association
between serum vitamin D [as 25(OH) vitamin D] with depression in non-pregnant
women ages 18-44 from the cross-sectional National Health and Nutrition
Examination Survey (NHANES) 2005-2008. Depression scores were calculated
based on the Patient Health Questionnaire-9 (PHQ-9) and categorized into total
depression, somatic and non-somatic depression. High depression score (PHQ-9 ≥
10) use was also used as an outcome, as well as individual symptoms of depression.
Serum 25(OH) vitamin D was categorized into deficiency (<50 nmol/L),
insufficiency (50-75 nmol/L) and sufficiency (>75 nmol/L). To account for NHANES’
complex survey design sample, we incorporated the sampling weights in the
analysis of 1,397 observations. Mean 25(OH) vitamin D did not differ by depression
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(56.7 vs 60 nmol/L, p=0.27), but suboptimal vitamin D levels were significantly
associated with higher odds for depression among women who had elevated CRP
(ORdeficiency: 6.55, p=0.02 and ORinsufficiency: 9.54, p=0.001). We observed a significant
trend for decreasing depression score with increasing vitamin D level for total
depression (p-trend:0.02) and somatic depression (p-trend: 0.006). When stratified
by BMI, vitamin D was positively associated with depression scores (p=0.01) among
underweight women. Among women who reported sleeping 7 or more hours per
night, vitamin D was inversely associated with depression, whereas the opposite
was true among women who slept less than 7 hours/night (p-interaction=0.01).
Sleep appeared to significantly modify the association between vitamin D and
depression among women. Further research is needed to determine how changes in
inflammation or sleep may contribute to vitamin D deficiency, and how altogether,
these lifestyle and behavioral factors may be used to prevent or treat depression
among women.

9.2 Introduction
Depression is common in the United States, with approximately 16% of
adults experiencing clinical depression at some point in their lives.1 Numerous
biological, psychological, and environmental risk factors for depression have been
proposed,2 among them vitamin D deficiency.3 Although vitamin D is mainly known
for its role in maintaining calcium homeostasis and bone health,4 brain
development and function also depend on vitamin D; 5–8 vitamin D receptors found
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in several regions of the brain may play a role in serotonin synthesis9 and have
been linked to mood regulation and affective disorders.10–12
Women are two- to three-times more likely than men to experience
depression, and among women, it is the leading source of disease burden.13–15
Recent national estimates indicate that suboptimal vitamin D status is common in
women, affecting up to 78% of U.S. women of childbearing age, although the
prevalence is even higher among non-Hispanic Black and Hispanic women.16
Suboptimal maternal vitamin D status poses multiple health risks for both women
and their offspring. Vitamin D deficiency during pregnancy or in the postpartum
period has been associated with increased risk of rickets, type 1 diabetes, allergies,
asthma, and schizophrenia in the offspring17 and with preeclampsia, gestational
diabetes, bacterial vaginosis and perinatal depression in the mother.18–22 Better
understanding of the role of vitamin D in depression among reproductive age
women could lead to additional treatment options.
Most studies investigating vitamin D and depression have produced
inconsistent results.23 In part, this may have been due to differences in populations,
heterogeneity of depression assessment, or the lack of inclusion of several lifestyle
and behavioral factors that may affect the association between vitamin D and
depression, such as inflammation, sleep, body mass index, and oral contraceptive
(OC) use. Inflammation has been linked to vitamin D deficiency in numerous in vitro
and in vivo studies24 since vitamin D receptors were discovered in cells of the
immune system. In humans, vitamin D supplementation decreases circulating Creactive protein (CRP), a pro-inflammatory marker.25 Inflammation has also been
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implicated as a potential risk factor for depression,26–28 and given vitamin D’s
immunomodulatory potential, the association between vitamin D and depression
may be affected by the presence of inflammation. To date, two studies have
examined whether the association between vitamin D and depression is partially
affected by CRP levels.29,30 Although both studies found an inverse association
between circulating vitamin D levels and depression, they did not find a significant
difference in risk of depression among subjects with low vitamin D and elevated
CRP,29 nor did they find CRP to mediate the association between vitamin D and
depression.30 However, these studies did not assess whether the association
between vitamin D and depression was symptom-specific, nor did they stratify by
gender, although vitamin D deficiency and depression both affect women
disproportionately.
Several lifestyle factors have been previously associated with inflammation,
vitamin D, and depression separately. Sleep duration has also been associated with
both vitamin D deficiency31,32 and depression;75 yet, to date, no studies have
assessed how sleep may affect the association between vitamin D and depression.
OC use is related to increased vitamin D levels,33 yet OC use has been found to both
increase34 or decrease35 risk of depression in different studies. And finally, BMI, a
proxy for adiposity, is linked to lower vitamin D levels36 and higher depression
score37,38 in several studies, but to date, its effect on the association between
vitamin D and depression has not been examined thoroughly. Therefore,
investigating the association between vitamin D, various lifestyle and behavioral
factors that may be more common among women, and individual symptoms of
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depression in addition to total depression scores offers an opportunity to explore
potential biological factors related to the etiology of depression that may not be
evident among mixed populations or when aggregate scoring is used.
The purpose of this study was to explore the relationship between vitamin D
status and depression among U.S. reproductive-age women and to determine
whether inflammation and other lifestyle factors modify the association between
circulating serum vitamin D levels and depression subtypes or individual symptoms
of depression among 1,397 women, aged 18-44 years, from the National Health and
Nutrition Examination Survey (NHANES) 2005-2008.

9.3 Methods
9.3.1 Study Design and Study Population
We analyzed cross-sectional data from the 2005-2008 National Health and
Nutrition Examination Survey (NHANES), which is national survey from the
National Center for Health Statistics of the Centers for Disease Control and
Prevention (CDC), designed to assess the health and nutritional status of the U.S.
population. NHANES employs a complex, multistage, probability sampling design to
select persons representative of the civilian, non-institutionalized US population,
with oversampling of special sub-populations, such as racial and ethnic minorities.
Detailed descriptions of the survey design and procedures are available at the study
website.39
Briefly, approximately 5,000 people are surveyed each year via in-person
interviews and physical examinations. The interview, which is conducted in
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participants’ homes, includes demographic, socioeconomic, dietary, and healthrelated questions; the examination component is comprised of medical, dental, and
physiological measurements, as well as laboratory tests, which take place in
specially-designed and equipped mobile examination centers (MEC) that travel
throughout the country. The National Center for Health Statistic’s Institutional
Review Board has reviewed and approved the NHANES protocol.
Participants were eligible for our study if they were women of reproductive
age (15-44 years old) who were not pregnant. From the initial sample of 2,609
eligible women, we excluded those with missing data for either depression (n=506)
or serum vitamin D (n=92). Depression data for individuals younger than 18 years
was not publicly available; therefore, our age range was restricted to women ages
18-44 years. We also excluded women with acute inflammation denoted by CRP
levels above 10 mg/L (n=201),40 those who were taking anti-inflammatory
medications including NSAIDs (n=70) or reported current antidepressant use
(n=135). The remaining sample contained 1,397 observations.

9.3.2 Assessment of Depression Status
The Patient Health Questionnaire-9 (PHQ-9)41 was administered during the
MEC interview and assessed depressive symptom severity over the past two weeks.
Based on the diagnostic criteria for major depressive disorder in the Diagnostic and
Statistical Manual Fourth Edition (DSM-IV), the PHQ-9 employs a 4-point scale
(0=not at all, 1= several days, 2= more than half the days, 3= nearly every day) to
determine the frequency with which respondents experienced the following nine
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symptoms of major depressive disorder: anhedonia, depressed mood, sleep
disturbance, fatigue, appetite changes, low self-esteem, concentration problems,
psychomotor retardation/agitation, and suicidal ideation. Total depression scores
range from 0 to 27, and scores of 10 or higher are classified as clinical depression.42
The PHQ-9 has been shown to be a reliable and valid questionnaire as indicated by
its high internal consistency and good sensitivity (88%) and specificity (88%) for
identifying cases of major depressive disorder in community samples.43–45
In addition to the total depression score, we calculated somatic and
cognitive-affective depression subscale scores. The somatic depression subscale was
calculated by adding the scores for frequency of the four somatic depression
symptom from the PHQ-9 (sleep disturbance, fatigue, appetite changes, and
psychomotor retardation/agitation) and the cognitive-affective subscale score was
calculated adding the scores for the five non-somatic symptoms (anhedonia,
depressed mood, low self-esteem, concentration problems and suicidal ideation).46
While previous factor analyses supported a one-factor model with all nine items,47,48
recent confirmatory factor analyses have found that subscales of depression
dimensions may provide a better fit to the data.49,50 Some also argue that given the
biological heterogeneity of symptoms for depression, individual symptoms should
be analyzed separately.51 Thus, we included a separate analysis for individual
depressive symptoms, coded as continuous variables (scores ranging from 0-3) and
as binary variables. To dichotomize the variable, those items with responses “more
than half the days” and “nearly every day” indicated the presence of the
symptom.52,53
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9.3.3 Serum Vitamin D
Fasting whole blood samples were collected during the medical examination.
Venipuncture was performed using standard phlebotomy techniques by NHANES
trained personnel. Serum specimens were processed, stored and shipped to the
Division of Environmental Health Laboratory Sciences, National Center for
Environmental Health, Centers for Disease Control and Prevention in Atlanta,
Georgia. Further detailed instructions on specimen collection and processing can be
found at NHANES website.39 Briefly, measurements of serum 25(OH) vitamin D, the
biomarker of vitamin D status, were performed with the DiaSorin RIA kit
(Stillwater, MN) for NHANES 2001-2006, and with liquid chromatography-tandem
mass spectrometry (LC-MS/MS) method for NHANES 2007-2008.54 In order to use
vitamin D data from these two different methods, NHANES converted the vitamin D
data from 2001-2006 assayed with the RIA method to equivalent 25(OH)D
measurements from a standardized LC-MS/MS method using regression analysis.
This adjustment was completed to allow researchers to use vitamin D data that are
equivalent to 25(OH)D measurements assayed with LC-MS/MS method.54 Serum
vitamin D was categorized into variables indicating vitamin D deficiency
(<50nmol/L), insufficiency (50 to 75 nmol/L) and sufficiency ( >75 nmol/L)
following previously used cut-offs for vitamin D status.4,55 Given that 25(OH)
vitamin D was not normally distributed, it was converted to its natural logarithm to
improve normality.
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9.3.4 Covariates and Confounders
We considered as possible covariates a selected set of demographic, lifestyle,
and socioeconomic factors available through data collected during the demographic
or household section of the NHANES questionnaire. The National Center for Health
Statistics (NCHS) standard definitions for ethnicities were used, and ethnicities
were categorized as non-Hispanic whites, non-Hispanic blacks, Mexican-Hispanics,
other Hispanics, and other race. Educational attainment was measured as the
highest completed grade of school regardless of age, and categorized into four
levels: less than high school, high school equivalent, some college, and college
graduate or above. The smoking assessment for respondents aged 18-19 years
(MEC) was not identical to that for respondents aged 20+ years (household
interview). For respondents aged 20+ years, we classified as current smokers those
who reported smoking at least 100 cigarettes during their lifetime and reported that
they now smoke cigarettes every day or some days. For respondents ages 18-19
years, we classified as current smokers those who reported smoking 15 or more per
day in the last 30 days. To create the alcohol groups, we used data obtained during
the alcohol use interview at the MEC and calculated the drinks per day as suggested
by Case and Stewart.56 Alcohol consumption, which was only available for
participants of legal drinking age (21 and older), was categorized into abstainer, one
or fewer drinks/day and more than one drink per day. Leisure-time physical
activity (LTPA) was assessed by asking participants about their involvement in 48
specific recreation activities of moderate or vigorous intensity. Frequency was first
multiplied by the duration in hours and divided by 4.3 to obtain hours of LTPA per
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week. To calculate MET hrs/week, each activity was multiplied by its MET level per
NHANES physical activity codes.57 Participants were then categorized into quartiles
of physical activity.
Body mass index (BMI), OC use, sleep, and C-reactive protein (CRP) have
been associated with both vitamin D levels and depression, and were examined as
potential confounders/mediators of the relationship between vitamin D and
depression. BMI (kg/m2) was computed from height and weight measurements and
categorized into four standard categories: underweight (BMI<18.5 kg/m2), normal
weight (18.5 ≤ BMI<25), overweight (25≤ BMI<30) and obese (BMI≥30 kg/m2). OC
use was determined by self-report of current use, and women were categorized into
either “current”, “past” or “never” users. Sleep duration was assessed by asking
participants how many hours of sleep they usually get on a weekday/workday, and
those who reported sleeping 12 or more hours were labeled as sleeping 12
hours/night. High sensitivity c-reactive protein was quantified using latex-enhanced
nephelometry using a Behring Nephelometer (Dade Behring Diagnostics Inc,
Somerville, NJ) and was classified into three categories: no inflammation (CRP
<1mg/L), low inflammation (CRP 1-3mg/L) and moderate inflammation (CRP 310mg/L) following previously used guidelines.40 CRP was also transformed to its
natural logarithm due to its skewed distribution.

9.3.5 Data Analysis
The complex survey design used for NHANES data collection was
incorporated into all data analyses using the “svy” command with appropriate
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weighting in Stata 12.0 (StataCorp LP, College Station, TX). Detailed information on
the procedures for taking into account survey sampling weights have been
described elsewhere.58
Descriptive statistics were calculated for the overall sample using frequency
distributions for categorical variables and means and standard errors for
continuous variables. Because both serum 25(OH) D and hs-CRP were
logarithmically transformed when analyzed as continuous variables, geometric
means (antilogarithms of the transformed means) and their 95% confidence
intervals are presented. Bivariate analyses were carried out for each covariate and
ln-transformed vitamin D and vitamin D categories as well as for covariates and
total depression, somatic/non-somatic depression and binary depression variables,
using weighted ANOVAs, Chi square tests and 2-sample t-tests as appropriate. Ttests and chi-square tests were completed to assess group differences in mean lntransformed serum 25(OH) D as a continuous variable and proportions of vitamin D
categories by individual depressive symptom. In linear regression modeling of
depression, all covariates that changed the estimated coefficient for the primary
predictor of interest by more than 10% were retained in the multivariable model. In
addition, known risk factors for depression, such as smoking, and education, were
retained in the model as well as those that were associated with both the predictor
and the outcome, such as LTPA and OC use. Model adequacy was assessed using
goodness of fit tests.
To examine whether vitamin D status was more strongly related to certain
dimensions of depression, we conducted a series of linear regression analyses in
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which total depression score, somatic depression score, non-somatic depression
score and each individual depression symptom served as outcome variables. A
similar series of logistic regression analyses was also completed for dichotomous
individual depressive symptoms. For all the individual depression symptoms, we
adjusted for the remaining depression symptom to account for any potential overlap
between different symptoms and to reduce the probability of type I error. Logistic
regression analyses were also carried out for depression PHQ-9 score of 10 or
greater.
C-reactive protein, OC use, sleep, and BMI were assessed as potential
mediators or effect modifiers by running mediation tests, stratifying regression
analyses, and by including interaction terms in the model estimates. To quantify the
effects of these variables on any observed relationships between continuous vitamin
D (ln-transformed) and depression, we carried out Sobel mediation tests and
Preacher and Hayes bootstrap tests of indirect effects.59,60 All linear and logistic
regression estimates were weighted using NHANES sample weights, which account
for the complex survey design, survey nonresponse, and post-stratification.

9.4 Results
Description of Study Cohort. The characteristics of the 1,397 women in our
final sample are shown in table 16. The mean age of women in our sample was 31.7
years. The majority of women were white (63.5%), married or living with a partner
(60.5%,), did not use OCs (77%), slept an average of seven hours per night, and
were nonsmokers (75.9%). Almost eight percent (7.3%) of our sample population
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reported moderate to severe depression symptoms, indicative of clinically
significant depression denoted by a score of 10 or higher on the PHQ-9.
In bivariate analyses (Table 16), all three depression scores (total, somatic
and non-somatic depression) were positively associated with BMI (p for trend <0.02
for all three depression scores) and CRP (p for trend<0.03 for all three depression
scores) and negatively associated with education (p for trend<0.001) and LTPA (p
for trend<0.001). Mean total depression score was lower for women currently
taking OCs compares to non-and past-OC users (p=0.01) and higher for smokers
compared to non-smokers (p<0.001 for all three depression scores). Women with
high depression scores slept less (6.1 vs 7.0 hours/night, p<0.001) compared to
those with low depression scores. The prevalence of depression was significantly
higher among women who were separated or divorced compared to married or
single women, among smokers compared to non-smokers, and among those who
reported the lowest levels of LTPA compared to those who reported higher levels of
LTPA.
Approximately two thirds of women (67.8%) were vitamin-D insufficient or
deficient (Table 17). These proportions varied greatly by race/ethnicity. About half
of non-Hispanic white females had optimal vitamin D levels, but only 2.5% and 6.3%
of non-Hispanic Black and Mexican-Hispanic women, respectively, had optimal
vitamin D levels (p<0.001). Serum vitamin D was negatively associated with BMI (ptrend <0.001), and positively associated with LTPA (p-trend: 0.001) and education
(p-trend<0.001). Serum vitamin D concentration was much higher in current OC
users compared to non-users (79.9 vs 55 nmol/L, p<0.001), and the percentage of
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women with sufficient vitamin D levels was much higher among current OC users
compared to past or never users (62.8 vs 27.2 vs 18.5%, p<0.001 for current, past
and never OC user, respectively). Women who provided blood samples between the
months of November and April had twice the prevalence of vitamin D deficiency
compared to those who donated blood between May and October (45.1 vs 21.3%,
p<0.001). Vitamin D levels did not vary by age, sleep duration, CRP level or smoking
status (Table 17).
Association of Vitamin D with depression scores. In univariate linear analyses,
vitamin D deficiency was associated with a higher total depression score (β: 0.66,
p=0.02) and somatic depression score (β: 0.39, p=0.005), but not a higher nonsomatic depression score (β: 0.27, p=0.11). These associations were attenuated and
were no longer significant after adjustment for demographics, lifestyle, behavioral
factors and season of blood draw (Table 18).
To assess whether inflammation affects the association between vitamin D
status and depression, we first visualized the relationship using bar graphs (Figure
7). Depression score tended to decrease with increasing vitamin D levels (p=0.03, ptrend:0.02) in the total population (Figure 7a). When stratified by CRP levels,
however, these trends were less clear. Among women with elevated CRP (310mg/L), those with vitamin D sufficiency had lower depression scores (p=0.003, ptrend:0.004, Figure 7a) and lower prevalence of high depression score (p=0.02,
Figure 7b). A similar pattern was found in linear regression models stratified by CRP
levels (data not shown). In unadjusted analyses, vitamin D deficiency and
insufficiency were associated with higher total depression score (β: 1.63, p=0.002
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and β:1.78, p=0.008), somatic depression score (β:0.85, p=0.003; β:0.98, p=0.008),
and non-somatic depression score (β:0.78, p=0.009; β:0.80, p=0.02), evident only
among those with moderate inflammation (CRP 3-10 mg/L). Adjustments for age,
race/ethnicity, education, BMI, sleep duration, LTPA, smoking, OC use, and
continuous CRP attenuated these results, all of which became non-significant.
Association of Vitamin D with Individual Depression Symptoms. To determine
which depression symptoms were associated with vitamin D status, we first looked
at the bivariate associations, followed by a series of linear and logistics models for
continuous and dichotomized symptoms. In bivariate analysis, women experiencing
the somatic symptoms of fatigue and abnormal appetite had significantly lower
mean serum vitamin D levels (54.7 vs 60.8 nmol/L, p=0.004 and 55.4 vs 60.3
nmol/L, p=0.03, respectively) compared to those without these symptoms (Table
19). In linear regression with individual depression symptoms, vitamin D deficiency
was significantly associated with a higher score for fatigue (β: 0.21, p=0.001),
changes in appetite (β: 0.13, p=0.008), psychomotor abnormalities (β:0.06, p=0.03),
anhedonia (β:0.12, p=0.004) and suicidal ideation (β:0.03, p=0.05). These
associations were completely attenuated after adjustment for demographics,
behavioral, lifestyle factors, and season of blood draw (data not shown).
In stratified analysis, among women with moderate inflammation, vitamin D
deficiency was associated with fatigue, abnormal appetite, psychomotor
abnormalities, anhedonia, depressed mood, low self-esteem, and suicidal ideation in
univariate analysis. In adjusted models, however, vitamin D deficiency was
significantly associated only with a lower score for sleeping disturbances (β: -0.34,
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p=0.01) (Table 20). Individual depression symptoms were not significantly
associated with suboptimal vitamin D levels in multivariable logistic models (data
not shown). Vitamin D insufficiency and deficiency were associated with higher
odds of depression among those with moderate inflammation (CRP 3-10mg/L) in
adjusted models (ORdeficiency: 6.55, p=0.02 and ORinsufficiency 9.54, p=0.001) (Table 21).
Effects of potential modifiers or confounders. To examine BMI as a potential
modifier of the vitamin D-depression association, we stratified our analysis by BMI
category and found that after full adjustments a one standard-deviation increase in
ln-transformed vitamin D was associated with a 1.7-point increase in total
depression score (β: 1.71, p=0.01), almost a 1-point increase in somatic (β: 0.95,
p=0.02), and 0.76-point increase in non-somatic depression score (β: 0.76, p=0.01)
only among those who were underweight. This association was not significant for
any other BMI group (Table 22). Despite this apparent interaction, addition of an
interaction term between continuous BMI and vitamin D in the final model was not
statistically significant (not shown).
To evaluate BMI as a potential mediator or confounder of the association
between vitamin D and depression, we ran a series of Sobel mediation tests
followed by bootstrap analysis for the Preacher and Hayes test of indirect effect.59,60
For total depression score, 41.5% of the total effect was significantly mediated by
BMI (p=0.01) (Figure 9). BMI also partially explained the association between
vitamin D and both somatic (35.2%, p=0.01) and non-somatic depression (52%,
p=0.03).
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Influence of sleep duration on the association between vitamin D and
depression. To determine whether sleep duration influences the association between
vitamin D status and depression, we first assessed differences in sleep by vitamin D
status. Mean sleep duration did not vary by vitamin D level (p=0.43), but mean
vitamin D levels were slightly higher among women who reported sleeping more
than 7 hours/night (60.9 vs 57.9, p=0.065). Adding an interaction term to the final
model indicated that sleep is a strong effect modifier of the association between
vitamin D and depression (p-interaction=0.01). When stratified by sleep
(dichotomized at the median- less than 7 hours or 7 or more hours per night),
vitamin D was inversely associated with odds of depression among women who
slept 7 or more hours, but was positively associated with depression among women
who slept less than 7 hours per night (Figure 9). We also ran logistic regressions
using the “mfpigen” command to create a plot for the odds of depression at different
hours of total sleep, and found a negative association between vitamin D and
depression among women who slept 7-9 hours per night, but this association was
positive among women who slept too little (5 hours/night) or too much (12 or more
hours per night) (Figure 10).
Influence of oral contraceptive use on the association between vitamin D and
depression. Mean vitamin D was much higher among current OC users (79.9
nmol/L), compared to past users (57.6 nmol/L) or never users (51.5 nmol/L;
p<0.001). In multivariable logistic regression, there were no statistically significant
associations observed between vitamin D and depression when stratified by OC use,
nor was a significant interaction evident.
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9.5 Discussion
In a large representative sample of reproductive age women, we found that
depression score was inversely related to 25(OH)-vitamin D level, and among those
with elevated CRP, suboptimal 25(OH)-vitamin D levels were associated with
increased odds of depression. Furthermore, the association between vitamin D
deficiency and depression was modified by sleep and by BMI. Although some studies
have reported an association between lower vitamin D status and increased
depressive symptoms among women,61–65 our study is the first to examine whether
inflammation and lifestyle factors influence the association between 25(OH)vitamin D status and various dimensions of depression among reproductive-age
women.
Although studies on vitamin D status and depression have yielded
inconsistent findings, those that assessed the different association between 25(OH)vitamin D and subtypes of depression have found that vitamin D deficiency is more
strongly related to somatic symptoms of depression, rather than non-somatic
symptoms.99 In our sample of women, we found a significant trend of increasing
total depression score and somatic depression score with decreasing 25(OH)vitamin D level, which was not evident for non-somatic depression score or in
adjusted models. Furthermore, women experiencing fatigue had significantly lower
mean serum 25(OH)-vitamin D concentration, suggesting that 25(OH)-vitamin D
may be involved in sleep regulation. Vitamin D receptors (VDR) have been found in
brain areas that control the endocrine-autonomic system as well as the motor
system.10 Fatigue may be common to both vitamin D deficiency and depression,
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since muscle weakness and chronic fatigue are commonly experienced by persons
with vitamin D deficiency.66,67 Mechanistic evidence, therefore, suggests that
25(OH)-vitamin D levels may affect somatic symptoms related to motor function
and sleep, and we found that suboptimal 25(OH)-vitamin D concentrations were
associated with increased score for psychomotor retardation among women with
elevated CRP levels, and these associations were borderline significant after full
adjustments (βdeficiency: 0.15, p=0.06; βinsufficiency: 0.12, p=0.09). These findings suggest
that in addition to vitamin D deficiency, a second trigger, such as inflammation, may
exacerbate somatic depressive symptoms.
Previous studies reported inverse associations between sleep and
depression68 as well as sleep and vitamin D status.31,32 When we stratified our
analysis by sleep duration, vitamin D-deficient women who slept seven or more
hours per night had higher depression scores and much higher odds of depression
than women who slept less (p for vitamin D x sleep = 0.01). Adequate sleep is an
indicator of health status69 and may be a proxy for health-related behaviors,70 so
our findings suggest that among otherwise healthy women who regularly get
enough sleep, vitamin D deficiency may be associated with increased odds of
depression, but this is not the case among women who sleep less than 7 hours per
night. The latter group may be experiencing insomnia, sleep apnea, stress, or other
unmeasured comorbidity that could allow for residual confounding to affect the
association between vitamin D and depression. When we adjusted for sleep, the
effect size of serum 25(OH)-vitamin D on depression was somewhat attenuated, and
mediation tests indicated significant indirect effects of 25(OH)-vitamin D on
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depression through sleep. Sleep may be acting as a mediator between vitamin D
deficiency and depression through the potential effects of vitamin D on neurons
thought to be involved in sleep regulation.10,31 Some evidence suggests that
insomnia leads to depression in 69% of cases of comorbid insomnia and depression,
whereas prior depression does not lead to insomnia.71 However, given the crosssectional nature of this analysis, we cannot determine whether sleep is acting as a
confounder or a mediator in the association between vitamin D and depression.
Adjustment for BMI significantly attenuated the association between vitamin
D and depression scores among women in our analysis, and this was especially true
for non-somatic depression, where inclusion of BMI in regression models reduced
the effect size of the association of vitamin D on depression by half. This finding
suggests that adiposity accounted for much of the association observed between
vitamin D and depression scores in crude analyses. From a physiologic perspective,
non-specific sequestering of vitamin D in adipose tissue72 suggests a mechanism
whereby increased adiposity leads to lower vitamin D levels.36 BMI has also
predicted future depression,73 and therefore could potentially act as confounder or
effect modifier of the association between vitamin D and depression. Although tests
for an interaction between BMI and vitamin D status were nonsignificant, when
stratified by BMI in multivariable analysis, serum 25(OH)-vitamin D was positively
associated with depression scores, and this was only evident among underweight
women. Among the rest of the women with higher BMI, the association was
negative, but not significant, suggesting potential effect modification by adiposity on
the association between vitamin D levels and depression.
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In our sample, underweight women had the highest mean 25(OH)-vitamin D
(mean 67.1 nmol/L, 95% CI 59.2-76, p<0.001) and the lowest prevalence of vitamin
D deficiency compared to women in the rest of the BMI categories. Two recent
cross-sectional studies74,75 found a positive association between 25(OH)-vitamin D
and CRP at 25(OH)-vitamin D concentrations above 52-62 nmol/L, suggesting that
below these levels, 25(OH)-vitamin D may have an anti-inflammatory effect, but
above these levels it may have a pro-inflammatory effect. Inflammation has been
positively associated with depression in numerous studies,28 and could potentially
explain why 25(OH)-vitamin D was positively associated with depression in this
group. If this is a true association, then the underlying mechanisms for a potential
pro-inflammatory role of vitamin D at higher concentrations still needs to be
discovered.
Consistent with previous research, OC users had higher 25(OH)-vitamin D
concentration compared to non-OC users.33,76,77 Since OC use has also been
associated with both higher and lower depression risk,34,35 we considered OC use as
a potential confounder. Including OC in the model significantly attenuated the
association between 25(OH)-vitamin D and depression. Based on the Sobel
mediation test, OC use can be considered a potential mediator of the association
between vitamin D and non-somatic depression scores. However, from a biological
perspective, mediation by oral contraceptive use seems unlikely, given that OC use
affects both exposure and outcome, and not the other way around. Estrogen
downregulates the main catabolic enzyme in the vitamin D pathway, 24hydroxylase,33,78,79 and may upregulate 1α-hydroxylase, the enzyme required to
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activate vitamin D. OC use may also affect the expression of the VDR and other
vitamin D binding proteins.33,78,79 Together, these actions may lead to elevated
circulating vitamin D levels, although the clinical significance of this effect remains
unknown.76 Although current OC users appeared to have lower odds of depression
compared to non-users in our unadjusted analysis, we did not find significant
evidence of effect modification by OC use.
Our study has important strengths, including use of a large, diverse sample of
women representative of the U.S. population, the use of a validated,
multidimensional depressive symptom measure, and the testing of multiple
candidate mediators or confounders, such as CRP, sleep, BMI, and OC use.
Furthermore, we excluded women who were currently taking antidepressants to
prevent nondifferential misclassification of outcome, given that some of the
common side effects of antidepressants reported by patients are the very symptoms
that are used to measure depression, such as insomnia, hypersomnia, agitation,
restlessness, fatigue, somnolence, weight gain or weight loss, and decreased or
decreased appetite.80 This overlap of antidepressant side-effects and depression
symptoms provides a compelling reason for analyzing symptoms separately from
total depression scores.51
Our study also has important limitations. First, due to the cross-sectional
nature of the NHANES study design, we were unable to determine the directionality
of the association between 25(OH)-vitamin D and depression symptoms. Although
previous studies have found depression scores to improve upon supplementation
with vitamin D in certain populations,81,82 conflicting evidence remains concerning
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the directionality of the association between vitamin D status and depression and
inconclusive findings in the vast majority of supplementation studies.83–85
Depression may affect vitamin D-enhancing activities, such as healthy eating,
exercising, or outdoor activities, and may lead to lower 25(OH)-vitamin D levels
through weight gain and sequestering of vitamin D in adipose tissue. Prospective
studies are warranted to establish directionality, and randomized clinical trials are
needed to understand the complexity of this association and to determine whether
there is, in fact, a direct link between 25(OH)-vitamin D and depression. Secondly,
we did not account for region of residence and latitude for the participants, but we
did account for the six-month period of blood draw, which was the only data
publicly available from NHANES that could be used to address seasonal variations in
serum 25(OH)-vitamin D levels. We do not consider this a major limitation since
surrogate markers of vitamin D concentrations, such as regional latitude, although
somewhat correlated to serum 25(OH)-vitamin D, have not been found to
adequately reflect circulating 25(OH)-vitamin D measures. In a large nested-case
control study of the Women’s Health initiative, mean annual solar irradiance only
explained 1% of the variation in serum 25(OH)-vitamin D levels.86 And finally, this
survey from a non-institutionalized population may represent only those with less
severe depression, because women experiencing severe depression may either be
institutionalized or may have disproportionately chosen not to participate in the
survey. Therefore, our results might not be generalizable to women with severe
depression or major depressive disorder.
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9.6 Conclusion
We found that suboptimal vitamin D status was associated with higher total
depression score and somatic depression score and higher odds of depression in the
presence of inflammation. We also found that among underweight women, 25(OH)vitamin D was positively associated with depression scores. Previous research on
vitamin D and depression has yielded inconsistent or null findings, which may be due
in part to a failure to account for inflammation or lifestyle factors, such as sleep, that
affect both vitamin D status and depression. Given the evidence linking inflammation
to vitamin D status and depression, additional studies are needed to determine to
what extent vitamin D influences depression through changes in adiposity,
inflammation and sleeping patterns.
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Table 16: Distribution of covariates by depression in women of reproductive age from NHANES 2005-2008 (N=1,397)
Total
Population
N
Total population sample

%

1397

Total PHQ-9 Score
(range 0-27)

Somatic
Depression Score
(range 0-12)

High Depression Score
(PHQ-9 score ≥10)

Non-Somatic
Depression Score
(range 0-15)

No

Yes

Mean

SE

p-value

Mean

SE

p-value

Mean

SE

p-value

N

%

N

%

p-value

2.9

0.1

--

1.8

0.1

--

1.1

0.1

--

1276

121

-0.27

Serum 25 (OH) D (nmol/L)*

59.8

57.1,
62.8

--

--

--

60.1

92.7
57.3,
60.3

56.7

7.3
50.6,
63.5

Age, years (mean, SE)

31.7

0.3

--

--

--

31.6

0.3

32.3

0.9

0.47

Sleep per night, hours (mean, SE)

6.9

0.1

--

--

--

7.0

0.1

6.1

0.2

<0.001

Body Mass Index (kg/m2)

0.06

0.13

0.10

0.42

47

3.5

2.6

0.5

1.7

0.3

0.9

0.2

45

96.9

2

3.1

18.5 to 24.9

552

44.4

2.6

0.1

1.7

0.1

0.9

0.1

507

93.6

45

6.5

25-29.9

400

26.6

3.0

0.3

1.8

0.2

1.1

0.1

365

91.5

35

8.5

30 or greater

396

25.7

3.4

0.2

2.1

0.1

1.3

0.1

357

91.9

39

8.1

less than 18.5

p-trend

--

Inflammation Categories

0.005

0.02

0.01

0.05

0.09

0.06

0.07

hs-CRP <1 mg/L

510

38.1

2.6

0.2

1.7

0.1

0.9

0.1

473

94.7

37

5.3

hs-CRP 1-2.99 mg/L

465

33.8

2.9

0.2

1.8

0.1

1.1

0.1

421

91.3

44

8.7

hs-CRP 3-10 mg/L

422

28.1

3.3

0.2

2.0

0.1

1.3

0.1

382

91.6

40

8.4

p-trend
Marital Status

0.01

0.03

0.02

0.11

0.17

0.06

<0.001

Single/Never Married

526

29.4

2.9

0.2

1.9

0.1

1.0

0.1

487

94.5

39

Married/with partner

731

60.5

2.7

0.1

1.7

0.1

1.0

0.1

670

93.4

61

6.6

Divorced/Separated/Widowed

140

10.1

4.1

0.6

2.4

0.3

1.7

0.3

119

83.4

21

16.6

Education

<0.001

<0.001

5.5

<0.001

<0.001

Less than Highschool

343

15.6

4.1

0.3

2.4

0.2

1.7

0.1

297

86.3

46

13.7

Highschool or GED

336

20.7

3.5

0.4

2.1

0.2

1.4

0.2

301

88.9

35

11.1

Some college

449

36.7

2.8

0.2

1.8

0.1

1.1

0.1

415

93.0

34

7.0

College graduate

268

28.00

1.9

0.2

1.4

0.1

0.5

0.1

262

98.7

6

1.3

p-trend

<0.001

<0.001
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<0.001

Race/Ethnicity

0.28

0.41

0.29

0.25

Non-Hispanic White

521

63.5

2.7

0.2

1.7

0.1

1.0

0.1

477

93.2

44

6.8

Mexican Hispanic

130

6.6

3.1

0.3

1.8

0.2

1.2

0.1

317

93.1

25

6.9

Other Hispanic

342

10.1

3.6

0.4

2.1

0.2

1.5

0.2

112

89.2

18

10.8

Non-Hispanic Black

329

12.6

3.3

0.2

2.1

0.1

1.3

0.1

298

89.8

31

10.2

75

7.2

2.7

0.3

1.7

0.2

1.1

0.2

72

96.0

3

4.0

Other Race

Smoke
Not current smoker
Current smoker

Leisure Time Physical
Activity
Q1 (0-64 MET minutes/week)
Q2 (65-594 MET minutes/week)
Q3 (595-1560 MET
minutes/week)

Q4 (>1560 MET minutes/week)

<0.001

<0.001

<0.001

<0.001

1082

80.3

2.4

0.1

1.6

0.1

0.9

0.1

997

95.5

63

4.5

246

19.7

4.4

0.4

2.7

0.2

1.7

0.2

242

83.6

56

16.4

<0.001

<0.001

<0.001

<0.001

343
291

23.9
26

4.2
2.5

0.3
0.2

2.5
1.6

0.2
0.1

1.7
0.9

0.2
0.1

286
273

84.7
95.2

57
18

15.3
4.8

256
297

24.6
25.5

2.4
2.10

0.2
0.2

1.5
1.3

0.1
0.2

0.8
0.7

0.1
0.1

244
284

96.1
96.4

12
13

3.9
3.6

p-trend
Oral Contraceptive use

<0.001

<0.001

<0.001

0.01

0.09

0.001

0.19

Never user

425

23.0

3.1

0.2

1.9

0.1

1.2

0.1

393

92.3

31

7.7

Past user

728

58.2

3.0

0.1

1.8

0.1

1.1

0.1

657

92.1

71

7.9

Current user

199

18.8

2.1

0.3

1.5

0.2

0.8

0.2

188

96.1

11

3.9

627

93.9

42

6.1

p-trend

0.02

Semester of blood draw
November 1 through April 30

0.09
0.27

669

41.6

2.7

0.2

0.01
0.43

1.7

0.1

0.17
1.0

0.1

0.23

728
58.4
3.0
0.2
1.9
0.1
1.2
0.1
649
91.8
79
8.2
May 1 through October 31
Weighted regression and t-tests for continuous depression scores and design-based pearson chi square for categorical depression variables. *Ln-transformed vitamin D presented as geometric
means and 95% CI.
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Table 17: Distribution of covariates by vitamin D variables in women of reproductive age from NHANES 2005-2008
(N=1,397)
Serum Vitamin D Categories
Serum 25(OH) Vitamin D*

Deficiency

(<50 nmol/L)

Total population
Depression Score (PHQ-9)**
Age (years)**
Sleep duration (hours)**
Body Mass Index (kg/m2)
less than 18.5
18.5 -24.9
25-29.9
30 or greater
p-trend
Inflammation Categories
hs-CRP <1 mg/L
hs-CRP 1-2.99 mg/L
hs-CRP 3-10 mg/L
p-trend
Marital Status
Single/Never Married
Married/Living with partner
Divorced/Separated/Widowed
Education
Less than Highschool
Highschool or GED
Some college
College graduate
p-trend
Race/Ethnicity
Non-Hispanic White
Mexican Hispanic
Other Hispanic
Non-Hispanic Black

Mean
59.8

95% CI
57.1, 62.8
----

p-value

--

Insufficiency
(50-75 nmol/L)

Sufficiency

(>75 nmol/L)

N
643
3.3
31.7
6.9

%
31.2
0.2
30.9, 32.5
6.7, 7.0

N
459
2.8
32.1
6.9

%
36.7
0.2
31.3, 32.8
6.8, 7.0

N
295
2.6
31.2
7.0

%
32.2
0.2
29.9, 32.4
6.9, 7.2

15
193
196
239

21.3
22.7
33.2
45.2

18
196
127
116

32.8
36.6
35.7
38.1

14
163
77
41

46.0
40.7
31.1
16.8

222
200
221

30.4
26.9
37.4

177
160
122

38.6
37.8
32.7

111
105
79

31.0
35.3
29.9

298
278
67

38.7
26.3
38.8

131
280
48

28.5
40.9
35.2

97
173
25

32.9
32.8
26.0

198
178
178.
0
88

48.6
37.3

105
94

33.0
34.0

40
64

18.5
28.7

25.4
24.2

158
102

37.8
39.3

113
78

36.8
36.5

78
208
69
252

14.4
56.8
56.7
75.1

207
114
38
70

39.8
36.9
26.2
22.4

236
20
23
7

45.8
6.3
17.1
2.5

<0.001
67.1
66.5
59.0
49.9

59.2, 76.0
62.9, 70.4
54.9, 63.4
46.5, 53.4
<0.001
0.07

60.5
61.6
57.0

57.1, 64.1
8.1, 65.4
53.1, 61.1

0.099

0.11
0.04
57.3
61.6
57.4

53.0, 61.9
58.4, 64.9
52.8, 62.3

51.8
58.3

47.2, 56.8
53.8, 63.2

62.0
63.3

58.7, 65.6
60.1, 66.6

0.003

<0.001

<0.001

<0.001
<0.001
71.4
46.6
49.5
36.2

68.6, 74.3
43.3, 50.2
44.8, 54.8
33.9, 38.6

p-value
-0.03
0.43
0.19
<0.001

<0.001
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Other Race
51.6
46.5, 57.4
36
42.7
30
42.9
9
14.3
Smoke
0.31
No
59.3
56.1, 62.7
496
31.0
349
37.2
215
31.8
Yes
62.1
57.7, 66.9
118
31.1
102
35.4
78
33.5
Leisure Time Physical Activity
0.003
Q1 (0-64 MET minutes/week)
54.7
48.8, 61.4
176
38.3
104
32.6
63
29
Q2 (65-594 MET
minutes/week)
62.1
58.5, 66.0
127
29.7
96
35.8
68
34.4
Q3 (595-1560 MET
minutes/week)
61.2
57.5, 65.2
104
27.7
91
39.7
61
32.6
Q4 (>1560 MET
minutes/week)
67.2
63.4, 71.2
110
20.4
103
37.9
84
41.7
p-trend
0.001
Oral Contraceptive use
<0.001
Never user
51.5
47.9, 55.3
248
44.8
132
32.8
45
18.5
Past user
57.6
54.6, 60.7
329
32.8
258
39.9
141
27.2
Current user
79.9
74.8, 85.3
50
10.9
51
27.2
98
62.8
p-trend
<0.001
Semester of blood draw
<0.001
November 1 through April 30
51.7
47.7, 56.0
405
45.1
188
33.7
76
21.3
May 1 through October 31
66.4
63.6, 69.4
238
21.3
271
38.8
219
39.9
*ln-transformed hs-CRP, with geometric means and 95% confidence intervals. ** Mean(SE) for continuous variables.
Analysis of variance for continuous vitamin D and weighted, design-based pearson chi square for categories of vitamin D.
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0.89

0.03

<0.001

<0.001

Table 18: Linear regression of the association of total depression score and
depression subtypes with vitamin D in women (n=1,397)
Depression defined as:
Total PHQ-9 score
(range: 0-27)

Somatic
Depression score
(range: 0-12)

Non-somatic
Depression score
(range: 0-15)

β
(95% CI)

β
(95% CI)

β
(95% CI)

p-value

p-value

p-value

Unadjusted Model
Vitamin D <50nmol/L

0.66
(0.11, 1.20)
Vitamin D 50-75 nmol/L
0.15
(-0.53, 0.83)
Vitamin D >75 nmol/L
ref
Adjusted Model
Vitamin D <50nmol/L
-0.03
Vitamin D 50-75 nmol/L

(-0.77, 0.72)
-0.13

Vitamin D >75 nmol/L

(0.86, 0.60)
ref

0.02

0.005

0.67

0.39
(0.12, 0.65)
0.06
(-0.36, 0.48)
ref

0.94

-0.03

0.72

(-0.36, 0.31)
-0.07
(-0.49, 0.35)
ref

0.11

0.78

0.27
(-0.06, 0.60)
0.09
(-0.23, 0.41)
ref

0.88

-0.001

0.99

0.74

(-0.47, 0.47)
-0.06

0.74

0.58

(-0.44, 0.32)
ref

Adjusted for age, race/ethnicity, education, smoking, oral contraceptive use, sleep duration, physical
activity, body mass index, high-sensitivity CRP, and season of blood draw.
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Figure 7: (a) Total depression score by CRP level and Vitamin D status. (b)
Prevalence of high depression score varies by CRP level, evident mainly among
women with CRP between 3-10mg/L.
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Table 19: Distribution of serum 25(OH)D and vitamin D categories by individual depression symptoms among
women (N=1,397)
Serum Vitamin D Categories
Serum Vitamin D*

Deficiency

Insufficiency

Sufficiency

(Vit D <50 nmol/L) (50-75 nmol/L) (≥75 nmol/L)

Trouble sleeping
No
Yes
Fatigue**
No
Yes
Abnormal appetite**
No
Yes
Moving or speaking too slow or too fast
No
Yes
Anhedonia
No
Yes
Depressed mood
No
Yes
Low self-esteem
No
Yes
Trouble concentrating
No
Yes
Suicidal ideation
No
Yes

Mean

95% CI

59.9
59.6

57.2, 62.7
54.6, 64.9

60.8
54.7

58.2, 63.6
49.9, 59.9

60.3
55.4

57.5, 63.2
50.9, 60.3

59.9
56.9

57.1, 62.9
49.7, 65.3

60.1
55.6

57.3, 63.0
48.8, 63.3

59.9
58.9

57.1, 62.9
52.0, 66.7

p-value

N

%

N

%

N

%

554
89

87.3
12.7

409
50

89.9
10.1

253
42

87.5
12.5

526
117

80.3
19.7

389
70

85.9
14.1

256
39

88.0
12.0

576
67

89.2
10.8

419
40

91.8
8.2

275
20

93.6
6.4

623
20

96.7
3.3

447
12

97.6
2.4

283
12

97.6
2.4

602
41

94.5
5.5

437
22

96.0
4.0

280
15

96.3
3.7

595
48

93.2
6.8

432
27

95.4
4.6

274
21

94.0
6.0

0.87

0.46

0.004

0.07

0.03

0.17

0.46

0.62

0.21

0.46

0.79

0.49

0.82
59.8
60.8

57.0, 62.8
52.9, 69.7

59.8
60.4

57.0, 62.8
53.1, 68.7

59.9
49.9

57.1, 62.9
39.2, 63.5

p-value

0.76
611
32

95.9
4.1

433
26

94.8
5.2

279
16

95.1
4.9

617
26

96.2
3.8

436
23

95.1
4.9

281
14

96.1
3.9

634
9

98.9
1.1

452
7

99.3
0.7

291
4

99.5
0.5

0.89

0.70

0.13

0.41

Weighted t-tests and design-based Pearson chi square for categories of plasma vitamin D. *ln-transformed vitamin D, reporting geometric mean and 95% CI. **Significant
p-value for trend test of proportions.
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Figure 8: Linear regression analysis assessing mediators/confounders of the
relationship between log-transformed vitamin D and (a) total depression
score, (b) somatic depression score and (c) non-somatic depression score
among women of reproductive age from NHANES 2005-2008.
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Table 20: Association of individual somatic depressive symptoms with vitamin D - stratified by
CRP levels
Somatic Depression Symptoms
Abnormal
Fatigue
appetite

Sleeping problems

Psychomotor
abnormalities

β
(95% CI)

pvalue

β
(95% CI)

pvalue

β
(95% CI)

pvalue

β
(95% CI)

pvalue

-0.01
(-0.25, 0.22)
-0.11
(-0.36, 0.14)
ref

0.91

0.14
(-0.16, 0.43)
0.06
(-0.20, 0.31)
ref

0.36

0.08
(-0.08, 0.23)
0.08
(-0.14, 0.30)
ref

0.33

0.02
(-0.07, 0.12)
-0.02
(-0.11, 0.07)
ref

0.64

0.00
(-0.22, 0.22)
-0.04
(-0.21, 0.14)
ref

0.99

0.08
(-0.17, 0.33)
0.04
(-0.12, 0.19)
ref

0.53

-0.01
(-0.15, 0.13)
0.08
(-0.15, 0.13)
ref

0.88

0.03
(-0.06, 0.12)
-0.01
(-0.10, 0.08)
ref

0.50

-0.07
(-0.32, 0.17)
-0.29
(-0.64, 0.05)
ref

0.54

0.19
(-0.04, 0.42)
-0.06
(-0.28, 0.17)
ref

0.10

0.09
(-0.13, 0.31)
-0.13
(-0.36, 0.09)
ref

0.41

0.01
(-0.12, 0.14)
-0.05
(-0.18, 0.09)
ref

0.86

0.08
(-0.16, 0.33)
-0.10
(-0.27, 0.07)
ref

0.49

0.08
(-0.18, 0.34)
-0.01
(-0.18, 0.15)
ref

0.53

0.06
(-0.15, 0.28)
-0.01
(-0.19, 0.17)
ref

0.55

-0.01
(-0.14, 0.12)
0.01
(-0.11, 0.14)
ref

0.84

0.09
(-0.10, 0.28)
0.19

0.35

0.32
(0.07, 0.58)
0.29
(-0.005,
0.59)
ref

0.02

0.25
(0.06, 0.45)
0.32

0.01

0.18
(0.09, 0.28)
0.18

0.001

CRP <1 mg/L
Unadjusted Model
25(OH)D <50nmol/L
25(OH)D 50-75 nmol/L
25(OH)D >75 nmol/L
Adjusted Model
25(OH)D <50nmol/L
25(OH)D 50-75 nmol/L
25(OH)D >75 nmol/L
CRP 1-3 mg/L
Unadjusted Model
25(OH)D <50nmol/L
25(OH)D 50-75 nmol/L
25(OH)D >75 nmol/L
Adjusted Model
25(OH)D <50nmol/L
25(OH)D 50-75 nmol/L
25(OH)D >75 nmol/L
CRP 3-10 mg/L
Unadjusted Model
25(OH)D <50nmol/L
25(OH)D 50-75 nmol/L
25(OH)D >75 nmol/L
Adjusted Model
25(OH)D <50nmol/L

(-0.08, 0.45)
ref

0.39

0.67

0.10

0.25

0.17

0.66

0.62

0.61

0.87

0.05

(0.05, 0.59)
ref

0.46

0.23

0.23

0.91

0.02

0.65

0.78

0.49

0.82

0.01

(0.05, 0.31)
ref

-0.34
0.01
-0.11
0.47
-0.14
0.38
0.15
0.06
(-0.60, (-0.003,
0.09)
(-0.42, 0.20)
(-0.46, 0.18)
0.31)
25(OH)D 50-75 nmol/L
-0.14
0.35
0.008
0.94
0.06
0.60
0.12
0.09
(-0.44, 0.16)
(-0.21, 0.23)
(-0.18, 0.31)
(-0.02, 0.26)
25(OH)D >75 nmol/L
ref
ref
ref
ref
Mutually adjusted model includes a variable sum of the remaining depressive symptoms. Adjusted model includes age, ethnicity,
smoking, oral contraceptive use, sleep duration, physical activity, body mass index, hs-CRP and season of blood draw.
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Table 21: Logistic regression analysis of the association of high depression
score with vitamin D in women (n=1,397)
High Depression Score (PHQ-9≥10)
OR
(95% CI)
CRP<1 mg/L
Unadjusted Model
Vitamin D <50nmol/L
Vitamin D 50-75 nmol/L
Vitamin D >75 nmol/L
Adjusted Model
Vitamin D <50nmol/L
Vitamin D 50-75 nmol/L
Vitamin D >75 nmol/L
CRP 1-3 mg/L
Unadjusted Model
Vitamin D <50nmol/L
Vitamin D 50-75 nmol/L
Vitamin D >75 nmol/L
Adjusted Model
Vitamin D <50nmol/L
Vitamin D 50-75 nmol/L
Vitamin D >75 nmol/L
CRP 3-10 mg/L
Unadjusted Model
Vitamin D <50nmol/L
Vitamin D 50-75 nmol/L
Vitamin D >75 nmol/L
Adjusted Model
Vitamin D <50nmol/L

p-value

1.13
(0.29, 4.47)
0.87
(0.17, 4.40)
ref

0.86

1.47
(0.20, 10.6)
1.44
(0.28, 7.29)
ref

0.69

0.89
(0.34, 2.30)
0.58
(0.18, 1.87)
ref

0.80

0.53
(0.15, 1.85)
0.59
(0.17, 2.01)
ref

0.31

8.15
(2.74, 24.3)
6.55
(2.16, 19.8)
ref

<0.001

0.87

0.65

0.35

0.39

0.002

6.55
0.02
(1.30, 32.8)
Vitamin D 50-75 nmol/L
9.54
0.001
(2.70, 33.6)
Vitamin D >75 nmol/L
ref
Adjusted for age, race/ethnicity, education, smoking, oral contraceptive use, sleep duration,
physical activity, body mass index, high-sensitivity CRP, and season of blood draw.
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Figure 9: Probability of depression changes with vitamin D levels based on
sleep duration (<7 hours vs 7 or more hours per night). Interaction term
significant at p=0.02 after adjustments for age, race/ethnicity, education, BMI, OC
use, LTPA, CRP, smoking, and season of blood draw.
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Figure 10: Probability of depression changes with vitamin D levels based on
sleep duration. For women who sleep too little or too much (5 hours or 12+
hours per night), vitamin D is positively associated with odds of depression.
Among women who sleep 7 or 9 hours per night, vitamin D is inversely related to
odds of depression. Interaction term significant at p=0.01 after adjustments for age,
race/ethnicity, education, BMI, OC use, LTPA, CRP, smoking, and season of blood
draw.
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Table 22: Linear regression of the association of total depression score and
depression subtypes with vitamin D in women of reproductive age from NHANES
2005-2008 stratified by Body Mass Index categories
Per 1 S.D. increase
in log-transformed
25(OH) vitamin D:
BMI <18.5 kg/m2
Unadjusted
Adjusted
BMI 18.5-24.9 kg/m2
Unadjusted
Adjusted
BMI 25-29.9 kg/m2
Unadjusted
Adjusted
BMI ≥30 kg/m2
Unadjusted
Adjusted

Total PHQ-9 score
(range: 0-27)
β
(95% CI)

pvalue

0.13
(-0.67, 0.94)
1.71
(0.41, 2.99)

0.73

-0.27
(-0.60, 0.06)
0.07
(-0.43, 0.57)

0.11

-0.14
(-0.61, 0.33)
0.11
(-0.44, 0.67)

0.55

-0.11
(-0.66, 0.44)
-0.22
(-0.83, 0.40)

0.68

0.01

0.78

0.69

0.48

Depression defined as:
Somatic
Depression score
(range: 0-12)
β
p(95% CI)
value
0.18
(-0.30, 0.66)
0.95
(0.16, 1.73)

0.44

-0.18
(-0.39, 0.04)
-0.006
(-0.28, 0.26)

0.1

0.02

0.97

-0.11
(-0.36, 0.14)
0.05
(-0.24, 0.33)

0.37

-0.09
(-0.40, 0.23)
-0.10
(-0.42, 0.23)

0.59

0.74

0.55

Non-somatic
Depression score
(range: 0-15)
β
p(95% CI)
value
-0.05
(-0.43, 0.33)
0.76
(0.18, 1.33)

0.80

-0.09
(-0.28, 0.10)
0.08
(-0.21, 0.36)

0.35

-0.03
(-0.28, 0.22)
0.06
(-0.23, 0.35)

0.81

-0.03
(-0.29, 0.23)
-0.12
(-0.49, 0.24)

0.83

0.01

0.59

0.67

0.50

Adjusted for age, race/ethnicity, education, smoking, sleep, physical activity, hs-CRP, continuous body mass
index, OC use and season of blood draw.
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CHAPTER 10
CONCLUSION AND SIGNIFICANCE
Our work highlights the complexity of the relationship among micronutrient
status, inflammation, and depression in women of reproductive age. The etiology of
depression remains to be fully understood, and given the higher prevalence of
depression among women, it is important to understand how nutrition,
inflammation, and lifestyle factors may contribute to different dimensions of
depression in this population. Body mass index, a proxy for adiposity, accounts for a
large portion of the association between c-reactive protein and serum 25hydroxyvitamin D with depression; vitamin B6 deficiency was associated with
increased odds of suicidal ideation, and sleep duration modified the association
between vitamin D concentration and depression. These findings altogether
indicate that the relationship between micronutrients and depression is
multifaceted, and inflammation and lifestyle factors, such as sleep and body mass
index, need to be considered when researching depression. Additionally, we provide
increasing evidence in support of analyzing symptoms separately from total
depression scores in order to shed light on the etiology of depression. This research
expands our understanding of how deficiencies of vitamin B6 or D, inflammation,
and other lifestyle factors affect depression symptoms among women and may help
identify potential prevention strategies or adjuvant treatments for depression that
incorporate changes in nutrition or lifestyle factors.
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CHAPTER 11
FUTURE DIRECTIONS
Our research has contributed to the field of nutrition and depression
research by identifying how vitamin B6 and vitamin D status may be related to
various dimensions of depression among women, and how inflammation, sleep
duration, and body mass index affect these associations. Our findings, which were
mainly limited by the cross-sectional nature of the study design, provide scientific
justification for future prospective studies where the directionality of the
association between inflammation and micronutrient status can be examined over
time to determine their contribution to each other and to the development of
depression. In the context of low-grade inflammation, research is warranted to
determine the optimal doses of vitamin B6 to achieve concentrations that are
associated with good health. It should be noted that future studies may lead to the
reassessment of the current Recommended Dietary Allowance for vitamin B6 among
women of reproductive age. Furthermore, our findings emphasize the need for
studies on vitamin D and depression to consider inflammatory status in order to
determine whether those with inflammation would benefit from higher doses of
vitamin D supplementation to alleviate depression symptoms.
Future studies can also assess how dietary inflammatory indices are related
to micronutrient status and depression in this population while considering lifestyle
factors. Although we did not assess dietary intake, ultimately, it is our goal as
nutrition researchers to find evidence as to how nutritional changes promote better
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health and reduce inflammation and to test whether these changes lead to improved
mental health and prevent or treat depression.
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